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General introduction and outline of this thesis
1
General introduction
The immune system is crucial to protect our body from non-self infectious agents such
as bacteria, viruses and fungi. In addition, it plays a pivotal role in cancer immune 
surveillance by recognizing altered self, including tumor cells. Immune responses
against malignant cells can be found in cancer patients, which can result in remission
of the disease. Importantly, the development and clinical exploration of various
immunotherapeutic strategies has accomplished a breakthrough in the treatment of 
several types of cancer. One of the first successful immunotherapies is allogeneic 
stem cell transplantation (allo-SCT), which is a potent treatment option for patients
suffering from high-risk hematological malignancies.1 Allo-SCT treatment can on the
one hand induce the beneficial graft-versus-tumor (GVT) response, which is an immune 
reaction of allogeneic donor-derived immune cells that recognize and attack the 
tumor.2 On the other hand, allo-SCT can cause life-threatening graft-versus-host-
disease (GVHD) when the donor-derived immune responses go awry against the 
healthy tissues of the recipient.3 Although, allo-SCT can be a curative treatment option,
many patients still suffer from relapses. Therefore, there is a medical need for 
additional immunotherapeutic strategies to boost the GVT effects, without eliciting 
or aggravating GVHD. In this thesis, we focus on induction and boosting of tumor-
specific T cells using dendritic cell (DC)-based strategies. Furthermore, we investigate 
the role of negative regulating immune checkpoint molecules in dampening tumor-
reactive T cell / natural killer (NK) cell responses and develop means to interfere with
negative immune cell signaling in order to improve overall survival of patients.
Hematological malignancies
Hematological malignancies comprise of a group of heterogeneous neoplasms 
originating from either the myeloid or lymphoid lineage. They can be classified in 
different groups, including acute and chronic leukemia’s, lymphoma’s and plasma cell 
disorders. Combined these malignancies account for approximately 8% of all new 
cancer diagnoses in Europe, with approximately 9,000 newly diagnosed patients 
every year in the Netherlands.4 Hematological malignancies are clonal diseases in the
bone marrow or peripheral tissue that have encountered multiple genetic hits resulting
in mutations. This can result in the loss of control of cell differentiation and/or division, 
or provide a growth advantage with the ultimate consequence that the malignant cells 
accumulate in the bone marrow and/or other lymphoid tissues. The malignant cell 
then occupies space and thereby hampers the normal hematopoiesis, resulting in 
lower numbers of normal functional blood cells. Clinical symptoms that occur in 
patients with hematological malignancies include fatigue, bleedings and/or infections
518627-L-bw-Hutten
Processed on: 11-4-2018 PDF page: 10
10
Chapter 1
due to reduced numbers of red blood cells, platelets and/or functional white blood
cells, respectively. Cause, incidence and prognosis greatly vary among the different
groups of hematological disorders. Genetic abnormalities of the tumor, as well as 
patient age and health status are important factors in the disease prognosis, and
consequently determine the choice of therapy. Important is a correct diagnosis for 
prognostication and for the prediction of response to specific forms of therapy. 
Diagnoses of hematological malignancies is dependent on various analyses and
techniques. Microscopic evaluation of bone marrow morphology is still a very
important diagnostic tool, together with immunophenotyping that is based on flow
cytometry.5, 6 Furthermore, molecular and cytogenetic analyses provide crucial
information on the genetic abnormalities and prognostic markers underlying the
disease.7
After diagnoses, standard treatment for hematological malignancies includes
chemotherapy and/or radiotherapy to reduce tumor burden and achieve clinical
remission. Besides these standard treatments, targeted therapies are being 
investigated and implemented. For instance, imatinib, a tyrosine kinase inhibitor that 
interferes with the BCR-ABL fusion protein, is nowadays the first-line therapy for 
chronic myeloid leukemia.8 Furthermore, lenalidomide is used for treatment of multiple 
myeloma to induce tumor cell apoptosis and inhibit angiogenesis.9 Moreover, 
antibody-based therapy including the CD20 antibody rituximab and the CD38 antibody 
daratumumab have significantly improved treatment of B cell lymphomas and multiple 
myeloma (MM). Finally, in acute myeloid leukemia (AML) and myelodysplastic 
syndrome (MDS) patients the hypo-methylating agents (HMA) azacitidine and 
decitabine show great clinical promise.10, 11 Next to these targeted therapies, strategies 
aimed at harnessing the cellular arm of the immune system to eradicate tumor cells
are highly attractive for the treatment of cancer patients. The goal here is to activate
and direct the immune system specifically towards the tumor and to establish
long-term immune surveillance, thereby improving relapse-free and overall survival.
One of the first successful immunotherapies is allo-SCT, where donor hematopoietic 
stem cell transplantation is exploited to introduce a healthy immune system in the 
cancer patient, capable of eradicating residual tumor cells. More recently developed 
immunotherapies include adoptive cell transfer (ACT), including ex vivo-expanded 
tumor infiltrated lymphocytes, chimeric antigen receptor (CAR) engineered T cells and 
ex vivo-expanded allogeneic NK cells, that are infused in the patient following non-
myeloablative conditioning.12-16 Furthermore, vaccination-based approaches are 
developed using various antigen formulations or different DC products.17-19 In addition,
antibody-based strategies using checkpoint blockers or bi-specific antibodies are
being investigated.20-23
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Allogeneic stem cell transplantation
Initially, SCT has been developed to provide patients suffering from a hematological 
malignancy with a new hematopoietic system after patients received intensive 
chemo-and/or radiotherapy to reduce the tumor burden and preventing graft rejection.
However the condition regimen does not only destroy the fast proliferating malignant 
cells, it also affects healthy hematopoietic stem cells and progeny.24 After transplanta-
tion, stem cells of the graft home to niches in the bone marrow compartment and form
a new hematopoietic system, which reconstitutes the various blood cell lineages. The 
graft can originate from an autologous source (auto-SCT), or from an allogeneic human
leukocyte antigen (HLA) mismatched/matched or haplo-identical donor (allo-SCT).25
In case of auto-SCT, the patient’s own stem cells are used, which are collected prior to 
the intensive chemo- and/or radiotherapy. Though this is a relatively non-toxic
procedure compared to allo-SCT, relapse of the malignancy is often observed because 
malignant cells can also be present in the harvested graft. Allo-SCT has curative 
potential, it can induce GVT responses and enable long-term remission and a possible
cure of the disease. However, allo-SCT can be accompanied by life-threatening toxicity, 
i.e. GVHD.26 To avoid induction of lethal GVHD, HLA-matching of the allo-SCT recipient 
and donor is essential, although nowadays more and more HLA haplo-identical trans-
plantations are being performed with a focus on preventing GVHD by depleting 
allo-reactive T cells.27 The HLA system is involved in the presentation of antigenic 
peptides to T cells. There are two classes of HLA molecules. HLA class I molecules 
(HLA-A, HLA-B, HLA-C) are present on all nucleated cells and present antigenic 
peptides to CD8+ T cells. HLA class II molecules (HLA-DR, HLA-DQ, HLA-DP) are present 
on antigen-presenting cells (APCs), which present peptides to CD4+ T cells. Although, 
there are many different genetic variants of HLA molecules, clinicians in Nijmegen aim
to transplant the patients with the best HLA-matched donor, this means a 8 to 10 out 
of 10 HLA molecules for an HLA-matched donor, not including HLA-DP. Patients after 
allo-SCT can be additionally treated with donor lymphocyte infusions (DLI) to prevent 
or treat relapse, and thereby induce longer-lasting durable remissions in leukemia 
patients by eliciting stronger GVT immune responses.28, 29 The major immune effectors 
involved in GVT responses are the donor-derived T cells and NK cells. NK cells recognize 
their target cells independent of HLA-antigen complexes, as their activation is 
dependent on the balance of signals delivered by activating and inhibitory receptors. 
T cells can recognize tumor associated antigens (TAA), neo-antigens or minor histo-
compatibility antigens (MiHAs) presented by HLA-molecules.30, 31 TAAs are antigens 
which are highly expressed by tumor cells, but generally also at low levels by healthy 
normal cells. MiHAs are antigens derived from polymorphic intracellular proteins, that 
differ between recipient and donor. Mostly these differences are based on single 
nucleotide polymorphisms (SNP) due to normal variation between people. These SNP 
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result in small differences in amino acid sequence of proteins, which, following
proteasomal cleavage, are presented to donor-derived T cells that recognize these
polymorphic peptides as foreign.32 A large panel of MiHA have been identified of which 
some are exclusively expressed by hematopoietic cells, making them lead candidates 
for selective boosting of GVT immunity. In addition, the occurrence of detectable
MiHA-specific T cell responses is also associated with improved relapse-free
survival.33-35
Dynamics of T cell responses
It has been well established that T cells together with NK cells are the key players in 
GVT immunity. T cells are part of the adaptive immune system and formed in the bone
marrow.36 Thereafter, T cells are educated in the thymus to recognize, via their T cell
receptor (TCR), non-self-peptides presented in HLA molecules. When these naïve 
T cells (Tn) encounter their cognate antigen, they can become activated and acquire
effector functions. For optimal T cell activation signaling via co-stimulatory receptors
like CD28:B7 and TNFR family members to become properly activated is required. APC, 
like DC, can provide these stimulatory signals via co-stimulatory molecules including
CD80 and CD86, expressed on their cell surface. Besides this co-stimulatory signaling 
pathway, various others activating molecules pathways exist including HVEM, CD70, 
OX40, CD137 and OX-40 with their respectively ligands on APC (Figure 1).37 In the
absence of co-stimulatory signaling, the T cell will become functionally anergic, and 
thereby tolerant to the antigen, which is one of the physiological mechanisms involved 
in elimination of self-reactive T cells. Next to co-stimulatory molecules, also co-
inhibitory pathways exist and these can be used to dampen immune responses.
Activated T cells can upregulate co-inhibitory receptors, whereas the corresponding 
co-inhibitory ligands can be expressed in all types of cells including APCs and tumor 
cells. In addition to these two essential signals, inflammatory cytokines can also
contribute to T cell activation.
Once activated, T cells clonally expand and differentiate into T effector (memory) cells
(Tem), that produce inflammatory cytokines like interferon (IFN)-ф, Interleukin (IL)-2
and tumor necrosis factor (TNF)-т. Furthermore, they have potent cytolytic potential 
against their target cells. Together this provides them with the ammunition to eradicate
antigen-expressing tumor cells. After the initial immune response, most T cells die 
through apoptosis during the contraction phase, but a small pool of long-lived memory
cells survives as central memory T cells (Tcm). These are capable of responding quickly 
to re-encounter of antigens or tumor cells due to their high proliferative capacity. 
These, Tcm are capable of terminally differentiating into the Tem cells, gain effector 
functions and show potent anti-tumor cytotoxicity.
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Boosting tumor-specific T cells
An appealing strategy to boost GVT immunity is via DC vaccination. Natural occurring 
DC derived from hematopoietic bone marrow progenitor cells and can be found
throughout the body, including the skin, lungs, stomach, lymphoid organs, bone 
marrow and blood. DC are the most professional APC of the immune system, as they 
are the key orchestrators of the innate and adaptive immune system.38 They can be
found in either a resting or an activated state, better known as immature and mature 
state. Immature DC routinely scan the peripheral tissues in search for foreign
pathogens, dead cells and altered self-antigens. They have a high capability of antigen 
Figure 1. Co-stimulatory and co-inhibitory signaling involved in regulation of GVT
immunity. The key immune players in anti-tumor immunity are T cells. Adequate T cell 
recognition is dependent on the interaction of the T cell receptor (TCR; blue receptor) with its
cognate antigenic peptide presented by human leucocyte antigen (HLA; yellow molecule) 
molecules on tumor cells. A plethora of co-signaling molecules is involved in the regulation of 
T cell responses. The sum of these co-stimulatory and co-inhibitory signals determines the 
activation state, magnitude and duration of the T cell responses, therby tightly balancing tumor 
tolerance versus elimination. co-stimulatory signals are provided by CD28, CD137, OX-40, CD27, 
LIGHT and/or DNAM-1 (green receptors). Co-inhibitory signals are mediated by PD-1, CTLA-4,
LAG-3, TIM-3, TIGIT, BTLA and/or CD200R (red receptors). The corresponding ligands are 
depicted in green (co-stimulatory action), red (co-inhibitory action) or grey (either co-stimulatory 
or co-inhibitory action). BTLA, B and T lymphocyte attenuator; CTLA-4, cytotoxic T-lymphocyte 
antigen-4; DNAM-1, DNAX accessory molecule-1; HLA, human leukocyte antigen; HVEM, herpes-
virus entry mediator; LAG-3, lymphocyte activation gene-3; PD-1, programmed death-receptor 
1; PD-L1/L2, programmed death-ligand 1/2; TCR, T cell receptor; TIGIT, T cell immunoreceptor 
with Ig and ITIM domains; TIM-3, T cell immunoglobulin and mucin domain-containing protein-3
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uptake and sequestration, but are not efficient in antigen processing and formation of 
stable peptide-HLA complexes.39 For their maturation, DC need to be triggered by
danger signals from the environment, including pathogen associated molecular 
patterns (PAMP) and damage associated molecular patterns (DAMP) that bind toll like 
receptors (TLR).40 During maturation DC upregulate co-stimulatory molecules and 
start to secrete cytokines like IL-1у, IL-12 and IL-15 to give proper activating signals to
the T cells. Maturation of DC is a terminal differentiation process transforming the cells 
to have an immune stimulatory phenotype to properly activate immune effector cells 
including T cells.41
DC possess general characteristics like antigen uptake, but the various subsets differ 
in their function to bias the immune system towards an appropriate response.42
Different subsets of DC have been identified, including tissue-resident DC subsets and 
blood DC subsets. In the human skin three major DC subsets have been characterized: 
the epidermis resident Langerhans cells (LCs), dermal interstitial DC (iDC) CD1a+, and
CD14+ DC.43, 44 Blood DC subsets can be divided into: BDCA1+ and BDCA3+ myeloid DC 
(mDC), and plasmacytoid DC (pDC).45 Differences in their transcriptional profile, their 
repertoire of TLRs, and cytokines produced upon maturation support their differential 
functions. For example, pDC express mainly TLR7 and TLR9 sensing respectively single
stranded RNA and un-methylated CPG motifs in the DNA.46, 47 The pDC secrete high 
amounts of type I interferon, giving them a pivotal role in anti-viral immunity.48
In contrast, both mDC subsets express TLR3 and TLR8 amongst others, with expression 
levels of TLR3 being highest for the BDCA3+ mDC. Upon maturation, mDC gain CCR7 
expression for homing to the lymph nodes and they produce a variety of pro-inflam-
matory cytokines including IL-1у, IL-6 and TNF-т. Furthermore, they can produce the 
T cell stimulatory cytokines IL-12, which is essential for activating T cell-mediated 
anti-tumor immunity.49-52 Notably, the BDCA3+ mDC are considered to be the most
efficient cross-presenting DC subset. Moreover, besides the individual contributions of 
each DC subset, they can work together and synergistically enhance each other 
stimulating potential.53, 54
The last decades, monocyte-derived DC (MoDC) vaccines have been explored for 
cancer patient treatment.55, 56 The aim of this therapy is to boost tumor-specific 
effector T cell responses to specifically and efficiently eradicate tumors and to induce 
immunological tumor control. Pre-clinical and clinical studies showed that DC
vaccination is a safe and promising strategy for the treatment of different malignancies.
However, so far, MoDC-based cancer vaccination strategies have only shown limited 
clinical efficacy, despite the detection of induced immune responses.57-59 This 
demonstrates the need to further optimize DC vaccine potency. As the activation of 
T cells is dependent on the balance of co-stimulatory and co-inhibitory signals,
manipulation of DC phenotype to improve their immunogenicity is an interesting
option. By lowering co-inhibitory molecule expression DC with superior immune
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stimulatory capacity can be generated for therapeutic purposes.60-62 Additionally,
vaccination with natural occurring DC is also appealing due to their differential
specialized functions and their capability to synergistically activate T and NK cells as 
compared to MoDC. The use of different DC subsets has already been proven to be
safe and showed promising immune responses in patients.63-65 In chapter 2 and
chapter 3 we developed and evaluated 2 different culture protocols to produce high
numbers of natural occurring DC subsets from hematopoietic stem and progenitor 
cells (HSPCs) for DC vaccination purposes. An alternative strategy to directly harness 
the patient’s natural DC subsets in vivo by infusion of long peptides, which are 
subsequently engulfed, processed and cross-presented by these DC.66 Notably,
preclinical studies have indicated that simultaneous engagement and cross-talk of 
multiple DC subsets is important for generating more potent and broader anti-tumor 
responses.67, 68 Another attractive therapeutic strategy is the use of antibody-antigen 
constructs to specifically target the natural occurring DC in vivo. Interesting cell surface 
molecules for in vivo antibody-mediated tumor antigen delivery into DC subsets are 
the endocytic C-type lectin receptors (CLR). CLR are pattern-recognition receptors that 
mediate recognition and uptake of pathogens, or antigens exposed or released upon
cell death. When the CLR binds its ligand it can induce intracellular signaling pathways 
regulating DC function.69, 70 These CLR include DEC-205, DC-SIGN and CLEC9A.71 Many 
factors need to be evaluated when selecting the most appropriate receptor to target,
including their expression pattern on DC subsets, intracellular routing, and capacity to 
deliver antigens in the cytoplasm for processing and subsequent presentation. In 
chapter 4, we evaluated the potential of CLEC12A, an endocytic CLR, as a new targeting 
candidate for simultaneous antigen delivery into human myeloid and plasmacytoid DC
subsets. CLEC12A is also known as MIC-L (myeloid inhibitory C-type lectin-like 
receptor), CLL-1 (C-type lectin-like molecule-1), DCAL-2 (dendritic cell–associated
C-type lectin 2), and CD371.72 Notably, CLEC12A is an attractive targeting candidate, as 
it is broadly expressed by human blood DC subsets, including mDC and pDC.73 In
addition, CLEC12A is also expressed on AML stem cells and blasts. Interestingly, it is
not expressed by healthy hematopoietic stem cells, indicating it can be used to
discriminate between normal stem cells and leukemic stem cells.74, 75 Notably, the 
CLEC12A receptor contains an immunoreceptor tyrosine-based inhibition motif (ITIM) 
and an immunoreceptor tyrosine-based switch motif (ITSM) within its intracellular tail, 
and upon stimulation recruits SH2 domain-containing protein tyrosine phosphatase 
(SHP)-1 and -2 for further downstream signaling. Zhao et al. demonstrated that CLEC12A
can be internalized upon binding by a CLEC12A antibody, but CLEC12A antibody 
binding also showed complement depended cytotoxicity and antibody-dependent 
cellular cytotoxicity against AML-derived cell lines.76 So far, the function of CLEC12A 
has not been extensively studied, although recently Neumann et al. found CLEC12A to 
be involved in the control of sterile inflammation by neutrophils.77 They reported that 
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monosodium urate crystals (MSU) bind to CLEC12A, which subsequently inhibited
inflammatory responses in vitro. Furthermore, CLEC12A-deficient mice were shown to 
exhibit hyper inflammatory responses after challenge with MSU or necrotic cells.
Lahoud et al. have proposed mouse CLEC12A as a potential target for specific Ag delivery. 
They showed in vivo induction of ovalbumin (OVA)-specific CD4+ and CD8+ T cell
responses after administration of OVA-conjugated anti-CLEC12A in mouse models.78-80
Immune checkpoint molecules in AML
After allo-SCT, potent GVT responses can be elicited, capable of eradicating residual
malignant cells. But, although long-lived memory is subsequently formed, many
patients eventually relapse. This is, amongst others, because the malignant cells have
developed various ways to escape the immune system. These include defects in antigen 
processing and presentation capacity, resistance to immune-mediated cytotoxicity,
secretion of immunosuppressive factors, recruitment of suppressive immune cells and
signaling via co-inhibitory molecules.81, 82 Tumor cells have wide range of co-inhibitory 
ligands which can interact with co-inhibitory receptors are expressed on T cells (Figure 1).
These immune checkpoints are critical for maintaining self-tolerance and resolving 
the immune response upon elimination of the target cells. However, these pathways 
are often employed by tumors to escape immune-mediated destruction.83 In hema-
tological and solid malignancies, low expression of co- stimulatory molecules and 
high expression of co-inhibitory ligands has been associated with poor prognosis.84, 85
Furthermore, tumor-reactive T cells have been shown to express multiple co-inhibitory 
receptors on their surface (Figure 1). The sum of co-stimulatory and co-inhibitory signals
determines the activation state, magnitude and duration of the T cell, thereby tightly 
balancing tumor tolerance and elimination. The key players with a role in dampening 
anti-leukemia immunity are discussed below.
CTLA-4
Cytotoxic T lymphocyte antigen 4 (CTLA-4; CD152) is a key co-inhibitory molecule 
expressed by activated CD4+ and CD8+ T cells, which competes with CD28 for binding 
to CD80 (B7-1) and CD86 (B7-2).86 Whereas CD28 is constitutively expressed on the
membrane of Tn cells, CTLA-4 is mainly localized in the cytoplasm. Upon activation, 
CTLA-4 is rapidly mobilized to the T cell membrane where it outcompetes CD28, due to
a 10- to 100-fold higher ligand binding affinity, and thereby dampens the T cell 
response.87 In addition, reports have shown that the YVKM motif in the cytoplasmic 
tail of CTLA-4 can directly inhibit T cell activation via SHP2 and serine/threonine
phosphatise 2A (PP2A).88 Notably, CTLA-4 is also expressed by regulatory T cells
(Tregs). The importance of CTLA-4 in regulating T cell homeostasis and central tolerance 
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became evident in CTLA-4 knockout mice, which developed lethal lymphoproliferative 
disease with multi-organ T cell infiltration.
Although CTLA-4 blockade was not very successful in in vitro models, mouse studies 
demonstrated its power to reverse T cell dysfunction in chronic viral infections and 
established tumor models.89 These data provided rationale for the clinical exploration
of anti-CTLA-4 treatment in cancer patients. The impressive results obtained in the 
phase III trial in metastatic melanoma patients, where patients achieved tumor 
regression and improved survival upon anti-CTLA-4 treatment, subsequently lead to 
the approval of ipilimumab by the US food and Drug Administration (FDA) and 
European Medicines Agency (EMA) in 2011.90 Yet, the drawback of releasing the 
immune brake is induction of toxicity in healthy tissues. Currently, two CTLA-4 blocking 
antibodies are available: ipilimumab and tremelimumab (Table 1). Up to 60% of the
patients treated with anti-CTLA-4 develops immune-related adverse events (irAEs), 
including rash, uveitis, colitis, and hepatitis.91 In a phase III trial with ipilimumab, 25%
of the irAEs were grade 3-4 toxicities and 10-15% were severe or life-threatening.90
Interestingly, these irAEs appear to be associated with positive outcomes including 
tumor regression and prolonged time to relapse.92, 93
Studies have also demonstrated a role for CTLA-4 in hampering T cell immunity against
hematological malignancies. AML blast were shown to express CD86 and in a lesser 
extend CD80, the ligands for CTLA-4.85, 94 Studies have reported that CD86 expression
by AML correlated with poorer outcome.95 The role of CTLA-4 in modulating immune 
responses in AML was confirmed with the CTLA-4 CT60 A/A genotype, i.e. a variant 
with stronger inhibitory function, which was associated with increased incidence of 
AML relapse and reduced overall survival after allo-SCT.96 Interestingly, CTLA-4 
triggering by recombinant CD80 and CD86 could mediate AML apoptosis.97 Notably,
in vitro blockade of CTLA-4 blockade resulted in significantly enhanced T cell reactivity 
against autologous AML cells.98 In addition, combined CTLA-4 and PD-L1 (CD274,
PDCD1LG1) blockade resulted in enhanced AML lysis in a mouse model of minimal 
residual disease (MRD).99 In the setting of allo-SCT, the timing of CTLA-4 interference 
is of high importance as demonstrated in mouse models. Treatment with anti-CTLA-4 
shortly after allo-SCT caused increased the incidence and severity of GVHD in a 
CD28-dependent manner.100 In contrast, delayed administration, augmented GVT 
immunity without substantially increasing GVHD-related side effects.101 Phase I trials
exploring ipilimumab treatment after allo-SCT are summarized in Table 2. Bashey et al.
demonstrated that a single infusion of ipilimumab, at a median of 1 year (range 0.3-6.5 
years) after allo-SCT or donor lymphocyte infusion, in patients with recurrent or 
progressive hematological malignancies (including 2 AML patients) resulted in an 
objective clinical response in 3 out of 29 patients.102 Importantly, neither induction 
nor exacerbation of GHVD was reported, although 14% of the patients showed 
organ-specific adverse events. Analysis of the T cells before and after single-dose
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ipilimumab administration revealed that CTLA-4 blockade was associated with
increased conventional CD4+ T cell activation and intracellular CTLA-4 expression
without affecting Tregs numbers.103 Another clinical trial enrolled 28 patients (12 with
AML) with relapsed disease after allo-SCT at a median time of 675 days (range 198-1830 
days).104 Here, 6 patients (21%) showed irAEs, of whom one patient died, and GVHD 
was observed in 4 patients (14%). Among 22 patients who received a dose of 10 mg/
kg, 5 (23%) had a complete response, 2 (9%) had a partial response and 6 (27%)
showed reduced tumor burden. Importantly, 4 of these patients had a durable 
response for more than 1 year. Responsiveness was associated with in situ infiltration of 
cytotoxic CD8+ T cells, decreased activation of Tregs, and expansion of Tem sub-
populations in the blood. Currently, ipilimumab and tremelimumab are being evaluated
in patients with AML or myelodysplastic syndrome (MDS) as a bridge-to-transplant, as 
well as in combination with allo-SCT and/or HMAs to improve anti-leukemia immunity. 
PD-1
Programmed death-1 (PD-1; PDCD1; CD279) is another key inhibitory player of the B7/
CD28 family. It is expressed on a broad variety of cells including activated CD4+ and
CD8+ T cells, B cells, monocytes, DC, and NK cells.105 PD-1 binds PD-L1 (B7-H1;
PDCD1LG1; CD274) and PD-L2 (B7-DC;PDCD1LG2; CD273), with the highest affinity for 
the PD-L2.106 PD-L1 can be widely expressed by hematopoietic and non-hematopoiet-
ic cells, although its expression is generally low on normal tissues.107 In contrast, 
PD-L2 expression is restricted to APCs, including DC and macrophages. Notably, PD-L1
expression was shown to be up-regulated by various tumor types upon exposure to 
inflammatory conditions (IFN-ф) or following activation of key oncogenic pathways 
involving phosphoinositide 3-kinase (PI3K) or mitogen-activated protein kinase
(MAPK).108, 109 Similarly, PD-L2 was found to be expressed by certain solid tumors,
including ovarian carcinoma and small cell lung cancer.110 Importantly, increased 
PD-L1/L2 expression by tumors was associated with poor prognosis.111 Upon 
interaction with its ligands, the cytoplasmic signaling motifs of PD-1 become
phosphorylated. This leads to recruitment of protein phosphatases like SHP1 and
SHP2, that mediate dephosphorylation of proximal TCR signaling molecules.112
Consequently, CD28/TCR-mediated activation of PI3K and Akt signaling is inhibited,
resulting in suppression of T cell activation 113.
Pre-clinical and clinical studies demonstrated an evident role for PD-1/PD-L signaling
in hampering immune responses in chronic viral infections and cancer. In 2014, the 
FDA approved the use of pembrolizumab and nivolumab, two PD-1 antagonists, for 
treatment of patients with metastatic melanoma.114 Currently, antibodies blocking
PD-1 (pembrolizumab, nivolumab), PD-L1 (BMS936,559 (MDX-1105), MPDL3280A 
(atezolizumab), MEDI4736 (darvalumab) and MSD0010718C (avelumab)) or PD-L2 
(AMP-224) are under clinical investigation in melanoma and numerous other solid and
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hematological cancers. Importantly, nivolumab treatment resulted in objective and 
durable responses in 28% of patients with melanoma, 18% of patients with non-small
cell lung cancer, and 27% of patients with renal cell carcinoma.115 Tumor cell PD-L1 
expression seemed to correlate with response. Notably, the occurrence and severity of 
irAEs upon PD-1 blockade appeared to be less than for anti-CTLA-4 treatment. 
Interestingly, in hematological malignancies nivolumab and pembrolizumab showed 
objective responses in 87% and 65% of patients with relapsed/refractory Hodgkin 
lymphoma (HL), respectively.116, 117 The clinical efficacy can be attributed to high
9p24.1/PD-L1/L2 gene amplification, causing strong PD-L1 expression levels by the
Reed-Sternberg cells, and high T cell infiltration in the tumor microenvironment. 
PD-1/PD-L signaling was also shown to play a role in dampening anti-leukemic 
immunity in AML. Multiple studies reported expression of PD-L1 and PD-L2 on human 
AML cells at diagnosis and relapse.118-121 Notably, ex vivo exposure to IFN-ф or 
chemotherapy resulted in up-regulation of PD-L1 expression on leukemic blasts.122
Similarly, treatment with HMA (decitabine/azacitadine) could also up-regulate PD-1, 
PD-L1 and PD-L2 gene expression in peripheral blood mononuclear cells (PBMCs) of 
patients with myeloid malignancies (MDS and AML).123, 124 In a mouse MRD leukemia
model, PD-L1 checkpoint blockade resulted in improved survival.99 Furthermore,
enhanced tumor-reactive T cell immunity and improved survival was demonstrated in 
AML-bearing PD-1 knockout mice and in wild type mice treated with antagonistic PD-L1 
antibodies.125 Blocking the PD-1/PD-L signaling pathway in AML patients is currently
under investigation (Table 1). In the allo-SCT setting, high PD-1 expression on 
donor-derived T cells was found to be associated with suboptimal GVT reactivity in 
mouse transplant models.126, 127 Correspondingly, we and others found high PD-1 
expression on allo-reactive MiHA-specific CD8+ T cells after allo-SCT. Subsequent ex 
vivo treatment with PD-1/PD-L1 blocking antibodies resulted in improved MiHA-specific 
CD8+ T cell reactivity, with most pronounced efficacy in relapsed patients.85 In addition,
MiHA-specific CD8+ T cell functionality could also be restored ex vivo and in mouse
models by treatment with PD-L1/L2 silenced DC vaccines.61, 128 Few clinical reports on 
PD-1 blockade in patients after allo-SCT have been published so far.129-135 Haverkos
et al. treated 31 classical Hodgkin lymphoma with PD-1 blocking antibodies because
of relapse after allo-SCT 136. Out of 30 evaluable patients, 15 had a complete response 
and 8 a partial response (77% overall response rate). Seventeen patients (55%) 
developed treatment-emergent GVHD following anti-PD-1 therapy, of whom 9 patients
suffered from grade III-IV acute or severe chronic GVHD. Only 2 of these 17 patients 
showed a complete response to GVHD treatment and 8 patients (26%) died because 
of GVHD. Interestingly, no GVHD was observed in the patients treated with a 
haploidentical HLA-mismatched transplant and post-transplant cyclophosphamide
and calcineurin inhibitor as GVHD prevention. It might be possible that the incidence 
of GVHD after checkpoint inhibitor administration varies depending on the type of 
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GVHD prophylaxis used. These data emphasize the care that should be taken with
checkpoint interference post allo-SCT. Although superior anti-tumor immunity can be 
achieved, the rapid onset of severe (treatment-refractory) GVHD is detrimental. Further 
investigation into the window of opportunity for PD-1 blockade after allo-SCT is 
warranted (Table 2). Currently, several trials are recruiting patients to investigate PD-1
blockade as monotherapy or in combination with anti-CTLA-4, KIR blocking antibodies
or anti-tumor vaccines in AML patients as well as patients post allo-SCT (Table 1).
Notably, care should be taken when combining checkpoint blockade with immuno-
modulatory agents. Recently, the FDA ordered a hold on all clinical trials exploring 
anti-PD-1 and immunomodulatory agents in MM patients due to the death of MM 
patients treated with pembrolizumab combinations.137
Novel checkpoint inhibitors
Numerous new receptor/ligand signaling pathways involved in dampening anti-tumor 
immunity have been identified as interesting targets for cancer immunotherapy. These 
include TIGIT, TIM-3, LAG-3, BTLA and CD200 receptor (CD200R).
TIGIT
TIGIT (T cell immunoglobulin and ITIM domain) is a member of the immunoglobulin (Ig)
superfamily that was discovered in 2009.138, 139 It is part of an intricate receptor 
network and competes with the CD96 and DNAM-1 (CD226) for binding to the poliovirus 
receptor (CD155) and nectin-2 (CD112). These ligands are expressed by (activated) DC,
T cells, and various non-hematopoietic cell types, including tumor cells.140, 141 CD112
and CD155 were shown to be expressed by DC located in para-follicular T cell regions 
in the lymph nodes, suggesting that these ligands contribute to the regulation of T cell
responses in secondary lymphoid organs in humans.140 Importantly, TIGIT and CD96 
deliver inhibitory signals upon ligation, whereas DNAM-1 provides stimulatory
signaling. While the cytoplasmic tail of TIGIT contains an inhibitory ITIM motif and an 
Ig tail-tyrosine (ITT)-like motif,142 CD96 possess both an inhibitory ITIM motif and a 
potentially stimulatory YXXM motif 143.
The expression of TIGIT is restricted to lymphocytes, including activated T cells as well
as memory T cells, Tregs, NKT cells and NK cells.138 The inhibitory function of TIGIT has
been primarily studied in NK cells and multiple mechanisms of action were identified. 
First, it was shown that that the inhibitory effect of TIGIT is attributed to phosphoryla-
tion of its ITIM motif (Y231) and/or the ITT-like motif (Y225), resulting in activation of 
SHP1 and subsequent inhibition of the PI3K and MAPK pathways.138, 144 This triggering 
of TIGIT by CD155-expressing targets cells reduced NK cell-mediated cytokine
secretion, degranulation and cytotoxicity.138 In addition, TIGIT was shown to inhibit T 
cell activation and effector functionality by down-regulation of the TCR т-chain and
CD3ц, causing disruption of the TCR complex.145 Second, TIGIT can outcompete 
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DNAM-1, due to its higher binding affinity for CD155, and thereby interfere with
co-stimulatory signaling.146 Third, TIGIT can interfere with cis-homodimerization of 
DNAM-1, thereby disrupting DNAM-1 co-signaling.147
TIGIT expression is highly expressed by CD8+ tumor-infiltrating lymphocytes (TILs) in
mouse and human non-small cell lung cancer, colon cancer and melanoma.147-149
Notably, TIGIT, TIM-3 and PD-1 co-expression marks CD8+ TILs with impaired cytotoxic 
activity and low capacity to produce TNF-т and IL-2.149 Similarly, TIGIT expression on
CD8+ T cells of AML patients was associated with poorer clinical outcome.150 These T 
cells showed functional defects, including a poor capacity to produce cytokines, which 
could be reversed by TIGIT silencing. Whereas CD8+ T cells of TIGIT knockout mice
exhibited enhanced cytotoxic and proliferative capacity.147, 149 Correspondingly, TIGIT 
blockade resulted in enhanced expansion and effector functionality of CD8+ TILs of 
melanoma patients.148 Furthermore, combined anti-TIGIT and anti-PD-1 treatment 
resulted in significantly improved cytokine production by CD8+ TILs in a mouse colon 
cancer model. Further studies are required to evaluate the efficacy of TIGIT blockade to 
restore T cell function and anti-leukemia immunity in mouse AML models and AML 
patients.
TIM-3
TIM-3 (T cell immunoglobulin and mucin domain-containing protein 3), is a type I
trans-membrane protein with a cytoplasmic tail that is devoid of ITIMs and ITSMs, the 
classical inhibitory motifs found in other co-inhibitory receptors.151 In contrast, TIM-3
possesses a conserved region of five tyrosine residues, which upon phosphorylation
interfere with downstream TCR signaling.152 TIM-3 expression was originally found to 
be associated with IFN-ф production by CD4+ and CD8+ T cells.151 Normally, activated T 
cells show only transient TIM-3 expression, though this can persist upon chronic
stimulation.153 In addition, TIM-3 is expressed by Tregs, NK cells, macrophages and DC. 
Carcinoembryonic antigen cell adhesion molecule 1 (Ceacam1) has been reported to
stabilize TIM-3 expression by formation of a heterodimer.154 Notably, TIM-3 has
multiple ligands, including galectin-9, high mobility group protein B1 (HMGB1), and 
phosphatidyl serine. These ligands are expressed in a variety of tissues, including
tumor cells.155
TIM-3 expression on type 1 T helper (Th1) cells was found to have an important role in
regulating T cell tolerance.156 Furthermore, high TIM-3 expression was observed on
dysfunctional T cells from patients with chronic HIV infection.157 Sakuishi et al. reported
similar observations on TILs in their mouse tumor models.158 Although, TIM-3 is rarely
found on Tregs in the periphery, the vast majority of tumor-infiltrating Tregs express
TIM-3. These Tregs preceded the infiltration of dysfunctional CD8+ TILs. Interestingly, 
TIM-3+ Tregs possessed the most potent regulatory functions. TIM-3 and PD-1 are 
usually co-expressed on TILs. In patients with advanced melanoma or non-small cell 
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lung cancer these PD-1+TIM-3+ TILs showed impaired proliferative capacity and 
cytokine production.159, 160 Importantly, these dysfunctional CD8+ T cells were also
found in different mouse models, and interference with TIM-3 signaling resulted in
improved anti-tumor immunity.158, 159, 161
In mouse and human AML, TIM-3 and PD-1 co-expression on T cells was associated 
with AML progression.162 Furthermore, T cells of newly diagnosed AML patients 
showed higher expression of TIM-3, as compared to healthy controls.163 In addition,
high co-expression of PD-1 and TIM-3 expression was associated with AML relapse in 
patients after allo-SCT.164 In a mouse AML model, combined blockade of the TIM-3 and 
PD-1 signaling pathways, using a TIM-3 fusion protein and anti-PD-L1, resulted in 
reduced tumor burden and improved survival. Either therapy alone was insufficient to 
rescue the mice from AML-related death.162 Recent studies also reported aberrant 
expression of TIM-3 on AML (stem) cells.165-167 Furthermore, it has been proposed that
TIM-3 can promote AML progression through direct suppression of CD4+ T cells by 
activating the IL-6/STAT3 pathway, resulting in inhibition of Th1 polarization, or through
activation of mTOR in AML cells.168, 169 So far, TIM-3 blockade has not been explored 
in cancer patients yet.
LAG-3
LAG-3 (lymphocyte activation gene 3; CD223) is another co-inhibitory player of the Ig 
superfamily. It is a transmembrane protein with high structural homology to CD4.
Similar to CD4, LAG-3 binds HLA-II molecules, though with higher affinity.170 LAG-3 is 
expressed on activated CD4+ and CD8+ T cells, Tregs, as well as a subset of NK cells, B 
cells and pDC.170-174 In resting T cells, LAG-3 is localized in endosmal compartments 
and mostly degraded within the lysosomal compartment.175 Following T cell activation,
LAG-3 is rapidly translocated to the cell surface. Here its expression is further regulated
by metalloproteases, which cleave LAG-3 from the cell surface. Within a tolerized 
environment, LAG-3 expression is retained on the surface of the activated T cells.176
LAG-3 has both cell intrinsic and cell extrinsic mechanism to impair T cell functionality.
Similar to CTLA-4, LAG-3 negatively regulates TCR-mediated signaling in effector T 
cells.177, 178 LAG-3 associates with the CD3-TCR complex on the surface of activated
CD4+ and CD8+ T cells and can thereby specifically negatively regulates T cell
proliferation and function.179 By means of interacting with HLA-II molecules, LAG-3
interferes with antigen-dependent activation of CD4+ T cells.180, 181
Interestingly, LAG-3 deficiency does not cause autoimmune disease in non-autoim-
mune-prone mouse strains nor affect T cell development or function, although reduced
NK cell cytotoxicity has been observed.182 This phenomenon probably underlies the 
reduced ability of LAG-3-deficient mice to control tumor growth.183 However, both 
LAG-3 blockade and LAG-3 deficiency accelerated the onset of diabetes.184 In
accordance, combined LAG-3 and PD-1 deficiency induced severe autoimmunity and
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early death in different genetic backgrounds.183, 185 These studies support a 
non-redundant role of LAG-3 regulating T cell responses. PD-1 and LAG-3 co-expression 
has been shown to correlate with T cell dysfunctionality in chronic viral infections. TILs 
and tumor-specific CD8+ T cells circulating in blood have also been shown to highly 
co-express LAG-3 and PD-1.186, 187 Data on LAG-3 is limited in hematological 
malignancies. T cells of CD30L-, but not CD30L+, AML patients were reported to express
LAG-3.188 In HL, the presence of LAG-3+ CD4 and Treg subsets in the tumor environment
correlated with defective tumor-reactive T cell responses.180 Subsequent deletion of 
the LAG3+ CD4+ T cells augmented IFN-ф production and proliferation of tumor-reactive
CD8+ T cells in vitro. Monoclonal antibodies directed against LAG-3 (BMS-986016 and 
LAG525) are currently evaluated, particularly in combination with anti-PD-1, in early 
phase clinical trials in patients with lymphoma and multiple myeloma (NCT01968109 
and NCT02061761). To date, no trials have been initiated to investigate the potential of 
LAG-3 interference in AML.
BTLA
BTLA (B- and T-lymphocyte attenuator; CD272)) is another co-inhibitory molecule
belonging to the Ig superfamily, with structural similarities to CTLA-4 and PD-1.189
BTLA has two conserved ITIM motifs in its cytoplasmic tail, which upon phosphoryla-
tion, recruit SHP1 and SHP2. These subsequently interfere with TCR and B cell receptor 
signaling.190 In addition, BTLA has been described to relay its inhibitory signals via 
GRB-2.191 The expression of BTLA is mainly limited to lymphoid tissues, including T 
cells and B cells, though expression is also seen on mature DC and macrophages.189
BTLA is expressed on naïve T cells, transiently up-regulated upon TCR engagement
and subsequently down-regulated on fully activated T cells. Though, similar to LAG-3,
BTLA levels remain high on tolerogenic T cells in vivo.192 BTLA is part of a complex
receptor/ligand network. Its ligand, herpesvirus entry mediator (HVEM; TNFRSF14), 
member of the tumor necrosis factor receptor superfamily, is expressed on T cells, B 
cells, NK cells, DC and myeloid cells including AML blasts.193, 194 Next to BTLA, HVEM
also interacts with Herpes simplex virus (HSV) glycoprotein D, lymphotoxin-т, CD160 
and LIGHT (TNFSF14). While CD160 also delivers inhibitory signals, LIGHT acts as a 
co-stimulatory molecule.195, 196 BTLA deficient mice gradually develop elevated levels
of self-antibodies, increased numbers of activated CD4+ T cells in the periphery and
inflammatory cell infiltrates in multiple organs. This can progress to hepatitis-like 
disease and reduces overall survival.197 The negative activity of BTLA on regulating T 
cell proliferation and cytokine production was further confirmed in in vitro studies.189
The formation of heterodimeric HVEM/BTLA complexes on naïve T cells renders HVEM
inaccessible to external ligands, thereby preventing co-stimulation.198
High BTLA expression on T cells is associated with poorer survival in gastric cancer 
and hepatocellular carcinoma in patients.199, 200 In melanoma patients, tumor cells 
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were found to exhibit high HVEM expression. In addition, BTLA and PD-1 were
co-expressed on the melanoma-reactive CD8+ T cells. Importantly, anti-BTLA synergized
with PD-1 and TIM-3 blockade and improved proliferation and cytokine production by
tumor-specific T cells in vitro, indicating a non-redundant role for BTLA.159 Similarly,
BTLA blockade combined with active immunization enhanced anti-tumor immunity 
and regression of large adenocarcinomas in mice.201 Interestingly, BTLA also plays a 
key role in modulating alloreactive T cell responses post allo-SCT. Single administration
of an agonistic BTLA antibody, directly after allo-SCT, completely prevented GVHD
induction in mice, without affecting GVT immunity. However, established GVHD could
not be reversed by this treatment.202 BTLA is highly expressed on MiHA-specific CD8+
T cells after allo-SCT. Notably, blocking the BTLA and/or PD-1 pathway resulted in
restored proliferation and functionality of MiHA-specific CD8+ T cells.194 Interestingly, 
some patients responded better to BTLA blockade as compared to PD-1 blockade, 
indicating the differential dominance of co-inhibitory signaling pathways among 
cancer patients. So far, no clinical trials have been initiated to investigate the safety,
toxicity and efficacy of BTLA blockade for cancer treatment.
CD200R
CD200R, also known as the OX-2 receptor or CD200R1, is an inhibitory receptor with
two Ig superfamily domains. Although it lacks the classical ITIM motifs, it has three 
tyrosine residues that can be phosphorylated. The exact mechanism of subsequent
intracellular signaling has not been elucidated so far.203 CD200R was originally 
described as a myeloid receptor, being expressed on macrophages, granulocytes and 
DC. Later it was also found to be expressed by T cells, B cells and NK cells.204 The only 
known ligand for CD200R is CD200, a type I membrane glycoprotein. CD200 is
expressed on thymocytes, activated T cells, B cells and DC, as well as non-hematopoietic 
cells, including hair follicle cells and vascular endothelial cells.205 The CD200R/CD200 
axis was found to be essential in preventing inflammatory responses and immune 
pathology during early microbial infection by elevating the threshold for immune 
activation.206, 207
Various humans cancers were shown to over-express CD200, including renal carcinoma,
head and neck carcinoma, testicular cancer, colon carcinoma and hematological 
malignancies208. Over-expression of CD200 in AML and MDS cells was associated
with increased relapse risk.209, 210 In mouse experiments, CD200 expressing AML cells 
showed enhanced tumor growth, which could be limited by CD200 Fc administration.211
In addition, in AML patients, CD200/CD200R signaling facilitated tumor immune 
evasion by impairing the frequencies and functionality of activated NK cells and
memory T cells, as well as promoting the expansion of FoxP3+ Tregs.212-214 Notably,
blockade of CD200 resulted in enhanced cytotoxicity and IFN-ф production of NK cells,
and restored the proliferative capacity of T cells.212, 215, 216 Nevertheless, it should be 
518627-L-bw-Hutten
Processed on: 11-4-2018 PDF page: 29
29
General introduction and outline of this thesis
1
emphasized that CD200R signaling not only dampens tumor-reactive immune
responses, it also limits pro-tumorigenic inflammation. Hence, blockade of the CD200/
CD200R pathway may not only improve anti-tumor immunity but also favor tumor 
progression due to enhanced pro-tumorigenic inflammation.205
Other checkpoint molecules
A number of other inhibitory receptors are emerging as interesting new targets for 
cancer therapy. For instance PD-1H/VISTA, a PD-1 homolog expressed on CD11b+
myeloid cells, including neutrophils, monocytes, macrophages, and DC, as well as 
CD4+ and CD8+ T cells, and Tregs.217 VISTA-deficient mice exhibited enhanced 
spontaneous T cell activation and responsiveness to neo-antigen immunization.218
Activation of this signaling pathway prevented acute GVHD in a mouse transplant 
model, though the mechanism of action has not been elucidated yet.219 Another 
interesting player is B7-H3, which inhibited T cell functionality in mouse models, 
especially Th1 responses were preferentially stalled.220 Next to the classical checkpoint 
molecules, innate receptors, including the killer cell immunoglobulin-like receptor 
(KIR) receptor family and NKG2A, are also involved in regulating tumor-reactive
immune responses. Although, these receptors have been mostly studied in the context of 
NK cell functionality, they are also expressed by T cells. The KIR blocking antibody
lirilumab augmented NK cell-mediated lysis of autologous HLA-C expressing AML 
blasts and MM cells, in vitro.221 Furthermore, lirilumab, in combination with anti-CD20, 
augmented NK cell reactivity against CD20+ B cell lymphoma cells in in vitro and in vivo
mouse models.222, 223 In elderly AML patients, lirilumab was shown to be safe in a 
dose-escalation study, capable of blocking KIRs with minimal toxicity and favorable
effects on overall and relapse-free survival.224 Mild and transient treatment-related
adverse effects were observed in 15/23 patients, and 1/23 patients had a grade III/IV 
treatment-related adverse effects. Interestingly, overall survival was significantly
improved in all 6 patients treated with ≥ 1 mg/kg lirilumab as compared to patients 
treated with ≤ 0.3 mg/kg lirilumab. A phase II study investigating lirilumab as 
maintenance therapy in elderly AML patients has recently been completed 
(NCT01687387). Two trials with lirilumab, in combination with azacitidine or nivolumab,
are ongoing in MDS and relapsed/refractory AML (NCT02599649 and NCT02399917 
respectively). 
An alternative strategy to improve anti-tumor, that could potentially synergize with 
blockade of the inhibitory checkpoint molecules, is the activation of co-stimulatory 
pathways. Interesting candidates in this regard are OX40 (TNFRSF4; CD134), 4-1BB
(TNFRSR9; CD137), CD27 and ICOS. These molecules are expressed by activated T 
cells, B cells, macrophages and APCs, and play a key role in the functional maturation 
of T cells.225-227 Studies evaluating the checkpoint landscape have shown OX40 and 
ICOS to be over-expressed in bone marrow of AML patients, especially in relapsed
518627-L-bw-Hutten
Processed on: 11-4-2018 PDF page: 30
30
Chapter 1
AML.228 Agonistic antibodies targeting these stimulatory checkpoint receptors are
currently explored in advanced solid malignancies and lymphoma.
Outline of this thesis
Immunotherapy has proven to be a highly powerful and potential curative therapy in
patients with hematological malignancies, as demonstrated with allogeneic stem cell 
transplantation (allo-SCT). The therapeutic efficacy of allo-SCT by the so called 
graft-versus-tumor (GVT) effect can be attributed amongst others to donor-derived
CD8+ T cells. These T cells can recognize antigens expressed on the recipient’ tumor 
cells, including minor histocompatibility antigens (MiHA). However, despite induction 
of these tumor-reactive (memory) T cell responses, many patients eventually relapse
after allo-SCT. This can be a result of multiple different factors. First is the inadequate
reduction of tumor load prior to transplant. Second, the numbers of tumor-reactive T 
cells and/or NK cells might be insufficient to effectively fight the tumor. Third is the 
dampening of anti-tumor immunity due to tumor immune evasion mechanisms. This 
underlines the importance to gain more knowledge of these mechanisms that hamper 
productive anti-tumor immunity. Furthermore, additive therapies should be developed 
to boost GVT responses and improve disease-free and overall survival. It is desired
that these therapies are tumor-specific and thus do not induce or aggravate graft-ver-
sus-host-disease (GVHD), a life-threatening complication of allo-SCT. The aim of this 
thesis is to gain more insight in the role of co-inhibitory signaling pathways in T cell
suppression after allo-SCT, and to develop and explore novel immunotherapeutic 
strategies to boost these tumor-reactive T cell responses to improve relapse-free
survival in patients with hematological malignancies.
In chapter 2 we established a new culture protocol to generate two dendritic cell (DC)
subsets, CD1a+ myeloid DCs (mDCs) and Langerhans cells (LC), to boost tumor-reactive 
T cell responses. Although routine application of monocyte-derived dendritic cell 
(MoDC) has shown promising results, more potent vaccines are needed to improve the 
clinical benefit of this adjuvant immunotherapy. Interestingly, the CD1a+ mDC and LC 
subsets possess potentially more powerful T cell stimulatory capacity compared to
MoDC. As a source for the generation of these DC subsets we used CD34+ hematopoietic
stem and progenitor cells (HSPCs) isolated form umbilical cord blood, because of their 
high expansion and differentiation potential. We defined the cell yield and purity of the 
culture. Furthermore, we studied the capacity of the generated DC subsets to induce 
and activate allogeneic as well as viral antigen-specific CD8+ T cells, both in vitro and
in vivo. Next, we further optimized the culture protocol and translated it into a more
GMP compliant procedure, as described in chapter 3. In this chapter we developed 
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blood DC subsets consisting of mDC and plasmacytoid DC (pDC). Here, we investigated 
the effect of the aryl hydrocarbon receptor with its antagonist StemRegenin 1 (SR1) on 
the expansion and differentiation of these DC subsets. Furthermore, we compared the 
phenotype and functionality by cytokine production of the mDC and pDC subsets with
their peripheral blood DC counterparts. In addition, the DC subsets were tested for 
their capacity to induce allogeneic T cell responses and to boost antigen-experienced
T cells, including MiHA-specific CD8+ T cells, in recall assays. Both DC products showed
very promising results and should be tested in clinical trials. However, the culture 
procedure is relatively time consuming and costly due to the increasing burden of GMP 
clean room cost. So, we additionally investigated an alternative way to harness the 
power of natural DC subsets to boost anti-tumor immunity. Therefore, in chapter 4 we
investigated the possibility to directly target DC in vivo with tumor antigens to
reinvigorate T cell responses. Here, we studied the endocytic C-type lectin receptor 
CLEC12A as a potential target for directed delivery of antibody-antigen conjugates to 
DC to facilitate antigen uptake, processing, presentation and consequently T cell 
activation. We validated the expression pattern of CLEC12A. In addition, we investigated
its internalization capacity and intercellular fate upon antibody ligation. We further 
studied CLEC12A’s efficacy to deliver and (cross)-present antigens to CD4+ and CD8+ T 
cells in vitro.
Although, allo-SCT can be curative treatment modality for patients with a hematological
malignancy due to the GVT response, still too many patients relapse. Tumor cells can
exploit various immune escape mechanisms, including downregulation of 
co-stimulatory molecules and upregulation of co-inhibitory molecules. When these
co-inhibitory molecules ligate with their counter receptors on the tumor-reactive T 
cells the subsequent inhibitory signals dampen T cell functionality, which can 
eventually result in T cell dysfunction. In chapter 5 we studied immune checkpoint 
molecule expression profiles on different memory T cell subsets, and on cytomegalo-
virus (CMV)- and/or MiHA-reactive CD8+ T cells of healthy donors and allo-SCT patients.
Furthermore, we evaluated whether expression profiles of co-inhibitory molecules 
correlated with relapse in patients after allo-SCT. A next step for treatment of patients
after allo-SCT, to prevent or treat relapse, would be the application of immune 
checkpoint blocking antibodies. Nevertheless, these patients are at risk of developing 
life-threatening GVHD upon systemic release of the immune brake. Therefore, in
chapter 6 we investigated a potential safer alternative for interfering with co-inhibitory
signaling pathways by using siRNA-mediated silencing of co-inhibitory ligands in AML 
cells, thereby reinstalling tumor-reactive T cell functionality. 
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Abstract
Autologous, patient-specific, monocyte-derived dendritic cell (MoDCs) vaccines have 
been successfully applied in the clinical studies so far. However, the routine application 
of this strategy has been hampered by the difficulties in generating sufficient numbers
of DC and the poor DC vaccine quality due to pathology or prior treatment received by 
the patients. The immunotherapeutic potential of other subsets of DC has not been
thoroughly investigated due to their rarity in tissues and difficulties associated with
their ex vivo generation. The high expansion and differentiation potential of CD34+
hematopoietic stem and progenitor cells (HSPCs), isolated from umbilical cord blood
(UCB), into different DC subsets make them an attractive alternative DC source for 
cancer immunotherapy. Therefore, the aim of this study was to generate a large 
number of different DC subsets from CD34+ HSPC and evaluate their functionality in 
comparison with MoDCs. Our culture protocol generated a clinically relevant number 
of mature CD1a+ myeloid DC and CD207+ Langerhans cells (LC)-like DC subsets from
CD34+ HSPCs with >95% purity. Both DC subsets exhibited a cytokine profile that favor 
CTL responses. Furthermore, UCB-DC and UCB-LC demonstrated superior induction of 
proliferation of both allogeneic as well as viral antigen-specific CD8+ T cells, both in
vitro and in vivo. Additional studies revealed that UCB-DC and UCB-LC can efficiently 
expand minor histocompatibility antigens (MiHAs) HA-1-specific CTL in the peripheral 
blood of leukemia patients and prime MiHAs HA-1 and HA-2-specific CTL in vitro. These
pre-clinical findings support the pharmaceutical development of the described culture
protocol for clinical evaluation.
518627-L-bw-Hutten
Processed on: 11-4-2018 PDF page: 45
45
DC subset vaccine for hematological malignancies
2
Introduction
Acute myeloid leukemia (AML) is the most common type of acute leukemia occurring 
in adults.1 Despite improvements in chemotherapy and supportive care, AML has still 
a very poor prognosis resulting in a 5-year overall survival rate of only 24%.2 One of the 
main causes for this bad prognosis is relapse of the disease after reaching complete
remission with classical polychemotherapy because of persistence of chemo-resistant 
malignant cells during remission.3, 4 Although, allogeneic hematopoietic stem cell
transplantation (allo-SCT) together with donor lymphocyte infusion (DLI) after poly-
chemotherapy is a curative option, the treatment-related mortality and morbidity 
issues, and lack of suitable donors limit its routine use in elderly AML patients.5, 6
Therefore, alternative treatment options are urgently required to improve the prognosis
of AML patients. 
 Evidence for immunosurveillance of AML and susceptibility of leukemia cells to both T 
and NK cell attack has paved way for the development of new immunotherapeutic 
strategies.7 At present, IL-2 administration,8 monoclonal antibody therapy,9 vaccination 
with peptides derived from Tumor associated antigens (TAA)10, 11 and cellular 
therapies12 are being explored as adjuvant therapies to eradicate minimal residual
disease (MRD) or to induce anti-leukemic immunity to control relapse of malignant 
disease. Among these cellular therapies, dendritic cell (DC)-based immunotherapy 
holds a great potential as an adjuvant cancer therapy in the setting of MRD to boost 
the patient’s immune system to eradicate AML cells and induce immunological 
memory that protects against disease recurrence. 
DCs are the most potent antigen presenting cells (APCs) identified to date. The unique 
capability of DC to activate naïve T cells and orchestrate primary immune responses 
make them an ideal candidate for cellular immunotherapy.13 The invention of the 
protocol to generate considerable numbers of DC from monocytes in vitro boosted the
enthusiasm for the clinical application of DC-based vaccines.14, 15 Since then, numerous
clinical trials have evaluated the safety, feasibility and clinical efficacy of DC-based
vaccines derived from patient’s monocytes or G-SCF mobilized CD34+ HSPCs in cancer 
patients.14, 16-22 Although the published results of clinical trials have clearly
demonstrated that monocyte derived DC (MoDC)-based cancer vaccination strategy
is feasible, safe and can induce potent anti-cancer immune responses, the clinical 
responses observed so far are limited.23, 24 In addition, the routine application of this
strategy has been hampered mainly by: a) the difficulties associated with the 
generation of sufficient numbers of DC for vaccination purposes, and b) poor DC
vaccine quality due to pathology or prior treatment received by the patients.12
Although DCs are composed of multiple subsets with specialized functions, the vast
majority of clinical studies conducted so far have used MoDC. The physiological 
standing of this subset and whether it is an ideal subset for cancer immunotherapy is 
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currently unclear. Alternatively, CD34+ HSPCs can be expanded and differentiated ex 
vivo into various types of myeloid DC (mDC) that resemble CD14+ dermal DC, CD1a+
interstitial or blood DC, BDCA3+ blood DC and CD207+ Langerhans cells (LC).25-31 So 
far, G-CSF mobilized peripheral blood (PB) HSPC from cancer patients have been used
for generation of autologous DC vaccines.32, 33
TAA usually trigger weak immune responses in contrast to potent allogeneic responses
directed against non-self human leukocyte antigen (HLA). These allogeneic immune 
responses are mediated by HLA class II-restricted CD4+ T cells that can promote
bystander antigen-specific cytotoxic T lymphocyte (CTL) responses.34 In DC vaccination
strategy, allogeneicity could therefore be exploited to promote immunogeneicity
towards tumor antigens by vaccinating cancer patients with TAA-loaded DC generated
from partial HLA-matched donors.
In this study, we explored umbilical cord blood (UCB) as an alternative source of HSPCs 
for generation of allogeneic DC-based vaccines for AML patients. By combining the
established approaches that either induced enormous expansion of DC precursors30,
31 or proper DC differentiation27, 29, we have developed a robust cytokine-based 
culture protocol that generates clinically relevant numbers of mature CD1a+ mDC and 
CD207+ LC-like DC from CD34+ HSPC. Furthermore, we compared the phenotype,
cytokine secretary profile and allogeneic, as well as, viral antigen-specific T cell
stimulatory capacity of generated UCB-DC and UCB-LC with MoDC. Most importantly,
model minor histocompatibility antigens (MiHAs) HA-1-specific CTL expansion and
HA-1 and HA-2 antigen-specific CTL priming capability of UCB-DC and UCB-LC was 
studied using the PB of leukemia patients or healthy donors, respectively.
Material and methods
Isolation of CD34+ cells from umbilical cord blood
UCB samples from full-term deliveries were obtained via the cord blood bank of the 
Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands, after written 
informed consent. Mononuclear cells were isolated from UCB by density gradient
centrifugation using Ficoll-Hypaque (1,077 g/mL; GE Healthcare, Uppsala, Sweden). 
CD34+ cells were purified from mononuclear cells, using the human CD34+ magnetic 
cell sorter (MACS) MicroBead Kit (Miltenyi Biotec, Bergisch Gladbach, Germany), 
according to manufacturer’s recommendations.
Generation of MoDC from buffy coats and UCB
MoDC were generated in 7-8 days from plastic adherent monocytes isolated from 
healthy donor buffy coats (Sanquin blood foundation, Nijmegen, the Netherlands) or 
UCB using 800 IU/ml GM-CSF and 500 IU/ml IL-4 (both Immunotools, Friesoythe,
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Germany) in X-VIVO-15 medium (Lonza, Verviers, Belgium) supplemented with 2%
human serum (HS, PAA laboratories, Pasching, Austria) (Figure 1). Maturation was 
induced by adding IL-6 (20 ng/ml), IL-1у (5 ng/ml), TNF-т (20 ng/ml; all from
Immunotools) and PGE2 (1 μg/ml, Pharmacia & Upjohn, Puurs, Belgium) and culturing 
for 3 additional days (Figure 1).
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Generation of UCB-DC and UCB-LC
Isolated CD34+ cells from UCB were expanded for 7 days by seeding them at
0.2x106cells/ml in Iscove’s modified Dulbecco’s medium (IMDM, GIBCO Invitrogen, CA, 
USA) supplemented with 10% fetal calf serum (FCS; PAA Laboratories, Colbe, Germany), 
Flt3L (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml) (all R&D Systems, Abingdon, UK)
and IL-6 (20 ng/ml) (Figure 1). During the additional 4 days of expansion, IL-3 and IL-6
in expansion medium was replaced with TPO (20 ng/ml). During the expansion period, 
medium was refreshed every other day. Expanded cells were differentiated into either 
UCB-DC with medium supplemented with GM-CSF (800 IU/ml) and IL-4 (500 IU/ml) or 
UCB-LC with medium supplemented with TGF-у1 (10 ng/ml, ImmunoTools) in addition
to GM-CSF and IL-4 (Figure 1). During the last 3 days of UCB-DC or -LC differentiation, 
TNF-т (20 ng/ml) was also added to the media. The cell density was maintained at 
0.25x106cells/ml and 0.5x106cells/ml during expansion and differentiation, 
respectively. Immature UCB-DC and UCB-LC were matured using the cytokine 
combination listed above for MoDC. 
Flow cytometric analysis of mature DC
Mature MoDC, UCB-DC and UCB-LC cultures were analyzed by flow cytometry (FC500,
Beckman Coulter, Fullerton, CA, USA) after staining with monoclonal antibodies 
conjugated with Fluorescein isothiocyanate (FITC): CD1a (HI149, Becton Dickinson), 
CD40 (HB-7, Becton Dickinson), CD80 (MAB104), CD86 (BU63, DAKO), CCR7 (150503, 
R&D Systems) and HLA-DR (Immu357). Phycoerythrin (PE): CD83 (HB15a), CD40
(MAB89), CD207 (DCGM4), CD11c (BU15). Electron coupled dye (ECD): HLA-DR 
(Immu358). PE-Cyanine-5 (PE-Cy5)-conjugated: CD11c (BU15). PE-Cyanine-7 (PE-Cy7)- 
conjugated: CD14 (RMO52) and CD11b (Bear1). All monoclonal antibodies were from 
Beckman Coulter, unless stated otherwise. The data was analyzed using Kaluza 
analysis software (Beckman Coulter).
Cytokine release and quantification
Immature UCB-DC and UCB-LC were plated at 5x104 cells/ml/well in a 24-well plate
(Corning Costar, Amsterdam, the Netherlands) and stimulated with or without
Resiquimod (R848) (5 μg/ml, Alexis biochemicals, Lausen, Switzerland) and Poly I:C 
(20 μg/ml, Sigma-Aldrich, St. Louis, USA) in IMDM with 10% FCS. After 24 hours, 
supernatant was collected for quantification of pro-inflammatory, T helper cell (Th)1
and Th2 cytokine production by UCB-DC / UCB-LC and stored at -20°C until evaluation
by Luminex assay or ELISA. The concentration of IL-1у, IL-4, IL-6, IL-10, TNF-т, GM-CSF 
and IFN-ф was quantified using the Human Cytokine Ten-Plex panel kit (Invitrogen,
Carlsbad, CA, USA) and IL-12 was quantified using the Human IL-12p70 ELISA
Ready-SET-Go! Kit (eBioscience, San Diego, CA, USA) following the methods provided 
by the manufacturer. 
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Allogenic Mixed Leukocyte Reaction (allo-MLR)
Allogeneic T cell stimulatory capacity of mature MoDC, UCB-DC and UCB-LC was tested 
in a CFSE-based MLR assay. Allogeneic peripheral blood mononuclear cells (PBMC) 
labeled with 5 μM carboxyfluorescein-diacetate-succimidyl-ester (CFSE, Molecular 
Probes Europe, Leiden, the Netherlands) were used as responder cells. Responder 
cells (0.5x106) were co-cultured in triplicate for a week with 5x104, 1x104 or 5x103
stimulator cells (MoDC, UCB-DC or UCB-LC) to get responder to stimulator cell ratios of 
1:10, 1:50 and 1:100. On days 4 and 7, culture samples were subjected to flow cytometric 
analysis after staining with CD4 (PE-Cy5, 13B8.2, Beckman Coulter) and CD8 (PE-Cy7, 
SFCI21Thy2D3, Beckman Coulter) antibodies to evaluate allogeneic CD4+ and CD8+ T
cell proliferation.
Expansion of Cytomegalovirus (CMV)-specific CD8+ effector T cells
In vitro: CD8+ T cell were isolated from CMV-positive donor buffy coats by positive 
selection with a magnetic cell sorting device (Miltenyi Biotec) and were stimulated 
with CMV pp65 peptide-loaded (5 μM, TPRVTGGGAM, RPHERNGFTVL) MoDC, UCB-DC 
or UCB-LC at a ratio of 10:1 (T cells:DC) in 1 ml IMDM with 10% FCS in a 24-well plate 
(Corning Costar). On day 4, IL-2 (50 U/ml, Immunotools) and IL-15 (5 ng/ml, Immunotools) 
were added to the cultures. On day 0, 4 and 7 post-stimulation, the frequency of 
CMV-specific CD8+ T cells was quantified after staining the samples with PE-labeled
HLA-B7 tetramers presenting the corresponding CMV pp65 peptide. Tetramers were
kindly provided by Prof. F. Falkenburg (Dept. of Hematology, Leiden University Medical 
Center, Leiden, the Netherlands).
In vivo: Twenty-four, six week old female NOD-SCID-IL-2Rф-/- mice were intraperitoneal-
ly injected (i.p.) with 3.5x106 peripheral blood lymphocytes (PBL) isolated from a 
CMV-specific CD8+ T cell positive healthy donor buffy coat. Four hours after PBL 
injection, 4 groups of 6 mice were injected with PBS or CMV peptide loaded MoDC, 
UCB-DC or UCB-LC (0.2x106 cells, i.p.). Additional PBS or CMV peptide loaded MoDC,
UCB-DC or UCB-LC (0.1x106 cells, i.p.) injections were given to the respective groups on
days 7 and 14 post-PBL injection. On day 21, mice were sacrificed, PB and spleen 
samples were collected, cell numbers were counted and the frequency of CMV-specific 
CD8+ T cells was quantified by flow cytometry. This animal experimental protocol was 
reviewed and approved by the institutional animal ethics committee of Radboud 
university medical center Nijmegen (Permit Number: 2011-178).
Expansion of MiHA-specific T cells ex vivo
PBMC samples of HA-1-specific CD8+ T cell positive AML patients were stimulated with 
HLA-matched, HA-1 negative, MoDC, UCB-DC or UCB-LC loaded with HA-1 peptide (5
μM, VLHDDLLEA) at a ratio of 10:1 in 2 mL IMDM supplemented with 10% HS in 24-well
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plates (Costar Corning). Non-peptide loaded MoDC, UCB-DC or UCB-LC were included
as negative controls. At day 4, culture medium was supplemented with 50 IU/mL IL-2
and 5 ng/mL IL-15 (Immunotools). At day 7, cells were harvested, counted and the
percentage of HA-1-specific CD8+ T cells was determined by flow cytometry after 
HA-1-specific tetramer and CD8 staining.
Induction of MiHA-specific T cells ex vivo
CD8+ T cell were isolated from HLA-A2+ healthy donor PBMC and were stimulated with
HLA-A2 matched, HA-1 or HA-2 negative MoDC, UCB-DC or UCB-LC loaded with HA-1 
peptide (5 μM, VLHDDLLEA) or HA-2 peptide (5 μg/ml, YIGEVLVSV) loaded MoDC, 
UCB-DC or UCB-LC at a ratio of 10:1 in 2 mL IMDM supplemented with 10% HS in 24-well
plates (Costar; Corning). Non-peptide loaded MoDC, UCB-DC or UCB-LC were included
as negative controls. At day 4, culture medium was supplemented with 50 IU/mL IL-2
and 5 ng/mL IL-15 (Immunotools). At day 7, cells were harvested, counted and the
percentage of MiHA–specific CD8+ T cells was determined by flow cytometry after 
MiHA-specific tetramer and CD8 staining.
Statistical analysis 
The data were analyzed by one or two-way ANOVA with Bonferroni post-hoc correction
using GraphPad Prism software.
Results
High numbers of DC and LC can be generated from UCB CD34+ cells
UCB-DC and UCB-LC precursors were expanded for 7 days in the medium supplemented 
with Flt-3L, SCF, IL-3 and IL-6. On day 7, IL-3 and IL-6 in expansion medium were replaced 
with TPO and cells were further expanded for 4 additional days (Figure 1). During the 
total expansion period of 11 days, UCB CD34+ cells expanded on average 467-fold
(Figure 2A). Expanded precursor cells were washed and resuspended in medium 
containing GM-CSF and IL-4 without or with TGF-у1 to differentiate them into either 
UCB-DC or UCB-LC, respectively. Addition of TNF-т during the last 3 days of differenti-
ation accelerated the process of differentiation of both immature UCB-DC and UCB-LC. 
Subsequently, immature UCB-DC and UCB-LC were matured by culturing them in
medium containing IL-1у, IL-6, TNF-т and PGE2. During the total culture period of 20 
days, the mean increase in total cell number was 648- and 338-fold for mature UCB-DC 
and UCB-LC, respectively (Figure 2A). 
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Mature UCB-DC and UCB-LC show phenotypic resemblance to MoDC
UCB-derived CD34+ cells gradually lost the expression of stem cell markers CD34 and
CD133, and expressed myeloid lineage marker CD33 upon expansion (Figure 2B and 
Supplementary Figure S1A). A part of the expanded cells also expressed CD14 and
CD11c, the markers expressed on monocytes and DC (Figure 2B and Supplementary 
Figure S1A). More than 60% of the expanded cells expressed HLA class II cell surface 
receptor HLA-DR on their surface (Figure 2B and Supplementary Figure S1A).
Both immature UCB-DC and UCB-LC expressed comparable levels of the mDC differen-
tiation marker CD1a and other markers expressed on DC such as CD11c, HLA-DR, CD40,
CD80, CD86 and CD83 (Figure 2C and Supplementary Figure S1B). However, UCB-LC 
expressed higher levels of the LC specific marker CD207 when compared to UCB-DC
(Figure 2C and Supplementary Figure S1B). Only a very low percentage of UCB-DC and 
UCB-LC expressed the monocyte marker CD14, indicating a proper DC/LC differentiation 
(Figure 2C, Supplementary Figure S1B and Supplementary Table S1). 
Figure 2. High numbers of phenotypically mature UCB-DC and UCB-LC can be
generated from UCB CD34+ cells. (A) The fold increase of UCB-DC and UCB-LC during 
expansion, differentiation and maturation is shown. (B-D) The phenotypic characteristics of 
precursor UCB-DC/UCB-LC (B), immature UCB-DC/UCB-LC (C) and mature UCB-DC/UCB-LC 
(D) analyzed by flow cytometry at day 11, 18 and 21, respectively, are shown. In addition,
the phenotypic characteristics of the mature MoDC are also shown (D). The data shown are
the mean ± SEM of 3 independent donors tested.
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Mature UCB-DC and LC generated from CD34+ cells phenotypically resembled the 
MoDC (Figure 2D and Supplementary Figure 1C) and expressed DC maturation marker 
CD83 and co-stimulatory markers CD80 and CD86 to the same extent as that of MoDC. 
UCB-DC and UCB-LC expressed no or low levels of the monocyte marker CD14 and 
high levels of CD11b, CD11c, HLA-DR and CD40 (Figure 2D and Supplementary Figure S1C). 
The expression levels of lymph node homing chemokine receptor CCR7 were comparable 
between all three DC subsets evaluated (Figure 2D and Supplementary Figure S1C).
The purity of mature UCB-DC and UCB-LC, quantified based on CD11c+CD83+ expression,
reached greater 95% and it was slightly higher compared to mature MoDC (Figure 2D 
and Supplementary Figure S1C).
UCB-DC and UCB-LC produce low levels of pro-inflammatory, but high
levels of Th1 cytokines and induce strong Allo-MLR 
The cytokine profile expressed by DC upon activation gives an indication on the 
magnitude and the type of the immune response initiated. The DC subsets producing 
cytokines that favor the differentiation of Th0 cells into Th1 cells are preferred for 
cancer immunotherapy. Therefore, the cytokine profile expressed by UCB-DC and 
UCB-LC was compared to that of MoDC. The data revealed that UCB-DC and UCB-LC
produced relatively lower levels of pro-inflammatory cytokines IL-1у, IL-6 and TNF-т,
but higher levels of the Th1 cytokine IL-12у when compared to MoDC (Figure 3A). 
Among the other cytokines measured, UCB-DC and UCB-LC produced slightly lower 
levels of IL-4 when compared to the levels produced by MoDC (Figure 3A).
Next, mature UCB-DC, UCB-LC or MoDC were used as stimulator cells and PBMC 
isolated from healthy donor blood were used as responder cells in allo-MLR. Both 
mature UCB-DC and UCB-LC induced equal (at E:T ratios 1:10 and 1:50) or significantly 
higher (at E:T ratio 1:100, P<0.001) proliferation of both CD4+ and CD8+ T cells in an
allo-MLR when compared to mature MoDC (Figure 3B).
UCB-DC and UCB-LC efficiently activate memory CTL both in vitro and in vivo
The antigen-specific memory CTL activation capacity of UCB-DC and UCB-LC was
evaluated in vitro by co-culturing HLA-A2 matched PBMCs containing either 
CMV-specific CD8+ T cells or HA-1-specific CD8+ T cells with CMV or HA-1 peptide-loaded
UCB-DC or UCB-LC. In these assays autologous MoDC loaded with the respective 
peptide were included as a control. The absolute number of antigen-specific T cells 
was determined at day 7 after co-culture. UCB-DC induced proliferation of both 
CMV-specific and HA-1-specific CD8+ T cells as efficiently as MoDC (Figure 4A,B). 
Although, there were no marked phenotypic differences in expression pattern of either 
maturation or co-stimulatory markers between UCB-DC, UCB-LC and MoDC, notably
UCB-LC induced the highest level of HA-1-specific T cells proliferation in comparison to 
UCB-DC and MoDC (Figure 4B).
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To evaluate the antigen-specific memory CTL activation capacity of UCB-DC and
UCB-LC in vivo, NOD-SCID-IL-2Rф-/- mice were engrafted with PBL isolated from a 
HLA-matched CMV antigen-specific T cell positive healthy donor blood and were 
injected with CMV peptide-pulsed UCB-DC, -LC or MoDC. After 3 rounds of vaccination 
with CMV peptide-pulsed DC/LC, the frequency of CMV-specific T cells in PB and 
spleen of NOD-SCID mice was evaluated by flow cytometry (Supplementary Figure S2). 
These data demonstrated that the efficiency of induction of CMV-specific T cell
proliferation of both UCB-DC and UCB-LC was equivalent to that of MoDC (Figure 4C).
UCB-DC and UCB-LC efficiently prime MiHA specific CD8+ T cells ex vivo
Tumor antigen-specific T cell priming capacity of UCB-DC and UCB-LC was evaluated 
using the MiHAs HA-1 and HA-2. For this, MoDC, UCB-DC and -LC were generated from
HLA-A*0201 positive, HA-1 or HA-2 negative UCB units. Those DC/LC were pulsed with
Figure 3. UCB-DC and UCB-LC exhibit cytokine proﬁles that favor Th1 immune 
responses. (A) Pro-inflammatory (IL-1у, IL-6 and TNF-т), Th2 (IL-4 and IL-10) and Th1 (IL-12у) 
cytokine production by UCB-DC and UCB-LC in comparison with MoDC upon stimulation with
Resiquimod (R848) (5 μg/ml) and Poly I:C (20 μg/ml) was quantified using Luminex and ELISA. 
The data shown are the mean ± SEM of 3 independent donors tested. The data was analyzed by 
one-way ANOVA with bonferroni correction. *P<0.05. (B) Allogeneic T cell stimulatory capacities 
of UCB-DC and -LC in comparison with MoDC were tested in a allo-MLR. In vitro generated 
UCB-DC, UCB-LC or MoDC were used as stimulators for CFSE-labeled PBMC that were isolated
from healthy donor buffy coats at a ratio of 1:100, 1:50 or 1:10 ratio (DC:PBMC). Five days later,
the proliferation of CD8+ and CD4+ T cells was analyzed by flow cytometry. This is a representative
result (mean ± SEM) of 3 experiments. The data was analyzed by two-way ANOVA with bonferroni 
correction. ***P<0.001.
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the corresponding peptide and were used to stimulate unprimed CD8+ T cells isolated
from HLA-matched MiHA- healthy donor PBMC. In these experiments, MiHA peptide-
pulsed autologous MoDC and MoDC generated from plastic adherent monocytes of 
UCB were included as a controls. The data showed that both peptide pulsed UCB-DC
and -LC can efficiently prime HA-1 and HA-2-specific CD8+ T cells in vitro (Fig. 5A-B).
Figure 4. UCB-DC and UCB-LC effectively activate and induce proliferation of both
viral antigen-speciﬁc and minor histocompatibility antigen HA-1-speciﬁc CD8+ T 
cells. (A) The absolute numbers of CMV-specific CD8+ T cells in the cultures re-stimulated
in vitro with CMV pp65 peptide loaded MoDC, UCB-DC or UCB-LC. CD8+ T cells were isolated 
from CMV positive HLA-B7+ donor buffy coats and were stimulated with DC subsets loaded with 
or without CMV pp65 peptide for 4 days. (B) The absolute numbers of HA-1-specific CD8+ T cells 
in the cultures re-stimulated with HA-1 peptide loaded MoDC, UCB-DC or UCB-LC. PBMC samples 
of HA-1 positive HLA-A2+ AML patients were stimulated with DC subsets loaded with or without 
HA-1 peptide for 7 days. The absolute numbers of CMV- or HA-1-specific CD8+ T cells were
quantified by flow cytometry after staining with respective tetramers and CD8 antibody. 
The data shown are the mean ± SEM that are corrected for background proliferation induced by 
the respective non-pulsed DC control from two independent experiments (CMV-specific T cell
re-stimulation) or 4 AML patient PBMC tested (HA-1-specific T cell re-stimulation). (C) The percentage 
of CMV-specific CD8+ T cells in the PB and spleen of CMV+ donor PBL engrafted NOD-SCID-IL2Rф-/-
vaccinated with CMV peptide loaded DC subsets. NOD-SCID-IL2Rф-/- mice were injected i.p. with 
3.5x106 PBL isolated from a HLA-B7+ CMV+ donor buffy coat. 4 hours after PBL injection, 4 groups of 
6 mice received either PBS or CMV pp65 peptide loaded MoDC, UCB-DC or UCB-LC (2x105, i.p.). 
Additional booster injections of PBS or CMV pp65 peptide loaded DC subsets (1x105, i.p.) were 
given on day 7 and 14. At day 21, mice were sacrificed, blood and spleen samples were collected
to evaluated the frequency of CMV-specific CD8+ T cells by flow cytometric technique after 
staining the samples with mouse CD45, human CD45, human CD8 and CMV tetramer. The data
shown are mean ± SEM of 6 mice tested per group.
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Animal serum free culture conditions also generates DC from
UCB CD34+ cells
In order to make the UCB-DC culture protocol suitable for clinical application,
subsequent attempts were made to generate UCB-DC in the presence of pooled HS 
instead of FCS using the cytokine mixtures listed in Figure 1. The replacement of FCS
with HS resulted in higher expansion rates (Figure 6A). The phenotype of the expanded 
pre-DC was only marginally affected by the replacement of FCS with HS in the expansion 
medium (Figure 6B). However, the percentage of UCB-DC expressing the HLA class II 
marker (HLA-DR), co-stimulatory marker (CD86) and DC maturation (CD83) was 
moderately reduced by the replacement of FCS with HS (Figure 6C). Most importantly, 
although UCB-DC generated in the medium supplemented with HS were less mature,
they met the accepted release criteria of >70% purity for therapeutic DC products and 
they did not greatly differ in their allogeneic T cell stimulatory capacity when compared 
to UCB-DC generated in the medium supplemented with FCS (Figure 6D). These data 
demonstrate that the UCB-DC vaccines can be efficiently generated in animal serum 
free culture conditions. 
Figure 5. UCB-DC and UCB-LC efﬁciently prime HA-1 and HA-2-speciﬁc T cells. The
bar diagrams show the absolute numbers of HA-1-specific (A) and HA-2-specific (B) CD8+ T cells
primed by MoDC, UCB-DC or UCB-LC pulsed with respective peptide. CD8+ T cells were isolated
from HLA-A2+ healthy donor PBMC and were primed with HA-1-negative or HA-2-negative, 
HLA-A2+ peptide pulsed DC subsets. After 7 days of priming, the frequency of HA-1 or 
HA-2-specific CD8+ T cells in the cultures was quantified by flow cytometry after staining the
samples with respective tetramer and CD8 antibody. Representative data of 4 experiments 
are shown.
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Discussion
Despite of the progress made in the field of modern treatment for leukemia, the outlook
for the majority of patients with AML has remained dismal with poor long term 
survival.12 Therefore, need for alternative therapies remains high to improve the 
prognosis for patients with AML. A broad array of immunotherapeutic strategies are 
under active investigation as adjuvant therapy to improve the overall survival of AML 
patients by eliminating residual leukemic cells following standard therapy.12 DC-based 
vaccination is an attractive immunotherapeutic strategy, because of its ability to 
Figure 6. High numbers of functional UCB-DC can be generated in animal serum
free culture conditions. (A) The fold increase of UCB-DC cultured in medium supplemented 
with FCS or pooled HS during expansion, differentiation and maturation is shown. The
phenotypic characteristics of precursor UCB-DC (B), and mature UCB-DC (C) analyzed by flow 
cytometry at day 8 and 17, respectively, are shown. (D) Allogeneic T cell stimulatory capacity of 
FCS-UCB-DC and HS-UCB-DC was tested in a allo-MLR. In vitro generated UCB-DC were used as 
stimulators for CFSE-labeled PBMC that were isolated from healthy donor buffy coats at a ratio
of 1:1000, 1:100 or 1:10 ratio (DC:PBMC). 5 days later the proliferation of CD8+ and CD4+ T cells
was analyzed by flow cytometry. The data shown are the mean ± SEM of 2 independent donors 
tested.
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induce leukemia-specific T cell responses, that offers the desired anti-tumor effects
with minimal toxicity. In AML, DC vaccines are generated either by differentiating AML 
cells into AML-derived DC or differentiating monocytes isolated from AML patients in 
remission to MoDC. Phase I clinical trials conducted so far have demonstrated that DC 
vaccines are safe and can induce immunological responses in AML patients. However,
the feasibility in terms of obtaining sufficient AML-DC vaccines and the clinical 
responses induced by AML-DC vaccines has been limited.35-38 The aim of this study 
was therefore to evaluate the possibility to generate clinically relevant doses of potent
AML-reactive T cell-inducing DC and LC vaccines from UCB CD34+ cells. Herein, we
report that clinically relevant doses of mature CD1a+ mDC and CD207+ LC-like DC can 
be generated from CD34+ HSPC. Most importantly, the generated UCB-DC and UCB-LC 
efficiently expanded MiHA HA-1-specific CTLs in the PB of leukemia patients and also 
primed MiHA HA-1 and HA-2-specific CTLs. In the final part of this study, an attempt 
was made to generate UCB-DC in animal serum-free culture conditions. The
replacement of FCS with clinically acceptable pooled HS in UCB-DC expansion medium
enhanced the expansion rate of DC precursors and did not affect the phenotype of the 
DC precursors. However, the use of HS in the DC differentiation and maturation medium 
had a marginal negative effect on the purity of mature UCB-DC.
The key role played by DC in inducing immunity has been the rationale for the 
application of DC-based vaccines in cancer immunotherapy. DCs, comprised of 
heterogeneous populations of HSPC-derived cells, have the unique ability to activate 
naïve T cells and direct the subsequent immune response towards a Th1, Th2, Th17 or 
T regulatory (Treg) profile. The distinct capacity of DC to induce immune responses or 
tolerance depends not only on their activation or maturation state, but also on the DC
subset involved.39 Human DC can be categorized into two major types depending on 
their lineage: 1. The mDC (also called classical or conventional DC) and 2. Plasmacytoid
DC (pDC). The DC subsets reside in the tissue wherein they are poised to capture 
antigen, or circulate in the blood. So far, human DC subsets in skin and blood are the 
best characterized, although DC also can be found in other tissues.40 Skin DC comprise 
of 3 types of mDC: the epidermal LC, the dermal interstitial CD1a+ DC and CD14+ DC.41
Blood DC comprise of 2 subsets of BDCA2+ pDC, (CD2high pDC and CD2low pDC) and 3 
subsets of CD11c+ mDC (CD1c+ mDC, CD141+ mDC and CD16+ mDC). Among mDC, LC21
and CD141+ mDC31 possess the most robust CD8+ T cell stimulatory capacity, followed 
by the CD1a+ interstitial DC, making them the most preferred subsets of DC for cancer 
immunotherapy.27, 39 Because of rarity of LC and CD141+ mDC in the tissues and
difficulties with their generation ex vivo, the majority of the studies have used 
autologous ex vivo-generated MoDC (that is, interstitial DC and CD1c+ blood DC
equivalent), whereas only few trials have used mDC derived from CD34+ precursors. 
Nevertheless, it has been suggested that DC generated from CD34+ cells are more 
potent inducers of anti-tumor T cell responses than MoDC.15, 42 The favorable effect of 
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DC generated from CD34+ cells was attributed to contaminating LC in the DC vaccines 
prepared from CD34+ cells. In light of the previously mentioned findings, we aimed at 
generating LC, dermal DC equivalent, CD141+ mDC and pDC from CD34+ cells isolated
from UCB. Notably, we succeeded in generation of higher numbers of mature LC
(UCB-LC)- like and dermal DC equivalent (UCB-DC) with high purity and high levels of 
expression of co-stimulatory molecules in contrast to the previously used protocol for 
generation of DC from CD34+ cells.42 Phenotypically both UCB-LC and UCB-DC
expressed typical mDC markers (CD1a, CD11c, HLA-DR, CD40, CD80, CD83, CD86) with
the exception that UCB-LC expressed higher levels of Langerin (CD207). Unlike 
previous reports, UCB-LC did not express e-cadherin or lacked expression of CD11b
and CD52.27 These phenotypic differences may in part be attributed to the discrepancies 
in the source of CD34+ cells (UCB in the current study vs. G-CSF mobilized) and the 
addition of IL-4 to the current UCB-LC differentiation medium. We observed the 
expression of LC marker Langerin in a small fraction of UCB-DC cultured with GM-CSF, 
IL-4 and TNF-т without TGF-у1. The presence of TNF-т in UCB-DC differentiation 
medium may explain this finding, as exposure of DC precursors to proinflammatory
cytokines such as TNF-т during their differentiation is known to induce Langerin
expression.28 In line with previous reports, UCB-DC and UCB-LC were slightly better 
than MoDC in stimulating allogeneic, as well as tumor-reactive T cells in vitro27 and all
the 3 studied subsets of DC pulsed with MiHA peptide exhibited comparable 
HA-2-specific T cell priming capacity. So far, the ability of LC to cross-present exogenous
antigens to CD8+ T cells via HLA class I pathway and induce very potent CTL responses 
makes them an attractive vaccine target for cancer immunotherapy,43 whether that
also holds true for UCB-LC still needs to be investigated.
Despite the ample success achieved so far with DC-based cancer vaccines, one of the 
main problems remains the limited number of DC available for immunotherapy.44 As 
DC play a pivotal role not only in the initiation of CTL responses but also in the 
maintenance of CTL, it may be crucial to repeatedly vaccinate cancer patients with DC 
vaccines.45 So far the general maximum dose of DC vaccines applied has been 30x106 
DC per injection,46 whether this is the maximum optimal dose for DC vaccines has yet 
to be investigated. Therefore, we aimed at generating a high number of DC for multiple 
DC vaccination rounds. The mature UCB-LC/UCB-DC yields obtained in the current 
protocol ranged between 34x106 and 65x106 from x105 UCB CD34+ cells. According to 
our previous report, on average 2x106 CD34+ cells can be isolated from an UCB unit.47
Thus, the current protocol will generate on average 6.8x108 and 1.3x109 mature UCB-LC 
and UCB-DC, respectively, from one UCB unit. Those achieved numbers should be
sufficient for multiple vaccinations of one or even multiple patients. The possibility to 
freeze aliquots of expanded precursors or fully mature DC provide an additional 
advantage for the preparation of our off-the-shelf DC vaccine batches that could be
applied to a group of patients at multiple time-points.
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Routinely applied DC vaccines in cancer immunotherapy have been generated from
autologous monocytes, but reports indicate that wide scale application of such DC 
vaccines suffers from a very high inter-patient variability38 and sometimes also the 
poor vaccine quality.14, 48 Alternatively, DC can be generated from G-CSF mobilized PB 
CD34+ cells.14 However, these DC are not preferred for cancer immunotherapy due to
their polarization towards the Th2 response. Furthermore, G-CSF treatment for 
mobilization of CD34+ cells poses an extra burden on the patients. In order to overcome
these limitations associated with autologous DC vaccines, allogeneic DC have been
considered as an attractive alternative. The major advantage of using allogeneic DC is
the feasibility of large scale production of more standardized DC vaccines in terms of 
phenotype and maturation status, that can be applied to all patients.38 In addition,
HLA-matched allogeneic DC vaccines are reported to induce strong anti-tumor immune 
responses and clinical responses in cancer patients.49, 50 In the current study, we
explored UCB as a source of CD34+ cells for generation of allogeneic DC.
UCB is an extremely attractive source of HSPCs not only for clinical transplantation, 
but also for the generation of a multitude of cell therapy products due to their strong 
multi-lineage expansion and differentiation potential. Unlike other allogeneic HSPC 
sources, UCB do not pose any risk to the donor and are readily available from the CB 
banks worldwide. As CB banks have large numbers of HLA-typed HSPCs available, 
there is a higher probability of finding a partially HLA-matched donor for generation of 
DC vaccines for immunotherapeutic purposes. A combination of UCB-derived HSPC for 
transplantation and DC generated from the same donor may provide an appealing new
treatment option for patients suffering from hematological malignancies. There are
few reports on the DC generation from UCB-derived CD34+ cells.51-55 However, the 
current study supersedes the number, purity and maturation status of the generated 
UCB-DC. Most importantly, this study is the first to describe the preclinical evidence
for the suitability of UCB-DC for either induction or re-activation of MiHA-specific T 
cells that are of clinical significance in transplanted patients suffering from 
hematological malignancies.
The type and the concentration of the serum present in the DC culture medium is 
known to affect the expression pattern of key DC and LC identification markers such as 
CD1a and CD207.56-58 Therefore, we initially generated UCB-DC and LC in medium 
containing FCS. Although, some clinical trials have used FCS for DC generation,59, 60 in
order to prevent immune responses against xenoserum constituents and transfer of 
xenoinfections, DC generated in serum-free or HS supplemented medium are preferred. 
Hence, we subsequently replaced FCS by pooled human serum in UCB-DC/UCB-LC 
generation medium and demonstrated the feasibility of the current UCB-DC culture
protocol for clinical application. However, the feasibility of UCB-LC culture protocol 
could not be demonstrated because of lack of expression of the LC specific marker 
Langerin on the cells cultured in the absence of FCS. The identification of key
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components in FCS that induce Langerin expression is crucial for further development 
of UCB-LC for the clinical application.
In conclusion, a very high number of mature DC can be generated from CD34+ HSPC for 
clinical evaluation using the current protocol. Both allogeneic, as well as tumor-reactive 
T cell stimulatory capacity exhibited by the mature UCB-DC make them a good vaccine 
candidate for leukemia. These pre-clinical findings support the further pharmaceutical
development of the described culture protocol for clinical evaluation.
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Supplementary Figure S1. The phenotypic characteristics of precursor, immature
and mature UCB-DC/ UCB-LC compared to the mature MoDC. The phenotypic charac-
teristics of (A) precursor, (B) immature UCB-DC/UCB-LC of a representative donor were assessed 
via flow cytometry. (C) The phenotypic characteristics of a representative donor of mature 
MoDC and UCB-DC/UCB-LC is depicted. Numbers represent the percentage positive cells in that 
gate. (D) Furthermore, the mean fluorescence intensity (MFI) of various phenotypic markers for 
mature MoDC and UCB-DC/UCB-LC are indicated.
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Supplementary Figure S1. Continued.
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Supplementary table S1.  The percentages of CD1a+ and CD14+  cells in immature 
and mature UCB-DC and UCB-LC cultures analyzed by flow cytometry at day 18 and 21,
respectively are presented.
Culture
#
CD1a
(immature)
CD14
(immature)
CD14
(mature)
UCB-DC UCB-LC UCB-DC UCB-LC MoDC UCB-DC UCB-LC
1 12 42.9 15.0 6.2 17.0 1.4 0.2
2 34.5 39.5 5.8 4.1 1.0 3.0 1.0
3 46.2 52.5 4.7 3.5 8.3 7.2 2.6
Supplementary Figure S2. CMV-antigen speciﬁc T cell stimulatory capacity of 
UCB-DC and UCB-LC in comparison with MoDC in vivo. (A) The experimental scheme.
(B) Engraftment of human CD3+ T cells in PB of NOD-SCID-IL2Rф-/- mice. The data shown are 
mean ± SEM of 6 mice tested per group. NOD-SCID-IL2Rф-/- mice were injected i.p. with 3.5x106
PBL isolated from HLA-B7+ CMV+ donor buffy coat. 4 hours after PBL injection, 4 groups of 6
mice were treated with either PBS or CMV pp65 peptide loaded MoDC, UCB-DC or UCB-LC 
(2x105, i.p.). Additional booster injections of PBS or CMV pp65 peptide loaded DC subsets 
(1x105, i.p.) were given at day 7 and 14. At day 21, mice were sacrificed, blood and spleen samples 
were collected to evaluated the frequency of CMV-specific T cells by flow cytometry after 
staining the samples with mouse CD45, human CD45, human CD8 and CMV tetramer.
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Abstract
The superiority of dendritic cells (DCs) as antigen-presenting cells has been exploited 
in numerous clinical trials, where generally monocyte-derived DCs (MoDCs) are 
injected to induce immunity in patients with cancer or infectious diseases. Despite
promising expansion of antigen-specific T cells, the clinical responses following
vaccination have been limited, indicating that further improvements of DC vaccine 
potency are necessary. Pre-clinical studies suggest that vaccination with combination
of primary DC subsets, such as myeloid and plasmacytoid blood DCs (mDCs and pDCs,
respectively), may result in stronger clinical responses. However, it is a challenge to
obtain high enough numbers of primary DCs for immunotherapy, since their frequency 
in blood is very low. We therefore explored the possibility to generate them from
hematopoietic stem and progenitor cells (HSPCs). Here, we show that by inhibiting the 
aryl hydrocarbon receptor with its antagonist StemRegenin-1 (SR1), clinical-scale 
numbers of functional BDCA2+BDCA4+ pDCs, BDCA1+ mDCs and BDCA3+DNGR1+
mDCs can be efficiently generated from human CD34+ HSPCs. The ex vivo-generated 
DCs were phenotypically and functionally comparable to peripheral blood DCs. They 
secreted high levels of pro-inflammatory cytokines such as IFN-т, IL-12 and TNF-т and
upregulated co-stimulatory molecules and maturation markers following stimulation
with TLR ligands. Furthermore, they induced potent allogeneic T cell responses and
activated antigen-experienced T cells. These findings demonstrate that SR1 can be 
exploited to generate high numbers of functional pDCs and mDCs from CD34+ HSPCs, 
providing an alternative option to MoDCs for immunotherapy of patients with cancer 
or infections.
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Introduction
Dendritic cells (DCs) are specialized in capturing, processing and presenting antigens 
to T cells, and thereby play a crucial role in initiating and shaping immune responses.1
The prominent role of DCs in T cell activation is the rationale for DC-based 
immunotherapy of cancer and infectious diseases, while their tolerogenic potential is
being exploited in the recently developing field of DC-based therapy for auto-immune 
diseases.1-3 In cancer, DC vaccination therapy aims to induce tumor-specific T cell 
responses, and to develop immunological memory to control tumor relapse. So far, the 
vast majority of DC vaccination studies have been performed with DCs differentiated 
ex vivo from monocytes (MoDCs).4, 5 This strategy has been reported to induce the 
expansion of tumor-specific T cells in the majority of patients, however only a fraction 
of the patients develop clinical responses.2, 6 Various strategies to improve the 
potency of DC-based vaccines are being investigated, such as using natural occurring
DCs from peripheral blood or combining multiple DC subsets in one vaccine to provide
cross-talk.4, 7, 8
DCs form a heterogeneous population of cells, comprising several subsets with 
different phenotypes and functional properties. In human blood two main DC subsets 
can be defined; CD11c+ myeloid DCs (mDCs) and CD11c-CD123hiBDCA2+BDCA4+
plasmacytoid DCs (pDCs). The mDCs can be further divided into BDCA1 (CD1c)+ and 
BDCA3 (CD141)+DNGR1+ cells.2 These pDC and mDC subsets express a diverse set of 
pattern recognition receptors, including Toll-like receptors (TLRs), and secrete different
cytokines and induce diverse T cell responses following activation by pathogens.9
mDCs are, for example broadly responsive to microbial stimulation, where they 
upregulate co-stimulatory molecules and secrete cytokines such as IL-12 and TNF-т
following activation.10 On the contrary, pDCs play a crucial role in initiating anti-viral 
immunity by secreting high levels of type I interferons (IFN-т/у) in response to TLR7
and TLR9 ligation by viruses.11 Additional studies indicate that pDCs and mDCs interact
during the development of immune responses.12-14 For example, it has been shown
that activated pDCs strongly enhance the ability of mDCs to stimulate potent anti-tumor 
cytotoxic T lymphocyte (CTL) responses.8, 15, 16 Therefore, combining these naturally 
occurring DCs appears to be attractive strategy to exploit for DC-based therapy.
However, since the frequency of pDCs and mDCs in the blood is very low, it is a
challenge to obtain high enough numbers for immunotherapy. It would therefore be
advantageous if high numbers of DCs, which are phenotypically and functionally 
similar to blood pDCs and mDCs, could be generated from CD34+ hematopoietic stem
and progenitor cells (HSPCs).
Recent findings indicate that the aryl hydrocarbon receptor (AhR) not only regulates 
toxic effects of environmental contaminants, but also plays a role in modulating 
hematopoiesis and the immune system.17 For instance, Boitano et al. reported that 
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StemRegenin-1 (SR1), a small molecule inhibitor of AhR, promotes the ex vivo expansion 
of human CD34+ HSPCs that are able to effectively engraft immunodeficient mice.18
Furthermore, differentiation of Langerhans cells (LCs) and monocytes in vitro from 
HSPCs was inhibited by the addition of the AhR agonist VAF347.19 In light of these data,
we investigated whether it was possible to generate DC subsets from CD34+ HSPCs by 
supplementing SR1. We observed that SR1 explicitly and simultaneously induced the
ex vivo differentiation of pDCs, BDCA1+ and BDCA3+ mDCs. Importantly, SR1 induced 
the generation of high numbers of all these DC subsets, high enough to be included 
in clinical vaccination studies. Furthermore, these different DC subsets were
phenotypically and functionally comparable to their blood counterparts and potently
stimulated antigen-specific T cell. Therefore, our SR1 culture system not only allows
detailed study of DC differentiation and molecular regulations in vitro, but it also offers
the opportunity to evaluate the in vivo efficacy of a combined pDC and mDC vaccine
in patients with cancer, viral infections or auto-immune conditions. 
Methods
Ex vivo generation of DCs from CD34+ hematopoietic progenitor cells
Umbilical cord blood (UCB) was obtained at birth after normal full-term delivery with
written informed consent from the cord blood bank of the Radboud university medical 
center (Nijmegen, The Netherlands). Mononuclear cells from UCB were isolated by 
Ficoll-Hypaque (1,077 g/ml; GE Healthcare, Uppsala, Sweden) density gradient
centrifugation. Next, CD34+ cells were isolated from mononuclear cells using anti-CD34
immunomagnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany). A small 
aliquot of CD34+ cells was obtained from stem cell donors after the CliniMACS (Miltenyi 
Biotech) selection procedure of G-CSF-mobilized blood after written informed consent. 
The purity of the isolated CD34+ cells from UCB and G-CSF-mobilized blood was 71 ± 
12% (n=9) and 90 ± 5% (n=3), respectively. CD34+ cells were either used freshly or 
cryopreserved until use.
CD34+ cells were plated at 104-105 cells/ml in 24-well tissue culture plates (Corning 
Costar, NY, USA) in Glycostem Basal Growth Medium (GBGM, Glycostem Therapeutics, 
s’Hertogenbosch, The Netherlands) with 100 ng/ml of the following cytokines: 
thrombopoietin (TPO), stem cell factor (SCF), Flt3L (Cellgenix, Freiburg, Germany) and
IL-6 (ImmunoTools, Friesoythe, Germany). Additionally, CD34+ cells were cultured in 
the presence of 1 μM SR1 (Cellagen Technology, CA, USA), which was identified as the 
optimal dose in dose titration experiments (see Supplementary Figure S1). The AhR
agonist VAF347 (Exclusive Chemistry, Obninsk, Russia) was used in the concentrations
0.05-50 nM. Corresponding concentrations of DMSO (Merck, Darmstadt, Germany) 
were used as control. Fresh medium containing cytokines and compounds was added 
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every 2-4 days, and the cells were split upon confluence and transferred to 6-well 
plates (Corning Costar) if needed. Cells were cultured at 37˚C, 95% humidity and 5% 
CO2. The total number of viable cells was determined by trypan blue exclusion counting 
on day 7, 14 and 21. At each time-point a sample was taken for flow cytometry analysis, 
and absolute numbers of DCs were calculated by multiplying the frequency of DCs with
the absolute number of total cells generated from 105 CD34+ cells.
Isolation of peripheral blood (PB)- and HSPC-DCs
PB-DCs were isolated from buffy coats (Sanquin blood bank, Nijmegen, The
Netherlands) of healthy individuals after written informed consent. First, Peripheral
blood mononuclear cells PBMCs were purified using Ficoll-Hypaque density
centrifugation. Subsequently, non-DCs were depleted from PBMCs by negative
selection with anti-CD3/CD14/CD19 magnetic beads (Becton Dickinson, Franklin 
Lakes, NJ, USA) or with Pan-DC enrichment kit (Miltenyi Biotech). Next the negative 
fraction was labeled with BDCA1, BDCA3, BDCA4 (all from Miltenyi Biotech), CD14,
CD20 (both from Biolegend, CA, USA) and CD19 (Dako, Glostrup, Denmark) antibodies. 
Finally, pDCs, BDCA1+ mDCs and BDCA3+ mDCs were sorted on an EPICS Elite cell 
sorter (Beckman Coulter, Fullerton, CA, USA) or FACS Aria (Becton Dickinson) as
BDCA4+BDCA1-CD14-CD19-, BDCA1+BDCA3-CD14-CD19-CD20- and BDCA3+BDCA1-
CD14- CD19-CD20- cells, respectively.
HSPC-DCs were sorted from the whole bulk of cultured cells at day 21 of culture. First,
the cultured cells were incubated with 10-20% human serum (HS; PAA Laboratories, 
Austria) at 4˚C to block Fc receptors. Next, the cultured cells were stained with CD123
(Biolegend), CD14 (Beckman Coulter), BDCA2 (Miltenyi Biotech), BDCA1 and BDCA3 
antibodies and sorted with the FACS Aria for pDCs (CD14-CD123hiBDCA2+ cells),
BDCA1+ mDCs (CD14-CD123lowBDCA1+BDCA3- cells) and BDCA3+ mDCs (CD14-CD123low
BDCA3+BDCA1- cells). Purity of isolated PB- and HSPC-DCs was >90%.
Flow cytometry
Immunophenotypical analysis was performed by flow cytometry, where cells were first 
washed with PBS/0.5% BSA and subsequently stained with appropriate antibody
concentrations for 30 min at 4˚C. To determine the phenotype and maturation state of 
DCs, following antibodies and isotype controls were used: BDCA1, BDCA2, BDCA3 (all 
from Miltenyi Biotech), CD83, CD123, lineage cocktail (CD3, CD14, CD16, CD19, CD20,
CD56) (all from Becton Dickinson), CD11c, CD14, CD80, CD86, HLA-DR, mouse IgG1,
mouse IgG2b (all from Beckman Coulter), DNGR1, CCR7, mouse IgG2a (all from 
Biolegend,) and CD86 (Dako) antibodies. To evaluate T cell proliferation in mixed
lymphocyte reaction (MLR), cells were stained with CD3, CD8 (both from Beckman 
coulter) and CD4 (Biolegend) antibodies. For all analysis, live cells were gated based 
on forward scatter and side scatter characteristics. Additionally, in some experiments,
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SYTOX blue stain (Invitrogen, CA, USA) was used to further exclude dead cells from 
analysis. Furthermore, cell doublets were excluded based on signal pulse height
and width. Acquisition was performed with the Coulter FC500 flow cytometer or CyAn
ADP analyzer and data analysis was performed with Kaluza or CXP analysis software 
(all from Beckman Coulter).
DC stimulation with TLR ligands
Sorted HSPC-derived pDCs, BDCA1+ mDCs and BDCA3+ mDCs were resuspended in
IMDM (Invitrogen) supplemented with 10% FCS (Integro, Zaandam, The Netherlands),
1% penicillin and streptomycin (PS; MP Biomedicals, Ohio, USA) and seeded in a
96-well round bottom plate (Corning Costar). 10 ng/ml IL-3 or 800 IU/ml GM-CSF (both
from ImmunoTools) was additionally added to the medium for survival of the pDCs and 
mDCs, respectively. Next, pDCs were stimulated with 3.4 μg/ml CpG ODN 2216 (CpG-A)
or CpG ODN 2006 (CpG-B, both from Enzo Life Sciences, NY, USA) whereas mDCs 
were stimulated with 20 μg/ml Poly I:C (Sigma-Aldrich, St. Louis, USA) and 5 μg/ml 
R848 (Enzo Life Sciences). After overnight stimulation, IFN-т, IL-6, TNF-т and IL-12 
concentrations were measured in the supernatant by ELISA according to manufacturer’s
instructions (Human IFN-т Module set ELISA (Bender MedSystems GmbH, Vienna, 
Austria); Human IL-6 ELISA Ready-Set-Go (eBioscience); PeliPair human TNF-т ELISA
reagent set (Sanquin, Amsterdam, The Netherlands); IL-12 ELISA (Pierce Endogen,
Rockford, IL, USA)) and phenotypical maturation was evaluated by flow cytometry.
Allogeneic MLR
HSPC-pDCs and mDCs were harvested and washed after overnight stimulation with
 3.4 μg/ml CpG-B or 10 μg/ml Poly I:C, respectively. Subsequently, they were co-cultured
with allogeneic PBMCs from healthy donors that were labeled with 1.25 μM CFSE 
(Molecular Probes Europe, Leiden, The Netherlands) as described previously.20
Cocultures were performed at a 1:10 ratio (DC:PBMCs) in IMDM supplemented with 
10% FCS and 1% PS in 96-well round bottom plates in triplicate. After 4-5 days of 
co-culture, supernatant was collected for cytokine analysis (Th1/Th2/Th17 cytometric
bead array, Becton Dickinson) and T cell proliferation was quantified by flow cytometry
by evaluating the CFSE dilution within the CD3+CD4+ and CD3+CD8+ T cell populations.
Antigen-specific T cell activation
CD8+ T cells specific for the minor histocompatibility antigen LRH-1 or HA-1 were
isolated from PBMCs obtained from patients that had chronic myeloid leukemia and
were treated with allogeneic stem cell transplantation and pre-emptive donor 
lymphocyte infusion as previously described.21, 22 Sorted HSPC-DCs from HLA-B7+ or 
HLA-A2+ donors were loaded with 1 μM LRH-1 peptide (TPNQRQNVC, IHB-LUMC 
peptide synthesis facility, Leiden, The Netherlands) or HA-1 peptide (VLHDDLLEA, 
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IHB-LUMC peptide synthesis facility), respectively. After 1 hour incubation at 37˚C, 
LRH-1-specific CD8+ CTL culture RP1 or CD8+ HA-1-specific T cell bulk containing 38% 
HA-1 tetramer positive T cells were added. At the same time, 5 μg/ml R848 was added 
for the maturation of pDCs or 5 μg/ml R848 and 10 ug/ml Poly I:C for the maturation of 
mDCs. Co-cultures were performed at 1:1 ratio (104 DCs with 104 T cells/well) in
replicates of three or six in 96-well round bottom plates in 200 μl IMDM supplemented 
with 10% HS, 1% PS and 10 ng/ml IL-3 or 800 IU/ml GM-CSF for pDCs and mDCs, 
respectively. After 24 hour incubation, IFN-ф production was measured by ELISA
(Pierce Endogen).
RNA isolation and real-time quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from PB-DCs, HSPC-DCs and total PBMCs with the Quick-RNA 
MinPrep isolation kit (Zymo Research, CA, USA) according to the manufacturer’s 
protocol. cDNA synthesis and PCR amplification were performed as previously 
described.20 qRT-PCR reactions were run on an ABI 7900-HT real time PCR system
(Applied Biosystems, Bleiswijk, The Netherlands) with 2 μl of cDNA, 1xSYBR green PCR 
master mix (Invitrogen) and 300 nM of following primers: TLR3-Fw: AGTTGTCATCGAAT-
CAAATTAAAGAG TLR3-Rv: CATTGTTCAGAAAGAGGCCAAAT TLR4-Fw: 5’-GGCATGCCT-
GTGCTGAGTT-3’, TLR4-Rv: 5’-CTGCTACAACAGATACTACAAGCACACT-3’, TLR7-Fw: 5’-TG-
CCATCAAGAAAGTTGATGCT-3’, TLR7-Rv: 5’-GGAATGTAGAGGTCTGGTTGAAGAG-3’, TLR8-Fw: 
CGGAATGAAAAATTAGAACAACAGAA TLR8-Rv: GAACCAGATATTAGCAGGAAAATGC TLR9-Fw:
5’-TGAAGACTTCAGGCCCAACTG-3’, TLR9-Rv: 5’-TGCACGGTCACCAGGTTGT-3’, phorpho-
bilinogen deaminase (PBGD)-Fw: 5’-GGCAATGCGGCTGCAA-3’, PBGD-Rv: 5’-GGGTAC-
CCACGCGAATCAC-‘3. PBGD primers were purchased from Eurogentec (Maastricht, 
The Netherlands). mRNA expression of TLRs in DCs is depicted as ΔΔCt values and 
was quantified relative to mRNA expression in total PBMCs, which was set at 1. ΔΔCt 
was calculated as follows: 2^-(ΔCtpDCs – ΔCtPBMCs) in which ΔCt was normalized for 
PBGD by calculating ΔCt = Cttarget gene – CtPBGD per sample.
Statistics
 Statistical analysis was performed using GraphPad Prism 5.0. One-tailed paired
Student’s t-test or one-way or two-way ANOVA with repeated measures, followed by
 Bonferroni post-hoc test, was used, as indicated in figure legends. P-values <0.05 were
considered significant. 
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Results
The AhR antagonist SR1 induces ex vivo diﬀerentiation of pDCs and 
mDCs from human CD34+ HSPCs
To simultaneously generate sufficient numbers of pDCs and mDCs for use in DC 
vaccination therapy, we studied the effect of inhibiting AhR during ex vivo DC differen-
tiation. Therefore, UCB CD34+ HSPCs were cultured for three weeks with the early 
acting cytokines TPO, SCF, Flt3L and IL-6.23-25 Additionally, we cultured the cells with 1
μM SR1 or DMSO as control. Interestingly, addition of SR1 promoted the emergence of 
pDCs (CD11c-CD123hi BDCA2+ cells), BDCA1+ mDCs (Lin1-HLA-DR+BDCA1+BDCA3- cells)
and BDCA3+ mDCs (Lin1-HLA-DR+BDCA1-BDCA3+ cells) (Figure 1A). After three weeks of 
culture, the frequency of these DC subsets was significantly higher in cultures with SR1 
compared to control conditions; 2.9% vs. 0.04% for pDCs, 4.6% vs. 0.5% for BDCA1+
mDCs and 1.1% vs. 0.1% for BDCA3+ mDCs (Figure 1B). The average yield after three 
weeks of culture with SR1 starting from 105 CD34+ HSPCs was 3.8 x 106 pDCs, 5.3 x 106
BDCA1+ mDCs and 1.2 x 106 BDCA3+ mDCs (Figure 1C, Supplementary Table S1). 
Furthermore, SR1 promoted the differentiation of DC subsets from CD34+ cells obtained
from peripheral blood of G-CSF-mobilized donors (Figure 1D). The average frequency
of DCs in these SR1-cultures was 4.7%, 3.8% and 0.9% for pDCs, BDCA1+ and BDCA3+
mDCs, respectively (Figure 1E), which is comparable to the frequency obtained from 
UCB CD34+ cells. The expansion potential of G-CSF-mobilized blood CD34+ HSPCs was
lower than that of UCB CD34+ cells, resulting in average DC yields of 0.6 x 106, 0.5 x 106
and 0.1 x 106 from 105 CD34+ cells (Figure 1F, Supplementary Table S2).
During the three weeks culture period the total nucleated cells continuously expanded 
(Figure 2A). Analysis of pDC differentiation in time revealed that the maximum
frequency of pDCs was already reached at day 14 (Figure 2B). However, the absolute 
number of pDCs was highest on day 21 (Figure 2C). The antagonizing effect of SR1 on
AhR signaling is mediated through direct binding and inhibition of AhR.18
To proof a similar effect of SR1 in our experiments, we evaluated if the SR1-induced 
DC differentiation was indeed AhR-dependent by adding the AhR agonist VAF347. 
The frequency of pDCs was partially decreased by addition of 5 nM VAF347 to the 
SR1-cultures, but 50 nM of VAF347 completely blocked the differentiation of HSPCs 
into pDCs (Figure 2D). Addition of VAF347 to the SR1-cultures did not inhibit the 
proliferation of total cells (Figure 2E). Collectively, these data demonstrate that the 
AhR pathway is a negative regulator of DC differentiation, and that by using SR1 
together with early acting cytokines, high numbers of pDCs, BDCA1+ and BDCA3+
mDCs can be generated from UCB and G-CSF-mobilized HSPCs ex vivo.
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SR1-generated HSPC-DCs have phenotypical and functional
characteristics of PB-DCs
Next, we assessed the phenotype and function of DCs generated in the presence of 
SR1 (Figure 3A). Similar to their naturally occurring counterparts in blood, we observed 
that the three different HSPC-DC subsets were negative for the monocyte marker CD14, 
while they all expressed HLA-DR. On the other hand, their expression of CD11c was 
diverse; HSPC-pDCs were negative for CD11c, while DNGR1+BDCA3+ mDCs expressed
CD11c. In contrast, only a fraction of the HSPC-BDCA1+mDCs expressed CD11c. Similar 
to their in vivo counterparts, the HSPC-pDCs selectively expressed BDCA2, while the
HSPC-BDCA3+ mDCs uniquely expressed DNGR1. HSPC-pDCs additionally expressed 
BDCA4, CD4, CD45RA and CD62L (supplementary Table S3) similarly as PB-pDCs.11, 26
Figure 1. Eﬀect of AhR antagonist SR1 on diﬀerentiation of pDCs, BDCA1+ mDCs 
and BDCA3+ mDCs from HSPCs. (A-C) UCB or (D-F) G-CSF mobilized CD34+ cells were
cultured for three weeks with 1 μM SR1 or 0.01% DMSO (control) after which the occurrence of 
pDCs and mDCs was evaluated by flow cytometry. (A,D) Dot plots show the percentage of pDCs 
(CD123hi), BDCA1+ mDCs and BDCA3+ mDCs within the total population of live cells. pDCs are
gated as CD11c- cells and mDCs as lineage marker-, HLA-DR+ cells. mDCs are further defined as 
single positive for either BDCA1 or BDCA3. (B,E) Frequency within total cultured cells, and (C,F)
total yield from 105 UCB CD34+ cells of pDCs, BDCA1+ mDCs and BDCA3+ mDCs. Data are 
depicted as mean ± SEM of 3-5 independent donors tested. Statistical analysis was performed 
with one-tailed paired Student’s t-test. *P<0.05, **P<0.01.
A
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To further characterize the HSPC-DCs, we isolated pDCs, BDCA1+ mDCs and BDCA3+
mDCs by cell-sorting on day 21 of culture and evaluated their TLR expression. PB-DCs
were sorted from healthy individuals for comparison. In line with published results,9, 27
we observed that both HSPC-pDCs and PB-pDCs had the highest expression of TLR7
and TLR9 (Figure 3B). In addition we observed that BDCA3+ mDCs, derived from HSPCs
or PB, had the highest expression of TLR3 of all the different DC subsets. However, the
expression of TLR3 was in general lower in HSPC-DCs than PB-DCs. TLR8 expression 
was highest in BDCA1+ mDCs, followed by BDCA3+ mDCs and lowest in pDCs. Similarly, 
the TLR4 expression was highest in BDCA1+ mDCs, however the expression was in 
generally low as it is depicted relative to total PMBCs, which contain high proportion
of TLR4-expressing monocytes.
Subsequently, phenotypical maturation and cytokine secretion by sorted HSPC-DCs in
response to TLR stimulation was analyzed. For that reason, HSPC-pDCs were cultured 
overnight with two different CpG oligonucleotide ligands, CpG-A or CpG-B, while 
HSPC-mDCs were stimulated with a combination of Poly I:C and R848. In addition, IL-3 
Figure 2. Time kinetics and AhR involvement in pDC diﬀerentiation. For panels 
A-C, CD34+ UCB cells were cultured for three weeks with 1 μM SR1 or 0.01% DMSO (control). 
Total cell number was determined at day 7, 14 and 21 and the frequency of pDCs was evaluated
at each time point by flow cytometry. (A) Fold increase of total nucleated cells in the cultures.
(B) Frequency of pDCs (CD123hi cells) at each time point and (C) total number of pDCs generated 
from 105 CD34+ HSPCs. For panels D-E, CD34+ UCB cells were cultured for three weeks with 1 μM 
SR1 and titrated concentrations of VAF347. At day 21, (D) the frequency of pDCs within the total 
cultured cells was evaluated by flow cytometry and (E) the fold increase of total nucleated cells
in the culture was determined on day 7, 14 and 21. Data are expressed as mean ± SEM of results 
from 5 (A-C) or 2 (D-E) UCB donors. Statistical analysis was performed using two-way repeated 
measures ANOVA (A-C) or one-way repeated measures ANOVA (D) followed by a Bonferroni 
post-hoc test. *P<0.05, **P<0.01, ***P<0.001.
A
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Figure 3. Phenotype of DCs derived from HSPCs in SR1 cultures. (A) CD34+ UCB 
cells were cultured for three weeks with 1 μM SR1 after which the expression of HLA-DR, CD11c,
CD14 and the DC specific markers, BDCA1, BDCA2, BDCA3 and DNGR1 on HSPC-DCs was
evaluated by flow cytometry. Dot plots are representative of cultures from at least 5 different
UCB donors and gated on live cells or live cells and CD14- cells as indicated in the figure. (B)
pDCs, BDCA1+ and BDCA3+ mDCs were sorted by flow cytometry from SR1 cultures at day 21
(HSPC-DCs n=4) or peripheral blood (PB-DCs, n=3). mRNA was extracted and expression of 
TLR3, TLR4, TLR7, TLR8 and TLR9 was determined by qRT-PCR. Expression was normalized to 
the housekeeping gene phorphobilinogen deaminase (PBGD), and is shown relative to that of 
PBMCs, which was set at 1.
A
B
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and GM-CSF was added to all conditions for pDCs and mDCs respectively, as we
observed that it enhanced their survival and activation (data not shown). Directly 
following sorting and before overnight culture, the DCs did not express CD80, CD86, 
CD83 or CCR7 (data not shown) and had intermediate levels of HLA-DR (Figure 3A). 
However, as seen in Figure 4A, the majority of HSPC-DC subsets upregulated 
co-stimulatory molecules and maturation markers upon TLR stimulation, and all of 
them highly expressed HLA-DR. We additionally observed that in the presence of IL-3 
or GM-CSF alone (medium), the DCs expressed low levels of CD80, CD86, CD83 and
CCR7 (Figure 4B, Supplementary Figure S2), but highly upregulated them upon
TLR-ligation. The only exception was CD80 on BDCA1+ mDCs, which was expressed to 
the same level with or without TLR stimulation (Figure 4B, Supplementary Figure S2).
Finally, we assessed the cytokine secretion by TLR-stimulated HSPC-DCs. HSPC-pDCs
activated with CpG-A secreted high levels of IFN-т and moderate amounts of TNF-т
and IL-6, while CpG-B-activated HSPC-pDCs secreted both IL-6 and TNF-т, but no
IFN-т (Figure 5A). This is in line with previous reports on responses of PB-pDCs to
different classes of CpG.28, 29 Furthermore, HSPC-pDCs also responded to R848 by 
secreting IFN-т and upregulating co-stimulatory molecules (data not shown). 
HSPC-BDCA1+ mDCs secreted TNF-т in response to TLR stimulation (Figure 5B) but no 
IL-12, while HSPC-BDCA3+ mDCs secreted both TNF-т and IL-12 (Figure 5C). Collectively, 
these data demonstrate that pDCs, BDCA1+ mDCs and BDCA3+ mDCs generated ex 
vivo by culturing CD34+ HSPCs with SR1 display similar phenotype and functional 
properties as PB-DCs.
HSPC-DCs are potent inducers of allogeneic T cell responses
To determine the T cell stimulatory capacity of HSPC-derived DCs, we performed 
allogeneic MLR assays where HSPC-pDCs, BDCA1+ mDCs and BDCA3+ mDCs were
matured overnight and subsequently co-cultured with CFSE-labeled PBMCs from 
allogeneic donors for 4-5 days. All the different HSPC-DC subsets induced robust
proliferation of both CD4+ and CD8+ T cells (Figure 6A,B). In addition, allogeneic T cells 
stimulated with HSPC-DCs secreted both IFN-ф and IL-2 (Figure 6C,D), while IL-4, TNF- т
and IL-17 were non-detectable and the concentrations of IL-10 were low in the 
supernatant (data not shown). These data show that the SR1-induced HSPC-DCs are 
potent inducers of allogeneic T cell responses.
Peptide-loaded HSPC-DCs induce activation of antigen-experienced T cells
In order to extend our observations of potent antigen-specific T cell activation by 
HSPC-DCs, we determined the level of IFN-ф produced by CD8+ T cells recognizing the
minor histocompatibility antigen LRH-1 or HA-1. Upon stimulation by HLA-B7+
HSPC-DCs loaded with LRH-1 peptide, LRH-1-specific CD8+ CTLs secreted significantly 
higher levels of IFN-ф than in response to non-peptide loaded DCs (Figure 7A). 
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Figure 4. Phenotypical maturation of HSPC-DCs with TLR agonists. pDCs, BDCA1+
and BDCA3+ mDCs were sorted by flow cytometry from SR1-cultured CD34+ cells at day 21 of 
culture and stimulated overnight with TLR agonists. Expression of maturation and co-stimulatory
molecules was evaluated by flow cytometry. (A) Histograms show expression of CD80, CD86, 
CD83, CCR7 and HLA-DR (black line) versus isotype control (grey line) for pDCs stimulated with 
CpG-B and BDCA1+ and BDCA3+ mDCs stimulated with R848 and Poly I:C. (B) The mean
fluorescent intensity (MFI) of CD80, CD86, CD83, CCR7 and HLA-DR for non-TLR stimulated and 
TLR-stimulated pDCs, BDCA1+ and BDCA3+ mDCs. All conditions were supplemented with IL-3 or 
GM-CSF for survival of pDCs and mDCs, respectively. Data depict mean ± SEM of results from
four (pDCs), two (BDCA1+ mDCS) or one (BDCA3+ mDCs) UCB donor.
A
B
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Furthermore, concurrent maturation of the DCs with TLR ligands significantly enhanced
the ability of the HSPC-DCs to activate IFN-ф secreting CD8+ T cells. Similarly, HA-1+
HLA-A2+ HSPC-DCs loaded with extra HA-1 peptide were used as stimulators of 
HA-1-specific T-cells. Activation of HA-1-specific T cells was higher in response to 
HSPC-DCs loaded with the HA-1 peptide than to HSPC-DCs without exogenous peptide
(Figure 7B), and the T cell activation was additionally potentiated by TLR-induced
maturation of pDCs. These data demonstrate that peptide-loaded HSPC-pDCs can 
effectively activate antigen-experienced T cells.
Figure 5. Cytokine secretion by HSPC-DCs in response to TLR agonists. pDCs,
BDCA1+ and BDCA3+ mDCs were sorted by flow cytometry from SR1-cultured CD34+ cells at day
21 of culture and stimulated overnight with TLR ligands. Concentrations of cytokines in the 
supernatant was measured by ELISA. (A) Concentrations of IFN-т, IL-6 and TNF-т secreted by 
pDCs seeded at 105 cells/ml. Data depict mean ± SEM of 4 independent UBC donors. Statistical
analysis was performed using one-way repeated measures ANOVA followed by a Bonferroni
post-hoc test, comparing stimulated cells (CpG-A/CpG-B) with non-stimulated cells (medium). 
**P<0.01, ***P<0.001. (B) Concentration of TNF-т secreted by BDCA1+ mDCs seeded at 5 x 105
cells/ml. Data show mean ± SEM of 2 independent donors. (C) Concentration of TNF-т and IL-12
secreted by BDCA3+ mDCs seeded at 1.8 x 105 cells/ml. Data of 1 out of 3 independent 
experiments is shown and bars are depicted as mean ± SD.
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Figure 6. T cell stimulation capacity of HSPC-DCs in allogeneic mixed lymphocyte
reactions. HSPC-DCs from SR1-cultured UCB CD34+ cells were sorted by flow cytometry at day
21 and stimulated overnight with TLR ligands (CpG-B for pDCs and Poly I:C for BDCA1+ and
BDCA3+ mDCs). Subsequently the DCs were used as stimulators of CFSE-labeled PBMCs from 
healthy donors at a ratio of 1:10 (DC:PBMCs). Five days later the proliferation of T cells was 
analyzed by flow cytometry and IL-2 and IFN-фmeasured in the supernatant by cytometric bead 
array. (A) Dot plots depict the proliferation of CD3+CD4+ and CD3+CD8+ T cells of one 
representative PBMC donor out of four tested. (B) Average CD3+CD4+ and CD3+CD8+ T cell
proliferation of four different PBMC donors. (C-D) Average concentration of IL-2 (C) and IFN-ф (D)
in the supernatant of co-cultures with four different PBMC donors. Data are expressed as mean 
± SEM and show the results of one representative experiment out of two experiments conducted 
with different HSPC donors. Statistical analysis was performed with one-tailed paired Student’s 
t-test. *P<0.05, **P<0.01.
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Discussion
DC-based vaccination is an attractive strategy to boost T cell immunity in patients with 
cancer and infectious diseases. So far, the vast majority of clinical trials have been 
performed with MoDCs. However, due to sub-optimal clinical effects, further improvements
of DC vaccine potency are essential. One strategy is to use primary DC subsets isolated 
from blood, such as pDCs, BDCA1+ mDCs and BDCA3+ mDCs. Recently, it has been 
shown that pDCs can recognize, process and cross-present foreign antigens to CD8+ T 
cells, a quality important for generation of effective anti-tumor responses.30-32
A seminal study by Tel et al. showed that some metastatic melanoma patients that 
were vaccinated with antigen-loaded pDCs, could induce antigen-specific CD4+ and 
CD8+ T cell responses and anti-tumor immunity.7 Pre-clinical studies have shown that
pDCs induce anti-tumor immunity not only by direct priming and activation of 
Figure 7. Antigen-speciﬁc T cell activation by HSPC-DCs. (A) LRH-1- HSPC-DCs from 
HLA-B7+ donor were sorted from SR1-cultured G-CSF-mobilized CD34+ cells by flow cytometry
at day 21 and loaded with or without 1 μM LRH-1 peptide. Subsequently, the DCs were matured 
with TLR ligands as depicted in the figure in medium supplemented with IL-3 or GM-CSF for pDCs 
and mDCs, respectively. Next, the DCs were co-cultured with CTLs specific for LRH-1 (RP1) at an
1:1 ratio. 24 hours later the concentration of IFN-ф was measured in the supernatant by ELISA.
(B) Similarly, HLA-A2+, HA-1+ HSPC-DCs were loaded with 1 μM HA-1, matured with TLR ligands
and used as stimulators for HA-1-specific CD8+ T cell bulk. Bars depict mean values ± SD. 
Statistical analysis was performed using one-way repeated measures ANOVA followed by a
Bonferroni post-hoc test. *P<0.05, **P<0.01, ***P<0.001.
A
B
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tumor-specific T cells, but also by the high amounts of type I interferons they secrete, 
which enhances cross-priming capacity of other DC subsets, and induces activation of 
NK cells.33-35 In addition, pDCs also interact with mDCs through cell-cell contact, such 
as by the CD40-CD40L axis, further enhancing the T cell stimulation capacity of 
mDCs.16 The therapeutic potential of this cross-talk between DC subsets has been
investigated in murine tumor models. For instance, Nierkens et al. published that
immunization of mice with mDCs activated in the presence of pDCs facilitated tumor 
clearance due to enhanced cross-priming capacity of the mDCs.8 Furthermore, Lou
et al. reported that immunization of mice with a combination of activated pDCs and 
mDCs resulted in increased levels of antigen-specific CD8+ T cells and enhanced 
anti-tumor response compared with immunization with either DC subset alone.15
These studies indicate that combination of pDCs and mDCs for DC-based immuno-
therapy would result in more favorable responses. 
Our novel SR1-based culture method demonstrates simultaneous generation of high
amounts of pDCs, BDCA1+ and BDCA3+ mDCs from UCB and G-CSF mobilized CD34+
HSPCs. We demonstrated that the HSPC-derived DCs were phenotypically and 
functionally similar to their naturally occurring counterparts found in blood. The 
HSPC-pDCs expressed both BDCA2 and BDCA4 which are surface-antigens specifically 
found on pDCs.26 Furthermore, they highly expressed TLR7 and TLR9 and responded
to stimulation with corresponding TLR-ligands by secreting high amounts of IFN-т, IL-6 
and TNF-т and upregulating co-stimulatory molecules and maturation markers. The 
HSPC-derived BDCA3+ mDCs exclusively expressed DNGR1, a C-type lectin receptor 
which mediates antigen uptake and cross-presentation by BDCA3+ mDCs.36, 37 These 
DCs responded to R848 and Poly I:C-stimulation by secretion of both TNF-т and IL-12 
and phenotypical maturation. BDCA1+ mDCs on the other hand did not secrete IL-12 in 
response to these TLR-ligands, which is in contrast to what has been described in the
literature for their in vivo counterparts.27, 38 Furthermore, only a portion of HSPC-BDCA1+
mDCs expressed CD11c, while BDCA1+ mDCs in blood all express CD11c.26 The lack of 
IL-12 secretion by BDCA1+ mDCs and heterogenous CD11c expression might indicate
that they are more immature than the other two DC subsets found in the culture, and 
require an additional maturation stimulus with for example GM-CSF. Nevertheless, the
BDCA1+ mDCs did potently activate antigen-specific T cells secreting high levels of 
IFN-ф, just as the other two DC subsets, indicating that their immune-stimulatory 
capacity is not impaired. 
Previously, various in vitro culture systems have been developed for understanding
the molecular regulations of DC development from human HSPCs and for generating 
DCs for immune-based therapies.23, 24, 37, 39-41 Recently, Poulin et al. reported that
functional BDCA3+DNGR1+ mDCs could be generated from human HSPCs, by first 
expanding HSPCs for 7-11 days and then differentiating them with Flt3L, SCF, GM-CSF 
and IL-4 in medium supplemented with FCS for an additional 12-14 days.37 On the other 
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hand, Blom et al. were the first to describe the ex vivo generation of pDCs, where Flt3L 
alone was sufficient for inducing the differentiation of pDCs from CD34++CD45RA-
hematopoietic stem cells.24 Later, Chen et al. reported that TPO acts in synergy with
Flt3L in expanding and differentiating CD11c-CD123+ pDCs from CD34+ HSPCs in vitro.23
Another group later described that culturing G-CSF-mobilized CD34+ HSPC with TPO 
and Flt3L additionally resulted in the differentiation of CD11c-CD123+, CD1c/b+ and 
DNGR1+ DCs.40 However, their numbers of DCs generated were generally low, and the 
supposed pDC population showed low CD123 expression and secreted relatively low 
levels of IFN-т. Furthermore, the DNGR1+ mDCs found in their culture did not express 
BDCA3.40 According to our DC culture protocol, we would be able to simultaneously 
generate 75 x 106 pDCs, 100 x 106 BDCA1+ mDCs and 25 x 106 BDCA3+ mDCs under 
serum-free conditions, given that on average 2 x 106 CD34+ cells can be isolated from 
one UCB unit.42 Moreover, since our culture protocol can also be applied to G-CSF-
mobilized blood CD34+ cells, the clinical application of SR1-induced HSPC-DCs can be 
expanded to both autologous and allogeneic settings. From 10 x 106 G-CSF-mobilized
CD34+ cells, 50 x 106 pDCs, 50 x 106 BDCA1+ mDCs and 10 x 106 BDCA3+ mDCs could
be generated. To the best of our knowledge this is the highest reported number of 
BDCA2+BDCA4+ pDCs, BDCA1+ mDCs and BDCA3+DNGR1+ mDCs that can be 
simultaneously generated ex vivo from CD34+ HSPCs, and additionally exceeds the
numbers that can be isolated from peripheral blood. However, additionally to an initial
CD34+ HSPC selection, our expansion protocol requires a 3-week culture in a clean 
room facility and several GMP-grade cytokines and SR1. But, paralleled isolation of 
BDCA4+ pDC and BDCA1+ mDC requires expensive magnetic bead isolation procedures. 
Furthermore, magnetic beads for isolating BDCA-3+DNGR1+ mDCs are currently not 
available. In addition, generating DCs ex vivo from HSPCs offers additional advantages, 
for example the possibility to manipulate the cells during differentiation, such as 
silencing their expression of co-inhibitory molecules. Such modulations could even
result in stronger anti-tumor responses, as it has been published that siRNA silencing
of the co-inhibitory molecules PD-L1 and PD-L2 on MoDCs augments expansion and
function of antigen-specific T cells.43
In this study, the different DC subsets were generated by culturing CD34+ HSPCs with 
Flt3L, SCF, TPO, IL-6 and the AhR antagonist SR1. The AhR has been extensively studied 
through the years, in AhR knockout mice and in the context of activation by environmental
contaminants. These studies demonstrate that AhR is involved in hematopoiesis and 
modulates immune responses in various mouse models of infectious and auto-immune 
diseases.44 Notably, HSPCs, DCs and T cells express high levels of AhR compared to 
other immune cells.45 Studies focused on T cell and DC functionality show that AhR 
activation differentially modulates their function, depending on the source of the cells
and the AhR ligands used.46 Furthermore, AhR function has shown to regulate the 
balance between proliferation and quiescence of hematopoietic stem cells (HSCs).
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Young AhR knockout mice have increased numbers of HSCs with higher proliferation 
rate than stem cells from wild type mice. This is also reflected in higher numbers of 
white blood cells in bone marrow, spleen and blood of AhR knockout mice.47-50
The same effect was reported for human HSPCs by Boitano et al., demonstrating 
that culturing CD34+ cells with SR1 strongly promotes their proliferation rate.18 With a 
comparable culture protocol, we now demonstrate for the first time that inhibition of 
human AhR promotes the differentiation of human pDC and mDC subtypes from CD34+
HSPCs. In line with our findings, Liu et al. recently reported that AhR knockout mice 
have a higher frequency and absolute numbers of pDCs in spleens and lymph nodes 
compared to wild type mice.51 In contrast, they found no differences in the proportion
and absolute numbers of CD11chiCD11b+I-Ab+ mDCs. Vorderstrasse et al. similarly
reported in 2001, that the number of splenic CD11chi mDCs was not significantly 
different between AhR knockout and wild type mice.52 These findings suggest that DC
differentiation might be differently regulated by AhR in mice and humans. Since there
is also increasing evidence for dysregulation of DC subtypes in distinct auto-inflam-
matory diseases, such as rheumatoid arthritis, systemic lupus erythematosus and 
psoriasis,53-55 it is also tempting to speculate whether interfering with the AhR pathway 
could dampen the mDC and pDC activation status in these diseases.
In conclusion, we show that SR1 strongly promotes differentiation of BDCA2+BDCA4+
pDCs, BDCA1+ and BDCA3+DNGR1+ mDCs from CD34+ HSPCs. The SR1-induced HSPC-DCs
are phenotypically and functionally comparable to their naturally occurring counter- 
parts in blood and induce strong antigen-specific T cell responses. This culture system 
allows the generation of clinical-scale numbers of pDCs and mDCs relevant for 
DC-immunotherapy of cancer patients and patients with chronic infectious diseases. 
Furthermore, this protocol can be used for investigating molecular pathways driving
aberrant DC development and function which has been shown to be instrumental for 
the pathogenesis of various auto-immune disorders.
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3Supplementary Figure S1. Titration of SR1. UCB CD34+ cells were cultured with TPO, SCF, 
Flt3L and IL-6 as well as titrated concentration of SR1 (0.1-2μM) and the frequency of pDCs 
(CD11c-CD123hiBDCA2+) was evaluated by flow cytometry at day 21. Data are expressed as mean 
± SEM of two UCB donors.
Supplementary Figure S2. Phenotypical maturation of HPC-DCs. pDCs, BDCA1+ and
BDCA3+ mDCs were sorted by flow cytometry from SR1-cultured CD34+ cells at day 21 of culture
and stimulated overnight with TLR agonists. Expression of CD80, CD86, CD83, CCR7 and HLA-DR 
was evaluated by flow cytometry and is depicted as % positive cells for non-TLR stimulated and
TLR-stimulated pDCs, BDCA1+ and BDCA3+ mDCs. All conditions were supplemented with IL-3 or 
GM-CSF for survival of pDCs and mDCs, respectively. Data depict mean ± SEM of results from
four (pDCs), two (BDCA1+ mDCS) or one (BDCA3+ mDCs) UCB donor.
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Abstract
Potent immunotherapies are urgently needed to boost anti-tumor immunity and 
control disease in cancer patients. As dendritic cells (DCs) are the most powerful
antigen-presenting cells, they are attractive means to reinvigorate T cell responses. 
An appealing strategy to employ the effective antigen processing and presentation 
machinery, T cell stimulation and cross-talk capacity of natural DC subsets is in vivo
tumor antigen delivery. In this context, endocytic C-type lectin receptors are attractive 
targeting molecules. In this study, we investigated whether CLEC12A efficiently delivers 
tumor antigens into human DC subsets, facilitating effective induction of CD4+ and 
CD8+ T cell responses. We confirmed that CLEC12A is selectively expressed by myeloid 
cells, including myeloid DC subsets (mDCs) and the plasmacytoid DC subset (pDCs). 
Moreover, we demonstrated that these DC subsets efficiently internalize CLEC12A, 
whereupon it quickly translocates to the early endosomes and subsequently routes to 
the lysosomes. Notably, CLEC12A antibody targeting did not negatively affect DC 
maturation or function. Furthermore, CLEC12A-mediated delivery of keyhole limpet
hemocyanin (KLH) resulted in enhanced proliferation and cytokine secretion by
KLH-experienced CD4+ T cells. Most importantly, CLEC12A-targeted delivery of HA-1 
long peptide resulted in efficient antigen cross-presentation by mDCs and pDCs, 
leading to strong ex vivo activation of HA-1-specific CD8+ T cells of patients after 
allogeneic stem cell transplantation. Collectively, these data indicate that CLEC12A is 
an effective new candidate with great potential for in vivo antigen delivery into mDCs
and pDCs, thereby using the specialized functions and cross-talk capacity of these DC
subsets to boost tumor-reactive T cell immunity in cancer patients.
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Introduction
The prominent role of dendritic cells (DCs) in orchestrating immune responses has 
provided the rationale for the development of DC-based strategies to boost anti-tumor 
immune responses in cancer patients.1 DCs are the most powerful antigen-presenting 
cells (APCs) and efficiently initiate and reactivate CD4+ and CD8+ T cell responses.2
Importantly, they have the unique capacity to cross-present extracellular antigens, 
including tumor antigens, in human leukocyte antigen (HLA) class I molecules to CD8+
T cells.3, 4 Upon tumor antigen presentation and co-stimulation by the DCs, tumor-
reactive T cells become activated, expand and attack tumor cells. Moreover, long-
lasting memory against recurrent disease is formed. Importantly, tumor regression 
has been observed following DC-based vaccination in patients with hematological 
cancers.5-7 In addition, productive T cell responses could be boosted by DC vaccination of 
patients treated with allogeneic stem cell transplantation (allo-SCT).8-11 In this context,
T cells could be directed against tumor antigens or recipient-specific allo-antigens 
restricted to hematological tumor cells, known as minor histocompatibility antigens
(MiHA).12, 13
Nevertheless, we and others have observed that often the induction and/or reactivation 
of anti-tumor immune responses is inadequate, contributing to disease progression or 
relapse.14 This observation illustrates the urgency to develop alternative DC-based 
strategies to more effectively boost anti-tumor immunity. One such strategy involves 
the exploitation of the powerful antigen presentation capacity of natural DC subsets 
by in vivo tumor antigen delivery. Two key populations of human DCs are myeloid DCs 
(mDCs) and plasmacytoid DCs (pDCs).15 mDCs are further subdivided based on surface 
expression of BDCA1+ (CD1c) and BDCA3+ (CD141). Each DC subset has its specialized 
function in the induction and maintenance of immune responses.16 Notably, pre-clinical
studies indicate that simultaneous engagement and cross-talk of multiple DC subsets
is important for generating more potent and broader anti-tumor responses.17-19
Attractive cell surface molecules for antibody-mediated in vivo tumor antigen delivery 
into DC subsets are the endocytic C-type lectin receptors (CLRs).20-25 CLRs are pattern-
recognition receptors that mediate recognition and uptake of pathogens, as well as 
antigens exposed or released upon cell death. Furthermore, their ligation can induce 
intracellular signaling pathways regulating DC function. In this study, we investigated 
the potential of a relatively unexplored CLR, C-type lectin domain family 12 member A 
(CLEC12A), as antigen delivery receptor. CLEC12A is also known as myeloid inhibitory 
C-type lectin-like receptor (MICL), C-type lectin-like molecule-1 (CLL-1), dendritic-cell-
associated C-type lectin 2 (DCAL-2) and CD371. Notably, CLEC12A is an attractive 
candidate, as it is broadly expressed by all human DC subsets.26 The function of 
CLEC12A has not been fully elucidated, although recently Neumann et al. found 
CLEC12A to be involved in the control of sterile inflammation by neutrophils.27 They 
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identified that CLEC12A binding to uric acid crystals, released by dying cells, inhibits 
neutrophil-derived reactive oxidant species production, thereby reducing infiltration
of immune cells to the site of damage. More recently, CLEC12A was reported to be 
involved in microbial defense in myeloid cells, in particular in bacterial autophagy.28
It was postulated that CLEC12A is involved early during bacterial autophagy at
the level of pathogen recognition initiated upon membrane damage. Notably, Chen 
et al. demonstrated that targeting of human monocyte-derived DCs (MoDCs) with 
тCLEC12A antibody modulated Toll-like receptor (TLR)-mediated maturation and
cytokine secretion.29 In addition, Lahoud et al. have proposed CLEC12A as a potential
target for specific antigen delivery.30, 31 They showed in vivo induction of OVA-specific
CD4+ and CD8+ T cell responses after administration of OVA-conjugated CLEC12A 
antibody in mouse models. Yet, still little is known about CLEC12A’s internalization 
mechanism, intracellular routing and fate, and most importantly whether CLEC12A can 
efficiently facilitate antigen cross-presentation by human DC subsets. Our aim was to
acquire insight into these mechanisms and to explore CLEC12A’s potential for targeted 
antigen delivery into human DCs to promote CD4+ and CD8+ T cell responses. In this
study, we validated the discriminative expression pattern of CLEC12A, and showed
that it is efficiently internalized by human BDCA1+ mDCs, BDCA3+ mDCs and pDCs
upon targeting with specific antibodies. We observed that CLEC12A initially translocates 
to the endosomes, whereupon it quickly routes to the lysosomes. Notably, CLEC12A 
antibody binding did not negatively affect DC phenotype or allogeneic T cell stimulation 
capacity. Importantly, we showed that antigens delivered via CLEC12A are efficiently 
processed by DCs and (cross-)presented to antigen-experienced T cells. These findings 
demonstrate that CLEC12A is an appealing targeting receptor for selective in vivo
delivery of tumor antigens into mDC and pDC subsets to boost tumor-reactive immune 
responses in cancer patients.
Material and Methods
Patient and donor material
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donor buffy 
coats (Sanquin, Nijmegen, the Netherlands) or from leukapheresis products using
Ficoll-Hypaque density centrifugation. PBMCs containing keyhole limpet hemocyanin 
(KLH)-specific T cells were obtained from multiple myeloma patients following
vaccination with KLH-pulsed tumor antigen-presenting DCs. PBMCs containing HA-1 
specific T cells were obtained from patients after allo-SCT.9, 10 Pre-vaccination 
leukapheresis material was used to isolate BDCA1+ mDCs, BDCA3+ mDCs and pDCs, 
and culture MoDCs. All material of patients and healthy donors was obtained after 
written informed consent, according to institutional guidelines.
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DC isolation and culture
To generate MoDCs, monocytes were isolated from PBMCs via plastic adherence in 
tissue culture flasks (Greiner Bio-One, Alphen a/d Rijn, the Netherlands) and cultured
in X-VIVO 15 medium (Lonza, Verviers, Belgium) supplemented with 2% human serum 
(HS; PAA laboratories, Pasching, Austria), 500 U/ml IL-4 and 800 U/ml GM-CSF (both 
Immunotools, Friesoythe, Germany). At day 3, immature MoDCs were harvested and
directly used in experiments or routinely matured for 48 hours with 500 U/ml IL-4, 800 U/ml
GM-CSF, 5 ng/ml IL-1ß, 15 ng/ml IL-6, 20 ng/ml TNF-т (all Immunotools), and 2.5 μg/ml
PGE2 (Pfizer; conventional cytokines).
PBMCs containing naturally occurring BDCA1+ mDCs, BDCA3+ mDCs and pDCs were 
labeled with fluorophore-conjugated CD11c, BDCA1, BDCA2, BDCA3 and CD123
antibodies (all Biolegend, CA, USA). Subsequently, CD11c+BDCA1+ mDCs, CD11c+BDCA3+
mDCs and CD123+BDCA2+ pDCs (Supplementary figure S1A) were sorted using the 
ARIA SORP (Becton Dickinson, Franklin Lakes, NJ, USA) with >95% purity. BDCA1+ and
BDCA3+ mDCs were matured with 800 U/ml GM-CSF, 10 μg/ml Poly(I:C) (Sigma Aldrich) 
and 5 μg/ml R848 (Enzo Life Sciences, Raamsdonkveer, the Netherlands), and pDCs
with 10 ng/ml IL-3 (Immunotools) and 5 μg/ml R848.
Expression and internalization
CLEC12A and DEC205 expression and their internalization capacity was analyzed by 
flow cytometry. Healthy donor PBMCs or day 3 MoDCs were incubated for 30 minutes
with 10 μg/ml CLEC12A antibody (clone 687317, R&D systems Minneapolis MN, USA) or 
mIgG2b isotype control (Biolegend) at 4°C. Subsequently, cells were incubated for 
0-90 minutes at 37°C to allow endocytosis. Then, goat anti-mouse Alexa-Fluor 647
(Life Technologies, Carlsbad, CA, USA) was added. To inhibit clathrin-mediated
endocytosis, cells were incubated in hypertonic 450mM sucrose solution (Boom,
Meppel, the Netherlands).32 Blockade of clathrin-mediated uptake was reversed by 
sucrose washout and resuspension in PBS. Subsequently, cells were labeled with 
fluorophore-conjugated BDCA1, BDCA2, BDCA3, CD123, CD11c antibodies (Miltenyi 
Biotec, Bergisch Gladbach, Germany; BD or Biolegend). DCs were analyzed on a CyAn
ADP or a Gallios flow cytometer (both Beckman Coulter) and gated as CD11c+BDCA1+
mDCs, CD11c+BDCA3+ mDCs and BDCA2+CD123+ pDCs (Supplementary figure S1B).
Data was analyzed with Kaluza V1.3 (Beckman Coulter).
Intracellular routing
To study CLEC12A internalization and investigate its intracellular routing, day 3 MoDCs 
were adhered to RetroNectin-coated (Takara, Otsu, Japan) coverslips. After blocking
Fc-receptors with total human IgG (hIgG; Sanquin) and goat serum (CDL, Nijmegen, the 
Netherlands), MoDCs were incubated for 30 minutes with 10 μg/ml CLEC12A antibody 
(mIgG2b, clone 687317, R&D systems) or DEC205 antibody (mIgG2b, clone MG38,
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eBioscience) at 4°C. Subsequently, cells were labeled with Alexa-Fluor 488 conjugated
goat anti-mouse IgG2b (Life Technologies, Carlsbad, CA, USA) and DCs were incubated 
for 0-60 minutes at 37°C. Subsequently, cells were fixated with 4% paraformaldehyde 
and incubated with HLA-DR/DP antibody (mIgG2a, clone Q5/13). Thereafter, HLA-DR/
DP staining was visualized using Alexa-Fluor 564 conjugated goat anti-mouse IgG2a
(Life Technologies). Then, after permeabilization, EEA-1 antibody (rabbit IgG, Abcam,
Cambridge, UK) or LAMP-1 antibody (rabbit IgG, Sigma Aldrich, St. Louis, MO, USA) 
was added for 30 minutes, followed by staining with Alexa-Fluor 647 conjugated goat 
anti-rabbit IgG (polyclonal, Life Technologies). Coverslips were mounted on slides with 
Mowiol (Sigma Aldrich). Images were acquired with an Olympus FV1000 Confocal laser 
scanning microscope (Olympus America Inc., Melville, NY, USA) or a LSM 510 META
confocal microscope (Zeiss, Jena, Germany). Isotype controls mIgG2b, mIgG2a and 
rabbit IgG (Biolegend, Miltenyi Biotec, Jackson ImmunoResearch Laboratories, 
respectively) did not show fluorescent staining. Pictures were analyzed with Image J
V1.46R and quantified with JACoP plugin V2.1.1.
DC phenotype and function upon CLEC12A antibody binding
Day 3 MoDCs were pre-incubated with 10 μg/ml CLEC12A antibody (hIgG1) or hIgG1
isotype control (Merus N.V., Utrecht, the Netherlands) and matured with conventional 
cytokines; 1 μg/ml LPS (Sigma Aldrich); 10 μg/ml Poly(I:C) or 5 μg/ml R848. After 48 
hours, IL-6, IL-10 and TNF-т concentrations were quantified by ELISA according to 
manufacturer’s instructions [Human IL-6 and IL-10 ELISA Ready-SET-Go! Kit 
(eBioscience, San Diego, CA, USA); PeliPair human TNF-т ELISA reagent set (Sanquin)]. 
MoDC phenotype was analyzed by flow cytometry using: CD14, CCR7, CD80, CD86,
HLA-ABC antibodies (all Biolegend), HLA-DR antibody (Beckman Coulter), CD83
antibody (BD) and appropriate isotype controls (all Biolegend). Cells were analyzed
using a FC500 flow cytometer (Beckman Coulter). For allogeneic mixed lymphocyte 
reaction (allo-MLR), T cells were prepared by depleting healthy donor PBMCs of CD14+
and CD19+ cells with magnetic beads (BD), and subsequently labeled with 1.25 μM 
CFSE (Life technologies)33. Next, 1x105 T cell-enriched leukocytes and 1x104 mature 
MoDCs were seeded in 200 μl IMDM (Life technologies) supplemented with 10% HS in 
round-bottom 96-well plates (Corning Costar) in triplicate or sixplicate. After 5 days of 
co-culture, supernatant was collected for IFN-ф ELISA (Pierce Endogen, Rockford, IL,
USA). Furthermore, cells were harvested, stained with CD4, CD3 antibodies (both
Biolegend) and CD8 antibody (Life technologies), and subsequently analyzed for CFSE 
dilution within CD3+CD4+ and CD3+CD8+ T cells using a Gallios flow cytometer.
KLH-specific T cell activation
Day 3 MoDCs were generated, and BDCA1+ mDCs and pDCs were isolated from
leukapheresis material. DCs were incubated for 30 minutes at 4°C with total hIgG 
518627-L-bw-Hutten
Processed on: 11-4-2018 PDF page: 103
103
CLEC12A-mediated antigen cross-presentation by DCs
4
(Sanquin) in the presence of 10 μg/ml CLEC12A antibody (mIgG2b or biotinylated
hIgG1) or isotype control antibody. Then, in case of mouse antibodies, secondary 
labeling with 10 μg/ml biotinylated goat anti-mouse IgG (Life technologies) was
performed for 30 minutes at 4°C. Subsequently, DCs were washed and 2 μg/ml
KLH-conjugated biotin antibody was added for 30 minutes at 4°C.21 Finally, cells were 
washed and MoDCs were matured for 48 hours, mDCs and pDCs for 24 hours. Next, 
patient PBMCs containing KLH-specific T cells were thawed, depleted from monocytes 
using CD14+ IMag beads (BD), labeled with 1.25 μM CFSE and resuspended in
IMDM/10% HS to a concentration of 0.5x106 cells/ml. These were added to the DCs at
a peripheral blood lymphocytes (PBLs):DCs ratio of 10:1 in 96-well round-bottom 
plates (in triplicate). Cells were co-cultured in a volume of 200 μl at 37°C. After 4 days, 
supernatant was harvested and pooled for analysis of IFN-ф production by cytokine 
bead array (CBA; BD) and CD4+ T cell proliferation was evaluated, as described before. 
HA-1 cross-presentation assay
To evaluate receptor-mediated antigen cross-presentation, synthetic long peptide for 
the MiHA HA-1 (azido propionic acid-KLKECVLHDDLLEARRPRAHE-biotin; LUMC, the 
Netherlands) was conjugated to CLEC12A antibody (hIgG1), DEC205 antibody (IgG2b,
clone MG38, BD) or respective isotype controls (hIgG1 and mIgG2b), using the 
copper-free click reaction.34 In short, a highly reactive succinimidyl-cyclooctyne 
variant, 2,5-dioxopyrrolidin-1-yl4-((((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethoxy)carbonyl)
amino) butanoate (BCN, Synaffix, Oss, the Netherlands), was incubated with the 
corresponding antibody at a 15 M excess, following manufacturer’s instructions. 
Thereafter, the BCN-conjugated antibody was incubated overnight with a 3 M excess
of HA-1 long peptide and purified using a 10-kDa dialysis cassette (Thermo scientific).
Conjugation efficiency was determined with ELISA. Furthermore, binding capacity and 
specificity of the HA-1 conjugated CLEC12a and DEC205 antibodies, as compared to 
the isotype controls, was validated by flow cytometry by staining the biotin-tag on the
HA-1 long peptide with biotin-FITC antibody. DC subsets, isolated from leukapheresis
material of HA-1 negative healthy donors, were pre-incubated for 30 minutes at 4°C
with 1 mg/ml total hIgG (Sanquin) to block Fc-receptors, followed by 30 minutes 
incubation at 4°C with 10 μg/ml тCLEC12A/HA-1, тDEC205/HA-1 or corresponding 
isotype/HA-1 conjugates. Furthermore, as an additional control, DCs were labeled with
тCLEC12A/HA-1 or тDEC205/HA-1 conjugate in the presence of 100 μg/ml excess 
unconjugated CLEC12A or DEC205 antibody to demonstrate receptor-specific uptake. 
As the peptide conjugation efficiency slightly differed with the corresponding isotype 
control antibodies, the CLEC12A or DEC205 block with excess unconjugated antibody 
was used in all cross-presentation assays. Subsequently, DCs were washed and
incubated at a concentration of 0.1x106 cells/ml in IMDM in 96-well round-bottom
plates at 37°C (in triplicate). As positive control, DCs were pulsed with 1 μM HA-1 short 
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peptide (VLHDDLLEA). After 3 hours of incubation, maturation stimuli and 10% HS 
were added and DCs were incubated overnight. Thereafter, DCs were co-cultured
overnight with HA-1 T cell receptor (TCR) transduced T cells 35 at a T:DC ratio of 1:1 in
a volume of 200μl in the presence of CD107a antibody (BD). Then, supernatant was 
harvested for IFN-ф ELISA, and T cells were stained with CD8 antibody (Beckman
Coulter) and CD137 antibody (Biolegend) and analyzed for activation using a Gallios 
flow cytometer.
In the antigen recall assay using primary patient T cells, BDCA1+ mDCs and pDCs were 
labeled with the тCLEC12A/HA-1 conjugate, as described before, and plated at a 
concentration of 0.8x106 cells/ml in IMDM in a 24-well plate. Due to limited availability 
of patient material these experiments were only performed with the тCLEC12A/HA-1
conjugate in the presence/absence of excess unjugated antibody as negative control. 
After 3 hours of incubation at 37°C, maturation stimuli and 10% HS were added and
DCs were cultured overnight. Thereafter, DCs were co-cultured for 7 days with CD14- 
depleted PBMCs containing HA-1 specific memory T cells obtained from HA-1 
mismatched patients after allo-SCT, at a ratio of PBL:DC of 5:1 in a total volume of 1 ml.
After 4 days, 1 ml IMDM supplemented with 10% HS, 100 U/ml IL-2 and 10 ng/ml IL-15 
(Immunotools) was added. At day 7, cells were harvested, counted and the percentage
of HA-1-specific CD8+ T cells was determined by staining with CD3 antibody (biolegend), 
CD8 antibody (Beckman Coulter), HA-1 PE and APC tetramers (both from LUMC, 
the Netherlands). Cells were analyzed on a Gallios flow cytometer. 
Statistical analysis
Data were analyzed using One-way ANOVA followed by a Bonferroni post-hoc test. 
P-values <0.05 were considered significant.
Results
CLEC12A is broadly expressed and efficiently internalized by human 
DC subsets
To study the suitability of CLEC12A as a targeting receptor for antigen delivery, we first 
validated its expression on human DC subsets using flow cytometry. We confirmed
that MoDCs and naturally occurring BDCA1+ mDCs, BDCA3+ mDCs and pDCs highly 
expressed CLEC12A (Figure 1A and Supplementary figure S2A). Since expression of 
CLEC12A was progressively lost during differentiation of MoDCs (Supplementary figure S2B), 
we selected day 3 MoDCs for further experiments.
Next, we investigated the CLEC12A internalization potential of day 3 MoDCs, BDCA1+
and BDCA3+ mDCs and pDCs using flow cytometry. Following incubation at 37°C,
CLEC12A was quickly and efficiently internalized by all DC types (Figure 1B). Although,
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Figure 1. CLEC12A is highly expressed and efﬁciently internalized by human DC 
subsets. (A) CLEC12A expression on day 3 MoDCs and BDCA1+ mDCs, BDCA3+ mDCs and pDCs
was analyzed by flow cytometry. Open black histograms correspond to cells stained with CLEC12A,
while filled gray histograms represent the isotype control. Numbers in the plots represent the 
mean fluorescence intensity. Data of one representative donor out of 3 is shown. (B) Day 3 MoDCs 
and mDCs and pDCs were labeled with CLEC12A antibody, followed by 0-90 minutes incubation at
37°C. Surface expression of bound CLEC12A antibody was analyzed by flow cytometry following 
labeling with goat anti-mouse IgG. CLEC12A internalization is calculated relative to the surface 
expression at start based on the mean fluorescence intensity (MFI). Data are shown as mean ±
SEM of 3 independent experiments. (C) Confocal analysis of CLEC12A internalization in day 3
MoDCs and FACS-sorted BDCA1+ mDCs and pDCs. DCs were stained with mouse тCLEC12A,
followed by labeling with Alexa-Fluor 488 conjugated goat anti-mouse IgG2b (green). Then, inter-
nalization was allowed for 1 hour at 37°C, with subsequent staining for extracellular HLA class II
with mouse anti-human HLA-DR/DP, followed by Alexa-Fluor 564 conjugated goat-anti-mouse 
IgG2a (red). Length of the scale bar is shown in the figure.
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CLEC12A expression was lower on pDCs than on mDCs, their CLEC12A internalization
efficacy was similar. These findings were confirmed by confocal microscopy. At start, 
CLEC12A was located on the plasma membrane and co-stained with HLA-II molecules 
(Figure 1C). Notably, after 1 hour incubation at 37°C, all DC types showed clear clusters 
of CLEC12A in intracellular compartments with hardly any CLEC12A expression on the 
cell surface. These data demonstrate that human BDCA1+ mDCs, BDCA3+ mDCs, pDCs 
and day 3 MoDCs highly express CLEC12A and efficiently internalize this CLR following 
antibody targeting.
Clathrin-independent CLEC12A translocation to the endosomal/lysosomal 
compartments
Intracellular fate and antigen release are essential parameters determining the efficacy
of antigen processing and presentation by DCs. Therefore, we investigated the inter-
nalization mechanism and intracellular routing of CLEC12A. The classical pathway for 
receptor-mediated endocytosis is dependent on clathrin-coated pits.36 The CLR 
DEC205 is known to internalize via this classical route. To evaluate whether the same 
endocytosis mechanism applies to CLEC12A, we disrupted clathrin-coated pits using 
hypertonic solution.32 Interference with clathrin-mediated uptake almost completely
blocked DEC205 internalization by day 3 MoDCs, BDCA1+ mDCs and pDCs (Figure 2A), 
while CLEC12A endocytosis was not affected. By means of sucrose washout, we could
restore DEC205 internalization, indicating that the observed effects are the result of 
the hypertonic milieu. 
Next, we studied the intracellular routing of CLEC12A, in comparison to DEC205, in 
time on day 3 MoDCs by analyzing their co-localization with EEA-1, an early endosome
marker, or LAMP-1, a marker of the late endosomal/lysosomal compartment. At start, 
both DEC205 and CLEC12A were localized on the cell membrane, yet already after 5 
minutes of endocytosis co-localization was observed with the early endosomes
(Figure 2B, Supplementary figure S3). Notably, whereas DEC205 co-localization with 
the early endosomes was lost after 15 minutes, CLEC12A still co-localized with EEA-1.
Gradually, both receptors routed to the lysosomes with clear co-localization at 60 
minutes after internalization. These co-localization patterns were confirmed with the 
Manders coefficient (Figure 2C-F).
Together, these data demonstrate that, in contrast to DEC205, CLEC12A is not 
internalized via the classical clathrin-coated pits, but follows a distinct endocytosis 
pathway. Yet, the intracellular routing of both receptors appears highly similar, as both 
co-localize with the early endosome after internalization and subsequently route to
the lysosomes.
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Figure 2. Clathrin-independent CLEC12A translocation to the endosomal/lysosomal
compartments. (A) Day 3 MoDCs, BDCA1+ mDCs and pDCs were labeled with DEC205 or 
CLEC12A antibodies and incubated for 30 minutes in isotonic or hypertonic (450mM sucrose) 
medium at 37°C. DEC205 and CLEC12A surface expression was assessed by flow cytometry
following Alexa-Fluor 647 conjugated goat anti-mouse IgG staining. CLEC12A internalization is
calculated relative to the surface expression at start based on the MFI. Data are shown as mean
± SEM of 3 independent experiments. (B) Confocal laser scanning microscopy analysis of 
DEC205 and CLEC12A internalization in day 3 MoDCs and co-localization with early endosomes
and lysosomes in time. MoDCs were incubated with DEC205 or CLEC12A antibodies, followed by
staining with Alexa-Fluor 488 conjugated goat anti-mouse IgG2b (green). Receptors were
allowed to internalize for 0-60 minutes at 37°C. Then, MoDCs were stained for membrane HLA-II 
molecules using HLA-DR/DP antibody, which was visualized with Alexa-Fluor 564 conjugated 
goat-anti-mouse IgG2a (blue). Finally, MoDCs were permeabilized, stained for early endosomes
(EEA-1) or late endosomes (LAMP-1), whereupon visualization with Alexa-Fluor 647 conjugated 
goat anti-rabbit IgG was performed (red). Images were acquired on a Olympus FV1000 Confocal
laser scanning microscope, 60× oil objective (NA, 1.47). Data of one representative donor out of 
3 independent experiments is shown. The size of the scale bar is 5 μm.
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CLEC12A targeting does not affect DC maturation and T cell
stimulatory capacity
As CLEC12A contains an immunoreceptor tyrosine-based inhibition motif (ITIM) motif 
in its cytoplasmic tail, it might function as an inhibitory receptor upon triggering.
Therefore, we investigated whether CLEC12A antibody binding, alone or in combination
with different maturation stimuli, modulated DC phenotype or function. CLEC12A
antibody binding by itself did not affect expression levels of maturation marker CD83,
co-stimulatory molecules CD80/CD86, co-inhibitory ligand PD-L1 nor HLA-DR (Figure 3A). 
Furthermore, 48 hours incubation of CLEC12A antibody labeled MoDCs in the presence 
of conventional cytokines, LPS, Poly(I:C) or R848 did not influence expression levels 
of DC maturation markers (Figure 3B), as compared to isotype control-treated DCs. 
Additionally, CLEC12A antibody binding did not affect production of the immuno-
regulatory cytokine IL-10 nor the pro-inflammatory cytokine TNF-т (Figure 3C). In contrast,
we observed an almost 2-fold increase in IL-6 secretion by LPS- and cytokine-matured
MoDCs following CLEC12A targeting, as compared to isotype control treatment.
Importantly, the capacity of mature MoDCs to promote allogeneic T cell proliferation
and IFN-ф secretion was not affected by CLEC12A targeting (Figure 3D-F). These data 
indicate that CLEC12A antibody targeting does not negatively affect DC maturation, 
phenotype, nor T cell stimulatory potential.
Figure 2. Continued. (C-F) The Manders coefficient was calculated for CLEC12A or DEC205 
co-localization with EEA-1 or LAMP-1 using Image J V1.46R and quantified with JACoP plugin 
V2.1.1. Data are shown as mean ± SEM of 3 independent donors where ≥10 cells were analyzed 
per condition/donor. Data were analyzed using One-way ANOVA followed by a Bonferroni 
post-hoc test, *P <0.05, **P <0.01, ***P <0.001.
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Figure 3. CLEC12A ligation does not negatively affect DC function. Day 3 MoDCs were 
incubated for 48 hours with CLEC12A antibody or hIgG1 isotype control in the absence or 
presence of different maturation stimuli. (A) Expression of CD83, CD80, CD86, PD-L1 and 
HLA-DR on non-matured CLEC12A antibody-treated (black line) or isotype-treated (dark grey 
line) MoDCs was determined by flow cytometry. Isotype controls for the respective maturation
markers are depicted in light grey. Data of one representative donor out of 4 independent 
experiments is shown. (B-C) Relative expression of the DC maturation markers CD83, CD80,
CD86 and CCR7 and (C) relative secretion of IL-6, IL-10 and TNF-т for antibody-treated MoDCs 
cultured with various maturation stimuli. Data are calculated for CLEC12A antibody-treated cells
relative to cells incubated with hIgG1 (CLEC12A/IgG). Graphs show the median with range of 7 
independent experiments. (D-F) Mature CLEC12A antibody (black lines/circles) or isotype-treat-
ed (grey lines/white circles) MoDCs were co-cultured with allogeneic CFSE-labeled T cells at a 
ratio of 1:10 for 5 days. Subsequently, T cell proliferation was determined by flow cytometry and
IFN-ф secretion by ELISA. (D) Representative histograms show CSFE dilution of CD4+ and CD8+ T 
cells of one T cell donor out of 4 donors. (E) CD3+CD4+ and CD3+CD8+ T cell proliferation and
(F) IFN-ф secretion of 4 different T cell donors tested. Data were analyzed using One-way ANOVA 
followed by a Bonferroni post-hoc test, *P <0.05.
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CLEC12A efficiently delivers KLH into DCs, resulting in potent 
CD4+ T cell recall responses
As CLEC12A is efficiently internalized and antibody binding does not affect DC function,
we next investigated whether CLEC12A could be used for antigen delivery. DC subsets 
were labeled with CLEC12A-biotin and biotin/KLH antibody conjugates, matured and 
then co-cultured with patients’ PBMCs containing KLH-experienced CD4+ T cells.
CLEC12A-mediated KLH delivery into day 3 MoDCs resulted in a 2-fold increase of CD4+
T cell proliferation (Figure 4A) and enhanced IFN-ф production (Figure 4B) as compared
to isotype control treatment. Importantly, CLEC12A-mediated KLH uptake and release 
into BDCA1+ mDCs showed superior induction of KLH-specific T cell proliferation
(Figure 4C). Moreover, these T cells secreted high levels of IFN-ф (Figure 4D).
Interestingly, despite lower CLEC12A expression, CLEC12A-mediated KLH delivery in
pDCs efficiently promoted proliferation and IFN-ф production of KLH-experienced 
T cells (Figure 4E,F). Although, T cell proliferation was lower in pDC co-cultures as
compared to mDC co-cultures, IFN-ф levels were equal in both co-cultures, indicating 
that pDC stimulation promotes higher IFN-ф secretion per T cell. These data demonstrate 
that CLEC12A efficiently enables KLH uptake, and its subsequent processing and 
presentation in HLA-II molecules, eliciting productive CD4+ T cell activation and 
proliferation.
CLEC12A-targeted long peptide is efficiently cross-presented by 
natural DC subsets to CD8+ T cells
For effective boosting of anti-tumor immunity, cross-presentation of internalized 
tumor antigens to cytotoxic CD8+ T cells is essential.37 Therefore, we investigated
whether CLEC12A-mediated delivery of MiHA long peptide leads to effective cross-
presentation by BDCA1+ mDCs, BDCA3+ mDCs and pDCs. For this, DC subsets were
labeled with тCLEC12A/HA-1 or тDEC205/HA-1 conjugates. Subsequently, DCs were 
matured and co-cultured with HA-1 TCR transduced CD8+ T cells. Notably, we confirmed
specific binding of the тCLEC12A/HA-1 and тDEC205/HA-1 conjugates to BDCA1+
mDCs, BDCA3+ mDCs and pDCs using flow cytometry by staining the biotin-tag on the
HA-1 long peptide with biotin-FITC antibody (Supplementary figure S4B). DCs labeled 
with either тCLEC12A/HA-1 or тDEC205/HA-1 conjugate in the presence of excess 
unconjugated specific antibody or isotype/HA-1 conjugates were incapable of activating 
HA-1 TCR-transduced CD8+ T cells (Figure 5A-D, Supplementary figure S4C). Importantly,
CLEC12A- and DEC205-mediated HA-1 delivery and cross-presentation by BDCA1+
mDCs, BDCA3+ mDCs and pDCs resulted in significant activation of HA-1 TCR-transduced
CD8+ T cells, as demonstrated by significant up-regulation of the degranulation marker 
CD107a (Figure 5A-D) and activation marker CD137 (Supplementary figure S4C).
Furthermore, DC subsets targeted with тCLEC12A/HA-1 or тDEC205/HA-1 conjugates 
efficiently promoted IFN-ф secretion, as compared to the controls (Figure 5B-D).
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Figure 4. CLEC12A-dependent antigen uptake leads to antigen presentation by 
different human DC subsets. (A-B) Day 3 MoDCs were labeled with CLEC12A antibody or 
mIgG2b isotype control, followed by labeling with biotinylated goat anti-mouse IgG, and 
subsequently targeted with KLH-conjugated biotin antibody. Next, MoDCs were matured for 48
hours with the conventional cytokines, harvested and co-cultured at 1:10 ratio with CFSE-labeled
KLH-responsive PBMCs. (A) After 4 days of culture, CD4+ T cell proliferation was analyzed by
flow cytometry. The mean ± SD of triplicate measurements is shown for one representative 
patient, out of 3 patients. (B) IFN-ф levels at day 4 of co-culture were determined on pooled 
supernatant using CBA. Data of 1 representative patient is shown. (C-F) FACS-sorted BDCA1+
mDCs or pDCs were incubated with biotinylated CLEC12A antibody or hIgG1 isotype control and 
subsequently targeted with KLH-conjugated biotin antibody. DCs were matured overnight and 
subsequently co-cultured with CFSE-labeled KLH-responsive PBMCs at a 1:10 ratio. (C,E) CD4+ T
cell proliferation was measured by flow cytometry and (D,F) IFN-ф production was analyzed by 
ELISA after 4 days of co-culture with (C,D) BDCA1+ mDCs or (E,F) pDCs. The mean ± SD of 
triplicate measurements is shown of two out of three representative patients. Data were
analyzed using One-way ANOVA followed by a Bonferroni post-hoc test, *P <0.05, ***P <0.001.
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Figure 5. CLEC12A-delivered HA-1 long peptide is efﬁciently cross-presented by
BDCA1+ mDCs, BDCA3+ mDCs and pDCs. FACS sorted BDCA1+ mDCs, BDCA3+ mDCs and
pDCs were incubated with long HA-1 peptide chemically conjugated to CLEC12A antibody 
(тCLEC12A/HA-1) or DEC205 antibody (тDEC205/HA-1). As negative controls, DCs were not 
labeled (DC-), labeled with isotype/HA-1 conjugates, or the specific conjugate in the presence of 
excess unconjugated antibody (blocked тCLEC12A/HA1 or тDEC205/HA1). As positive control,
DCs were pulsed with 1 μM short HA-1 peptide. BDCA1+ mDCs, BDCA3+ mDCs and pDCs were 
subsequently matured overnight, followed by 24 hour co-culture with HA-1-TCR transduced T 
cells (between 40% and 66% HA-1-tetramer positive, data not shown) at a ratio of 1:1. T cell
activation was assessed by determining the percentage of CD107a positive CD8+ T cells using 
flow cytometry, and by analysis of IFN-ф secretion using ELISA. (A) Dot plots show CD107a 
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Interestingly, CLEC12A and DEC205 showed similar capacity to deliver antigens for 
cross-presentation and activation of HA-1 specific CD8+ T cells.
To evaluate the efficacy of CLEC12A as an attractive target for facilitating antigen
cross-presentation to patient-derived T cells, we stimulated PBLs of allo-SCT patients
containing HA-1-reactive CD8+ memory T cells with BDCA1+ mDCs (Figure 6A) or pDCs 
(Figure 6B) loaded with the тCLEC12A/HA-1 conjugates or short HA-1 peptide (i.e. 
positive control). After 7 days of co-culture, increased percentages of HA-1-specific 
CD8+ memory T cells were observed as compared to stimulation with non-peptide 
loaded DCs. Moreover, when DCs were labeled with the тCLEC12A/HA-1 conjugate in 
the presence of excess unconjugated тCLEC12A, no increase in the percentage of HA-1
specific CD8+ T cell was observed. Furthermore, also augmented absolute numbers of 
HA-1 specific CD8+ T cells were detected upon stimulation with BDCA1+ mDCs (Figure 
6C) or pDCs (Figure 6D) labeled with the тCLEC12A/HA-1 conjugates or short HA-1 
peptide. Collectively, these findings demonstrate that CLEC12A effectively mediates 
HA-1 long peptide delivery and cross-presentation by BDCA-1+ mDCs and pDCs,
resulting in strong activation of HA-1 reactive CD8+ T cells of patients after allo-SCT.
expression after co-culture with тCLEC12A/HA-1 targeted or non-targeted BDCA1+ mDCs of one
representative donor. (B-D) Percentage of CD107a+CD8+ T cells and IFN-ф production after 
co-culture with (B) BDCA1+ mDCs, (C) pDCs targeted with тCLEC12A/HA-1 or тDEC205/HA-1 or 
(D) BDCA3+ mDCs targeted with тCLEC12A/HA-1. Data are depicted as the mean ± SD of triplo 
measurements of one representative donor. For the тCLEC12A/HA-1 conjugate n=6 (BDCA1+ 
mDC), n=5 (pDC) or n=1 (BDCA3+ mDC) independent experiments were performed. For 
тDEC205/HA-1 n=2 independent experiments were performed. Data were analyzed using 
One-way ANOVA followed by a Bonferroni post-hoc test, ***P <0.001.
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Figure 6. CLEC12A-delivered HA-1 long peptide is efﬁciently cross-presented by 
BDCA1+ mDCs and pDCs to stimulate patient CD8+ T cells. FACS-sorted BDCA1+ mDCs 
and pDCs were incubated with long HA-1 peptide chemically conjugated to CLEC12A antibody 
(i.e. тCLEC12A/HA-1 conjugate). As controls, DCs were not labeled (DC-) or labeled with the 
conjugate in the presence of excess unconjugated тCLEC12A (blocked тCLEC12A/HA1; negative 
control) or with 1 μM short HA-1 peptide (positive control). BDCA1+ mDCs and pDCs were
subsequently matured overnight, and co-cultured with patient PBLs at a ratio of 1:5. At day 7, the 
expansion of HA-1-specific CD8+ memory T cells was assessed by determining the percentage 
HA-1 tetramer-positive CD8+ T cells and absolute counts. (A-B) Dot plots show the percentage
of HA-1 tetramer-positive CD8+ T cells out of total CD8+ T cells after co-culture with тCLEC12A/
HA-1 targeted or control (A) mDCs or (B) pDCs. (C-D) Absolute number of HA-1 specific CD8+
T cells after co-culture with (C) mDCs or (D) pDCs; one out of two donors is shown.
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Discussion
Although the immune system is capable of eliciting tumor-reactive immune responses, 
the magnitude and functionality of these responses is often inadequate.38, 39 Therefore,
powerful strategies are needed to boost anti-tumor immunity in order to prevent 
disease progression. As DCs are the most powerful APCs, they are highly attractive 
vehicles for boosting T cell responses.40, 41 An appealing strategy to employ the
specialized functions and cross-talk of natural DC subsets and exploit their potent 
antigen processing and presentation machinery is targeted delivery of tumor antigens 
in vivo via endocytic receptors.24, 25, 42 In this study, we evaluated the potential of 
CLEC12A, an endocytic CLR, as a new targeting candidate for simultaneous antigen
delivery into all human DC subsets.
We confirmed that the expression pattern of CLEC12A is restricted to hematopoietic
cells of myeloid origin, including monocytes, granulocytes, BDCA1+ mDCs, BDCA3+
mDCs and pDCs, as has been reported by others.26, 43 Next, we demonstrated that 
CLEC12A is efficiently internalized by all human DC subsets. Most CLRs, such as DCIR44,
DC-Sign45 and DEC20521 endocytose via the classical clathrin pathway. Interestingly,
CLEC12A endocytosis was not affected in hypertonic conditions, indicating that its 
mechanism of internalization does not involve clathrin-coated pits. Alternatively,
similar to Langerin (CD207)46, CLEC12A might be endocytosed via the caveolin 
pathway. However, so far we were not able to demonstrate caveolin involvement in
CLEC12A internalization (data not shown). Next to the capacity to internalize, the 
intracellular fate and cargo release are key parameters determining the suitability and
efficacy of CLEC12A for targeted antigen delivery and presentation via HLA-I and HLA-II 
molecules. In general, receptor/antigen trafficking to the lysosomes is considered to
result in loading onto HLA-II molecules and subsequent CD4+ T cell activation.47 In
contrast, pre-lysosomal localization has been postulated to be more favorable for 
antigen processing and cross-presentation via HLA-I molecules to CD8+ T cells.48-52
Nevertheless, DEC205, which quickly routes to the lysosomes, can efficiently facilitate 
antigen cross-presentation.52-55 To elucidate the intracellular fate of CLEC12A we 
performed co-localization studies. CLEC12A and DEC205 showed similar intracellular 
routing: initial co-localization with the early endosomes, followed by further trafficking 
to the lysosomes where they were retained. However, CLEC12A co-localization with the
early endosomes lasted longer. In accordance, Begun et al. recently reported CLEC12A 
co-localization with Rab5 another early endosome marker.28 These findings suggest 
that CLEC12A might provide a good window for endosomal escape of targeted antigen, 
thereby facilitating effective cross-presentation.
CLRs are known to shape immune responses via the signaling motifs in their 
cytoplasmic tails or via the association with adaptor molecules that elicit downstream
signaling cascades. CLEC12A contains an inhibitory ITIM motif in its cytoplasmic tail. 
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Recently, Neumann et al. identified that CLEC12A expressed on neutrophils is involved 
in controlling sterile inflammation.27 They discovered that CLEC12A, upon triggering by
uric acid crystals, inhibits Syk-dependent reactive oxygen species production, thereby 
limiting infiltration of immune cells to the site of damage. In contrast, Chen et al. 
observed positive as well as negative effects on DC phenotype and function upon
CLEC12A antibody binding, dependent on the type of TLR activation.29 In this report,
we showed that binding of our CLEC12A antibody did not promote DC maturation. 
Moreover, no effect on CD86, CD80, CD83 or CCR7 expression was observed following 
CLEC12A antibody binding in combination with different maturation stimuli. In contrast, 
Chen et al. observed increased expression of CCR7 following тCLEC12A ligation in 
combination with TLR4 stimulation.29 These opposite findings might be attributed to
differences in epitope recognition of the used antibodies or isotype-related effects.
Surprisingly, we observed augmented IL-6 secretion upon CLEC12A targeting in the
presence of conventional cytokine maturation or LPS-mediated TLR-4 stimulation. 
Despite this effect on IL-6 secretion, no difference in allogeneic T cell stimulatory 
capacity was observed for тCLEC12A versus isotype control-treated MoDCs.
Because of its efficient internalization capacity and the lack of negative effects
following antibody binding, we consider CLEC12A to be an interesting candidate for 
targeted antigen delivery into DCs. Importantly, we demonstrated that targeted
delivery via CLEC12A enabled KLH presentation onto HLA-II molecules of human
BDCA1+ mDCs, pDCs and MoDCs, thereby promoting profound proliferation and IFN-ф
secretion by KLH-experienced CD4+ T cells. Furthermore, we provided the first 
mechanistic evidence that human mDCs and pDCs are capable of cross-presenting 
natural tumor antigens delivered via CLEC12A, facilitating strong activation of 
tumor-reactive CD8+ T cells of cancer patients. Although data on the BDCA3+ mDC are 
merely indicative as experiments were only performed for one donor. Previously, 
Lahoud et al. reported induction of humoral and cellular immune responses after CLE-
C12A-mediated ovalbumin delivery into mouse antigen presenting cells in vivo. Yet,
they demonstrated CLEC9A and DEC205 to be more effective targets than CLEC12A.29,30
In contrast, in our studies CLEC12A performed equally well as DEC205 in antigen 
cross-presentation assays by human DC subsets. These opposing findings could 
possibly be attributed to differences in epitope recognition of the used antibodies and
functionality after cargo conjugation or to differences in conjugation efficiency, or may
be related to differences in the murine and human model systems.
In addition to other CLRs for which antibodies are currently in phase I/II clinical
investigation, CLEC12A holds great promise for future cargo delivery applications. 
Using nanoparticles combined delivery of tumor antigens and immunomodulatory
agents, such as TLR ligands or small interfering RNA (siRNA) against co-inhibitory 
molecules, could be realized to further improve DC immunogenicity in vivo. Previously, 
we showed that silencing the co-inhibitory molecules PD-L1/L2 on DCs resulted in 
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superior T cell stimulatory potential.56, 57 Another interesting application for CLEC12A
targeted cargo delivery is in the setting of acute myeloid leukemia and myeloid 
dysplastic syndrome. CLEC12A is differentially expressed by myeloid leukemia stem 
cells and blasts, but not by healthy hematopoietic stem cells.43, 58 By favorably
modulating the immunogenicity of leukemic stem cells and blasts, more powerful
tumor-reactive T cell responses could be elicited.
In conclusion, we showed that human BDCA1+ mDCs, BDCA3+ mDCs, pDCs and ex vivo
generated MoDCs highly express CLEC12A. CLEC12A is efficiently internalized via a
clathrin-independent mechanism and is quickly translocated from the early endosomes
to the lysosomes. Notably, we did not observe negative effects of CLEC12A antibody
binding on DC phenotype or functionality. Most importantly, we demonstrated that 
CLEC12A targeted antigen delivery results in potent activation of KLH-reactive CD4+ T
cell responses and highly effective cross-presentation to HA-1 reactive CD8+ T cells of 
allo-SCT patients. These data indicate that CLEC12A is an attractive candidate for in
vivo targeting of human DC subsets with tumor antigens, thereby employing the 
specialized functions and cross-talk of these DCs to boost tumor-reactive T cell
immunity in cancer patients.
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Supplementary Figure S1. Flow cytometry gating strategies for human DC subsets.
(A) Gating strategy for flow-assisted cell sorting of BDCA1+ mDCs, BDCA3+ mDCs and pDCs from 
leukapheresis products. First, single cell leukocytes were gated using forward- and side-
ward-scatter characteristics. Then, CD14- and CD19-negative cells were selected. Finally, 
BDCA1+ mDCs were defined as CD11c+BDCA1+ cells, and BDCA3+ mDCs as CD11c+BDCA3+ cells. 
pDCs were characterized based on BDCA2+ and CD123+. Density dot plots of one representative
donor are shown. (B) For phenotypical analyses and functional experiments, DC subsets were 
gated as follows: leukocytes were defined by forward-and sideward-scatter characteristics, and
single cells were gated using time of flight (TOF). Next, dead cells were excluded using sytox 
blue staining. BDCA1+ mDCs were defined as CD11c+BDCA1+ cells, and BDCA3+ mDCs as
CD11c+BDCA3+ cells. pDCs were characterized as BDCA2+CD123+. Density dot plots of one
representative donor are shown.
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Supplementary Figure S2. Expression of CLEC12A is limited to cells of myeloid
origin and immature MoDC. (A) Expression of CLEC12A on CD8+ T cells, CD4+ T cells, B cells,
NK cells, monocytes, BDCA1+ mDCs, pDCs and granulocytes was analyzed using flow cytometry. 
Data are expressed as ΔMFI, N=5 healthy donors. Lines indicate the mean. (B) Expression of 
DEC205 and CLEC12A during MoDC differentiation was analyzed by flow cytometry. MoDCs were 
analyzed at the immature stage (day 3 and day 7), and after maturation with conventional 
cytokines (day 9). Expression of DEC205 and CLEC12A is shown in black lines, and the
corresponding isotype controls are depicted in light grey. Numbers in the plots represent the 
mean fluorescence intensity. Data of one representative donor out of 3 independent experiments
is shown.
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Supplementary Figure S3. CLEC12A co-localization with the endosomal/lysosomal 
compartments. Confocal laser scanning microscopy analyses of DEC205 (A,C) and CLEC12A
(B,D) internalization in day 3 MoDCs and co-localization with early endosomes (A,B) and 
lysosomes (C,D) in time. MoDCs were incubated with DEC205 or CLEC12A antibodies, followed 
by staining with Alexa-Fluor 488 conjugated goat anti-mouse IgG2b (green). Receptors were 
allowed to internalize for 0-60 minutes at 37°C. Then, MoDCs were stained for membrane HLA-II 
molecules using HLA-DR/DP antibody, which was visualized with Alexa-Fluor 564 conjugated 
goat anti-mouse IgG2a (blue). Finally, MoDCs were permeabilized, stained for early endosomes
(EEA-1) or late endosomes (LAMP-1), whereupon visualization with Alexa-Fluor 647 conjugated
goat anti-rabbit IgG was performed (red). Images were acquired on a Olympus FV1000 Confocal
laser scanning microscope, 60x oil objective (Numerical Aperture, 1.47) and were analyzed
using Image J V1.46R software. Data of one representative donor out of 3 independent 
experiments is shown. The size of the scale bar is 5μm.
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Supplementary Figure S4.ʸCLEC12A/HA-1 and ʸ DEC205/HA-1 long peptide conjugates 
are efﬁciently generated, and speciﬁcally deliver antigen for cross-presented by 
human mDCs and pDCs. (A) To compare conjugation efficiency of HA-1 long peptide to
CLEC12A antibody, DEC205 antibody, hIgG1 and mIgG2b isotype controls, a direct ELISA was 
performed. For this, titrated concentrations of conjugated antibody/HA-1 constructs were
allowed to adhere overnight to Nunc high immuno absorbance plates (Thermo scientific,
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Roskilde, Denmark). As the HA-1 long peptide has a biotin tag, conjugation efficiency was
subsequently determined by incubation with streptavidin-HRP (Sanquin), followed by a color 
reaction with 3,3’,5,5’-Tetramethylbenzidine (TMB) peroxidase substrate solution (KPL, 
Gaithersburg, MD, USA). This enzymatic reaction was stopped with 1 M H3PO4 (Merck) and
absorbance was measured at 450 nm. Graphs show CLEC12A and DEC205 antibody conjugates
(closed symbols), or isotype control conjugates (open symbols). (B) Binding efficacy of the 
antibody/HA-1 conjugates was determined by flow cytometry. PBMCs of healthy donors were
incubated with 1 mg/ml total human IgG (sanquin) to block Fc-receptors, followed by staining
with 10 μg/ml тCLEC12A/HA-1 or тDEC205/HA-1 (green lines) or the corresponding isotype/
HA-1 (black line) conjugates. As a control for specificity, 10x excess unconjugated CLEC12A or 
DEC205 antibody (red line) was added to block specific binding prior to incubation with 
antibody/HA-1 conjugates. Finally, binding of antibody/HA-1 construct was visualized by 
addition of biotin-FITC antibody. Light grey lines in histograms depict staining with тbiotin-FITC 
alone (C) BDCA1+ mDCs and pDCs were incubated тCLEC12A/HA-1 or тDEC205/HA-1 long 
peptide conjugates. As negative controls, DCs were not labeled (DC-), labeled with corresponding 
isotype control/HA-1 conjugates, or labeled with the antibody/HA-1 conjugate in the presence
of excess unconjugated CLEC12A or DEC205 antibody (blocked тCLEC12A/HA1 or тDEC205/
HA1). As positive control, DCs were pulsed with 1μM short HA-1 peptide. BDCA1+ mDCs, and
pDCs were subsequently matured overnight, followed by 24 hour co-culture with HA-1 TCR 
transduced CD8+ T cells (between 40% and 66% HA-1-tetramer positive, data not shown) at a
ratio of 1:1. T cell activation was assessed by determining the percentage of CD107a and CD137 
positive CD8+ T cells using flow cytometry, and by analysis of IFN-ф secretion using ELISA. Data
are depicted as the mean ± SD of triplo measurements of one representative donor. For the 
тCLEC12A/HA-1 conjugate n=6 (BDCA1+ mDC) or n=5 (pDC) independent experiments were 
performed. For тDEC205/HA-1 n=2 independent experiments were performed.
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Abstract 
Allogeneic stem cell transplantation (allo-SCT) can be a curative treatment for patients
with a hematological malignancy due to allo-reactive T cell responses recognizing
minor histocompatibility antigens (MiHA). Yet, tumor immune escape mechanisms can 
cause failure of T cell immunity, leading to relapse. Tumor cells display low expression
of co-stimulatory molecules and can up-regulate co-inhibitory molecules that inhibit 
T cell functionality on ligation with their counter-receptors on the tumor-reactive T cells. 
The aim of this explorative study was to evaluate immune checkpoint expression 
profiles on T cell subsets, and on cytomegalovirus (CMV)- and/or MiHA-reactive CD8+
T cells of allo-SCT patients using a 13-color flow cytometry panel, and to correlate
these expression patterns to clinical outcome. MiHA-reactive CD8+ T cells exhibited an 
early differentiated CD27++/CD28++ phenotype with low KLRG-1 and CD57 expression.
These T cells also displayed increased expression of PD-1, TIM-3 and TIGIT compared 
to total effector memory T cells and CMV-specific CD8+ T cells in healthy donors and
allo-SCT patients. Remarkably, high co-expression of PD-1, TIGIT and KLRG-1 on 
MiHA-reactive CD8+ T cells was associated with relapse after allo-SCT. Together, these
findings indicate that MiHA-specific CD8+ T cells of relapsed patients have a distinctive
co-inhibitory expression signature compared to patients who stay in remission. This 
phenotype may serve as a potential monitoring tool in patients. Moreover, these 
findings suggest that PD-1 and TIGIT play an important role in regulating T cell-mediated 
tumor control, providing rationale for immunotherapy with blocking antibodies to treat
relapse after allo-SCT.
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Introduction
Immunotherapy is a potent treatment modality in hematological malignancies. A well- 
established example in this regard is allogeneic stem cell transplantation (allo-SCT).1, 2
In which a patient receives a donor hematopoietic stem cell graft to replace host 
hematopoiesis and to invoke a graft-vs-tumor (GVT) immune response towards residual
malignant cells. One important aspect for establishing successful GVT immunity is 
the induction of donor CD8+ T cell responses targeting recipient-specific minor histo-
compatibility antigens (MiHAs) and tumor-associated antigens (TAA) expressed by 
residual tumor cells. Upon activation, these T cells acquire effector functions, and thereby 
the capacity to eradicate the malignant cells.3, 4
Although allo-SCT can be curative due to establishment of long-lived tumor-reactive
T cell memory, relapse remains the leading cause of treatment failure.5, 6 Tumor cells
evade T cell immunity by exploiting different mechanisms. Low expression of co- 
stimulatory molecules in combination with increased expression of co-inhibitory 
molecules by the tumor cells is associated with poor prognosis.7 Tumor-reactive T cells
can up-regulate co-inhibitory receptors, including CTLA-4, PD-1 and TIM-3, and subsequent
inhibitory signaling dampens T cell functionality.8-11 We and others previously
demonstrated the inhibitory role of PD-1 and BTLA on tumor-reactive T cell functionality 
in transplanted patients.12-14 In recent years, antagonistic antibodies against PD-1 and
CTLA-4 have been investigated for treatment of multiple cancers, with impressive 
improvement in disease outcome.15-17 However, not all patients respond and others
acquire resistance to these checkpoint blockers. Recently, a plethora of new co-
inhibitory molecules have been implicated in tumor immune escape.8, 18-22 It has been 
demonstrated that signaling through multiple co-inhibitory molecules on the same 
T cell can aggravate T cell dysfunction.8, 23 In this context, it was shown that simultaneous 
blockade of two or even three co-inhibitory molecules, such as PD-1 and CTLA-4, leads 
to synergistic improvement of anti-tumor T cell responses.20, 24 This prompted us to 
investigate the expression profiles of a comprehensive panel of co-signaling receptors
on MiHA-specific CD8+ T cells of patients after allo-SCT and to analyze these in relation
to clinical outcome. 
Here, we analyzed the expression of 15 co-signaling molecules on T cell subsets of 
allo-SCT patients (n=30) and healthy donors (n=10) by 13-color flow cytometry. Using 
tetramer technology we identified (low-frequency) circulating antigen-specific CD8+ T 
cells ( cytomegalovirus [CMV], MiHA). We observed distinct co-expression profiles of 
co-signaling molecules during T cell differentiation. Importantly, MiHA-specific CD8+ T
cells retained an early differentiated phenotype with high expression of the co-
stimulatory molecules CD27 and CD28, whereas CD57 expression was relatively low. 
In addition, these T cells showed increased levels of PD-1, TIM-3 and TIGIT. Of note, 
high co-expression of PD-1, TIGIT and KLRG-1 on MiHA-specific CD8+ T cells was 
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associated with relapse after allo-SCT. Taken together, the data from our explorative
study suggest that multiple co-signaling molecules may act together in regulating
T cell-mediated tumor control. Treatment with antibodies targeting multiple co-signaling 
molecules would be an attractive adjuvant treatment strategy to boost the potency of 
these highly activated, potentially dysfunctional, tumor-reactive T cells for treatment
of relapse after allo-SCT.
Material and Methods
Patient and donor material
Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Hypaque 
(Healthcare, WI, USA) density centrifugation of healthy donor buffy coats (Sanquin,
Nijmegen, the Netherlands) or peripheral blood of allo-SCT patients. Healthy donors
were selected for Human leukocyte antigen (HLA)-B7 positivity and presence of CMV- 
specific CD8+ T cells. Allo-SCT patient/donor pairs were screened for MiHA disparity 
using allele-specific PCRs.25 Patients were selected based on detectable MiHA- or 
CMV-specific CD8+ T cell responses following allo-SCT.4 Patients were treated as
described previously4, characteristics are summarized in Table 1 and Supplementary
Table S1 and S2. Patient and donor material and data were obtained in accordance 
with the Declaration of Helsinki and institutional guidelines and regulations (CMO
2013/064).
Flow cytometry
Expression of co-inhibitory and co-stimulatory molecules on PBMCs of healthy donors 
and allo-SCT patients was analyzed by 13-color flow cytometry. Cryopreserved cells 
were incubated for 15 minutes at room temperature in PBS + 0.5% BSA supplemented
with 1 mg/ml total hIgG (Sanquin). Thereafter, cells were stained with 0.2 μg BV605- 
and BV711-labeled tetramers specific for the corresponding CMV or MiHA epitopes
(Table 2),4 and incubated for 30 minutes at room temperature. Then, cells were labeled 
with the following antibodies: CD3 BV510 (UCHT1), CD8 PerCP (SK1), CD45RA Alexa-Fluor 
700 (HI100), CCR7 PE-CF594 (150503), and CD56 BUV737 (NCAM16,2; all from BD
Biosciences (BD), Franklin Lakes, NJ, USA). For detecting co-stimulatory and
co-inhibitory molecules, the following antibodies were used: CD27 FITC (M-T271), ICOS
PE (DX29), CD28 PE-Cy7 (CD28.2), CD137 APC (4B4-1), CTLA-4 BV421 (BNI3, all from 
BD); CD200R FITC (380525; R&D Systems, Minneapolis MN, USA), 2B4 PE (2-69, BD),
OX-40 PE-Cy7 (BER-ACT35; Biolegend, San Diego, CA, USA), TIGIT APC (741182, R&D
systems), CD57 BV421 (NK-1, BD); KLRG-1 FITC (REA261; Miltenyi Biotec, Bergisch
Gladbach, Germany), BTLA PE (J168-540, BD) TIM-3 PE-Cy7 (F38-2E2, Biolegend),
LAG-3 APC (polyclonal goat IgG, R&D Systems), PD-1 BV421 (EH12.1, BD); IgG1 FITC, PE, 
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APC, and BV421 (MOPC-21), IgG2a FITC, PE, and BV421 (MOPC-173) IgG2b FITC, and APC 
(MPC-11; all Biolegend), IgG1 PE-Cy7 (679.1Mc7, Beckman Coulter, Fullerton, CA, USA), 
IgG APC (R&D Systems). Cells were incubated for 30 minutes at 4°C, and thereafter 
washed with PBS. For live/dead discrimination, cells were then incubated for 30 minutes 
at 4°C with 1:1000 diluted Fixable Blue Dead Cell kit (Thermo Fisher Scientific, Waltham,
MA, USA). The panel design and laser alignment is summarized in Supplementary 
Table S3. Cells were analyzed on a 5-laser FACS ARIA II SORP (BD).
Data and statistical analysis
Flow cytometry data were analyzed using Kaluza version 1.5a (Beckman Coulter) or 
FlowJo version 10.2 (FlowJo, LLC, Ashland, OR, USA). The gating strategy is depicted in 
detail in Supplementary figure S1. First, singlets and live cells were gated, then auto-
fluorescence negative cells (using an unstained empty flow channel) were selected,
and subsequently lymphocytes were gated using forward- and side-scatter. CD4+
T cells were defined as CD56-CD3+CD8-; CD8+ T cells as CD56-CD3+CD8+. Within the
CD8+ T cell population CMV- or MiHA-specific T cells were gated as positive for both 
tetramer-BV605 and tetramer-BV711. Furthermore, memory cell subsets were gated
and defined as follows: CCR7+CD45RA+ naïve(-like) T cells (Tn), CCR7+CD45RA- central
memory T cells (Tcm), and CCR7- effector/effector memory T cells (Tem). Isotype-
matched controls were used to evaluate the positivity for the co-signaling molecules 
(i.e. each isotype gate was set at ≤1% positive). Tetramer-positive CD8+ T cell
populations were additionally analyzed using the bh-SNE algorithm in CYT software 
version 2.0 from Dana Pe’ers lab and Matlab software (MathWorks Inc., Natick, MA, 
USA).26 In Brief, the algorithm converts multi-dimensional data into bi-dimensional 
maps by first calculating a pairwise distance matrix for the high-dimensional space 
and transforming it into a similarity matrix using a varying Gaussian kernel. A random
bi-dimensional map is rendered and pairwise similarities are calculated for the low-
dimensional space created. The map is then optimized in iteration steps using the 
calculated similarity between any given two cells to optimally redistribute them on the 
map. Data quantifications were made in Graphpad Prism version 5.03 (GraphPad 
Software, La Jolla, CA, USA), SPICE version 5.3 (NIAID, Rockville, MD,USA) and CIMminer 
(NIH, Bethesda, MD, USA).27 For a statistical comparison of SPICE pie charts, the 
built-in test in SPICE software was used; applying 1,000,000 permutations; as 
described by Roederer et al. and Legat et al.28, 29 For heatmap clustering analyses in 
CIMminer software with average linkage and the Pearson coefficient was used to
determine the correlation between subset populations and expression of the different 
co-signaling molecules. Other p-values were obtained using a two-tailed t-test or 
One-way ANOVA followed by a Bonferroni post-hoc test as indicated, with * p<0.05; ** 
p<0.01, *** p<0.001.
518627-L-bw-Hutten
Processed on: 11-4-2018 PDF page: 132
132
Chapter 5
Table 1. Patient characteristics.
Pt. no. Disease CMV reactivation
(months after
allo-SCT)
Antigen-speciﬁc CD8+
T cell response
(HLA restriction)
Sampling date
(months after
allo-SCT)
DLI prior to
sampling date
(months after
allo-SCT)
1 MM No HA-1 (A2) 6 Yes, 6 
(Prophylactic)
2 NHL No SP110 (A3) 3 Yes, 2
(Boost)
3 CML No HA-1 (A2) 6 Yes, 4 
(Prophylactic)
4 MDS No HY (B7) 8 No
5 MDS No HA-1 (A2) 5 No
6 MDS Yes, 8 HA-1 (A2) 11 Yes, 6 
(Prophylactic)
7 AML No ARHGDIB (B7) 7 Yes,6 
(Prophylactic)
8 AML N.A. HY (A2) 12 No
9 AML No HA-1 (A2) 1 No
10 AML Yes, 4 ARHGDIB (B7) 6 No
11 AML N.A. HA-8 (A2) 6 No
12 AML N.A. ARHGDIB (B7) 14 Yes, 8
(Prophylactic)
13 MM No PANE (A3) 6 No
14 NHL No HY (A2) 4 Yes, 4
(Therapeutic)
15 NHL No ARHGDIB (B7) 11 No
16 CML No LRH-1 (B7) 14 Yes, 10 + 12 
(Therapeutic)
17 AML No LRH-1 (B7) 40 Yes, 5
(Prophylactic)
18 AML No HY (A2) 3 No
19 AML No HY (A2) 5 No
20 AML No ARHGDIB (B7) 3 No
Abbreviations: FU, follow-up time-point; NHL, non-Hodgkin lymphoma; CML, chronic myeloid leukemia; 
AML, acute myeloid leukemia; MM, multiple myeloma; MDS, myelodysplastic syndrome; Age, age in years
at time of allo-SCT; Cond Regimen, conditioning regimen; Cy, cyclophosphamide; Ida, idarubicin; TBI, total 
body irradiation; Bus, busulphan; Dec, decitabine; SIB, sibling donor; MUD, matched unrelated donor; CMV, 
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Disease status at
sampling date
GVHD at
sampling date
ISD at
sampling date
Relapse
(months after
allo-SCT)
Alive
(at last FU,
months after
allo-SCT)
CR No No No Yes, 86
CR Yes (aGvHD, Grade 3) MMF, prednison,
etanercept 
and inolimomab
No
CR Yes (aGvHD, Grade 3) No No No, 15 (NRM)
CR Yes (cGvHD, extensive) No No Yes, 43 
CR No Tacrolimus No Yes, 24
CR Yes (cGvHD, extensive) CSA and prednison No No, 49 (NRM)
CR Yes (aGvHD, Grade 1) CSA and Prednisone No Yes, 151
CR No (resolved) CSA No Yes, 199
CR No CSA No Yes, 39
CR Yes (cGvHD, extensive) CSA and prednisone No Yes, 39
CR Yes (cGvHD, mild) CSA No Yes, 255
CR No No No Yes, 145
CR Yes (cGvHD, mild) No Yes, 9 No,10 (RRM)
Relapse No CSA Yes, 3 No, 19 (RRM)
CR No No Yes, 21 Yes, 250
Relapse No No Yes, 9 No, 75 (RRM)
Relapse No No Yes, 38 and 75 No, 94 (RRM)
CR Yes (aGvHD, Grade 3) MMF Yes, 10 No, 10 (RRM)
Relapse No No Yes, 4 No, 5 (RRM)
MRD Yes (aGvHD, Grade 2) No No Yes, 32
cytomegalovirus ; DLI, donor lymphocyte infusion; CR, complete remission; VGPR, very good partial 
response; PR, partial remission; MRD, minimal residual disease; N.A., not available; cGVHD, chronic graft-
versus-host-disease; aGVHD, acute graft-versus-host-disease; ISD, immune suppressive drugs; CSA, 
cyclosporin A; MMF, mycophenolic acid; RRM, relapse-related mortality; NRM, non-relapse mortality.
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Results
Distinct co-inhibitory molecule expression profiles during T cell 
differentiation
To evaluate differences in T cell subset composition and expression profiles of 
co-signaling molecules, CD4+ and CD8+ T cells of healthy donors and allo-SCT patients
(at a median of 6 months after allo-SCT; range 1-40 months) were analyzed by flow 
cytometry. Figure 1A shows representative flow cytometry plots of the CD4+ and CD8+
T cell subsets in a healthy donor and an allo-SCT patient. The majority of both CD4+
and CD8+ T cells of allo-SCT patients had a Tem phenotype (CD4+: 65.3 ± 3.2%, CD8+:
86.4 ± 1.6%), while these populations were substantially smaller in healthy donors
(CD4+: 29.8 ± 3.4%, CD8+: 68.3.4 ± 4.0%; Figure 1B and Supplementary Table S2). 
Of note, the CD45RA+CCR7+ T cell population of allo-SCT patients contains both 
genuine naïve T cells, as well as CD95-positive “naïve-like” or stem cell memory T cells,
as described by us previously.30 Subsequently, we determined co-signaling molecule 
expression levels on CD4+ and CD8+ T cell memory subsets of healthy donors, and
performed unsupervised clustering analyses (Figure 1C). Interestingly, for the CD8+
T cells perfect clustering of the different differentiation stages was observed based 
on distinct expression profiles of co-signaling molecules. In case of the CD4+ T cells
the clustering was partial. As expected, CD27, CD28 and BTLA were highly expressed
by naïve CD4+ and CD8+ T cells, and expression gradually decreased upon T cell
differentiation. In contrast, expression of KLRG-1, CD57, PD-1 and TIGIT was gained
during T cell differentiation with highest expression levels on Tem cells.29 Of note, 
also in allo-SCT patients clustering of T cell differentiation stages was observed based
on co-signaling expression profiles, despite differences in expression levels as compared
to healthy controls (data not shown). 
Table 2. Labeled tetramers containing CMV- or MiHA-specific peptide sequences 
used for analysis of antigen-specific T cell populations.
Antigen HLA restriction Sequence
CMV B7 RPHERNGFTVL
HA-1 A2 VLHDDLLEA
HA-8 A2 RTLDKVLEV
HY A2 FIDSYICQV
PANE A3 RVWDLPGVLK
SP110 A3 SLPRGTSTPK
ARHGDIB B7 LPRACWREA
HY B7 SPSVDKARAEL
LRH-1 B7 TPNQRQNVC
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We next investigated whether co-signaling molecules were differentially expressed by 
the different effector/memory T cell subsets of healthy donors compared with allo-SCT 
patients. The results are displayed for CD4+ T cells (Figure 2) and for CD8+ T cells
(Figure 3). A slight decrease in CD28 expression on CD8+ T cells of allo-SCT patients 
Figure 1. Co-signaling molecules show distinct co-expression proﬁles during T cell 
differentiation. CD4+ and CD8+ T cell subsets of healthy donors (HD) and allo-SCT patients 
(allo-SCT pt) were examined for expression of co-inhibitory and co-stimulatory molecules using
flow cytometry. T cell differentiation stages were analyzed by gating on CD45RA and CCR7 
expression. (A) Representative flow cytometry plots of the CD8 and CD4+ subset composition
in 1 HD and 1 allo-SCT pt (no. 3). (B) Combined data of CD4+ and CD8+ T cell subset composition 
for HD and allo-SCT pt are shown (HD: n=10, allo-SCT pt: n=30). Naïve/naïve-like T cells (Tn), 
CD45RA+CCR7+ (black); central memory T cells (Tcm), CD45RA- CCR7+ (grey); effector memory
T cells (Tem), CCR7- (white). Data are shown as mean + SEM for each subset as proportion of 
the CD4+ and CD8+ T cell populations. (C) Unsupervised clustering analysis with the pearson
coefficient was performed on co-signaling molecule expression levels on CD4+ and CD8+ T cells
of healthy donors (n=10). Data are shown in a heat-map with a color code illustrating expression
from 0% (blue) to 100% positivity (red) for the corresponding marker. Each row represents a 
different co-signaling molecule, and each column represents a T cell subset from one particular 
donor. Below the heat-map, the classical differentiation stages based on CD45RA and CCR7
expression are indicated with a colored asterisk: Tn (green), Tcm (orange) and Tem (red).
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could be observed compared to healthy donors. Furthermore, we detected increased 
OX-40 expression on the CD4+ Tcm and Tem cells of allo-SCT patients, and elevated ICOS 
expression on the Tcm cells. Interestingly, KLRG-1 was expressed by the “naive-like” 
T cells, whereas PD-1 and CD57 expression was significantly higher on Tcm and Tem of 
both the CD4+ and CD8+ T cell populations in allo-SCT patients. Collectively, these data
indicate that the CD4+ and CD8+ T cell populations of allo-SCT patients have distinct 
co-signaling molecule profiles that change during T cell differentiation, similar to those
of healthy donors.
MiHA-specific CD8+ T cells show an early differentiation phenotype 
accompanied with high expression of co-inhibitory molecules
We next examined the co-signaling molecule expression profiles on antigen-specific 
CD8+ T cells. We compared MiHA-specific CD8+ T cells with CMV-specific CD8+ T cells
from healthy donors and allo-SCT patients using a flow cytometry-based dual color 
tetramer staining approach.4 Figure 4A shows representative flow cytometry plots of CMV- 
and MiHA-specific CD8+ T cells and their respective effector/memory subset composition.
Almost all CMV-specific CD8+ T cells from both healthy donors (84.6 ± 7.7%) and 
Figure 2. OX-40, ICOS, CD57, PD-1 and TIGIT are higher expressed by CD4+ memory 
T cells of allo-SCT patients. Expression of co-signaling molecules in the context of CD4+
T cell differentiation was analyzed using flow cytometry for healthy donors (HD; white bars; n=10) 
and allo-SCT patients (Allo-SCT pt; grey bars; n=30). Statistical analysis was performed using
a two-tailed t-test. *P<0.05, **P<0.01, ***P<0.001.
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allo-SCT patients (95.1 ± 1.3%) displayed a Tem phenotype, as did the MiHA-specific 
CD8+ T cells (91.9 ± 1.6%; Figure 4B and Supplementary table S2). Therefore, we 
compared the expression of co-signalling molecules on CMV- and MiHA-specific CD8+
T cells with the corresponding expression profiles of the total CD8+ Tem cell population 
of allo-SCT patients (data of healthy donors are provided in Supplementary figure S2). 
The phenotype of MiHA-specific CD8+ T cells was found to significantly differ from the
total CD8+ Tem population and CMV-specific CD8+ T cells based on augmented
expression of CD27, CD28, CD278 (ICOS) and CD137 (4-1BB) (Figure 4C,D). In addition,
we observed lower expression levels of KLRG-1 and CD57 on MiHA-specific CD8+
T cells, reflecting their early differentiation stage. Of note, along with lower expression 
of terminal differentiation markers and increased expression of the aforementioned 
co-stimulatory molecules, significantly elevated levels of PD-1, TIM-3 and TIGIT were
observed as well. Findings were similar for percentage positive cells and expression 
based on mean fluorescence intensity (MFI) (data not shown). Together, these data
indicate that MiHA-specific CD8+ T cells display a recently activated and early differen-
tiation phenotype with high expression of PD-1, TIGIT and TIM-3, which may be the
result of activation-induced up-regulation29 but could also reflect T cell exhaustion.
Figure 3. PD-1 and CD57 are highly expressed by CD8+ memory T cells of allo-SCT
patients. Expression of co-signaling molecules in the context of CD8+ T cell differentiation was 
analyzed using flow cytometry for healthy donors (HD; white bars; n=10) and allo-SCT patients 
(Allo-SCT pt; grey bars; n=30). Statistical analysis was performed using a two-tailed t-test. 
*P<0.05, **P<0.01, ***P<0.001.
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Figure 4. MiHA-speciﬁc CD8+ T cells exhibit an early differentiation phenotype
accompanied with high expression of co-inhibitory molecules. Antigen-specific CD8+
T cells of healthy donors (HD) and allo-SCT patients (allo-SCT pt) were examined for expression 
of co-inhibitory and co-stimulatory molecules using dual color tetramer-based flow cytometry.
(A) Representative plots of CMV- and MiHA-specific CD8+ T cells and their respective differenti-
ation stage are shown for 1 HD and 1 allo-SCT pt (no. 24) with a detectable CMV-specific CD8+ T
cell response, and 1 allo-SCT pt (no. 15) with a detectable MiHA-specific CD8+ T cell response. 
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MiHA-specific CD8+ T cells exhibit distinctive clustering profiles with 
increased expression of inhibitory and stimulatory receptors
Co-expression profiles of co-signaling molecules on antigen-specific CD8+ T cells of 
healthy donors and allo-SCT patients were compared using different clustering 
analyses. First, tetramer-positive T cell populations were analyzed using the bh-SNE 
algorithm. Here, analysis was performed separately for each flow cytometry panel,
clustering individual CMV- or MiHA-specific CD8+ T cells based on the fluorescence
intensities of the 5 co-signaling molecules in each panel (Figure 5A and Supplementary
figure S3). Interestingly, MiHA-specific CD8+ T cells exhibited a distinct clustering 
pattern compared to CMV-reactive CD8+ T cells based on differential expression of 
CD27, CD28, CD137 (panel 1; Supplementary figure S3A), high TIGIT and lack of CD57 
(panel 2, Supplementary figure S3B), and high expression of PD-1, TIM-3 and BTLA and 
lack of KLRG-1 (panel 3, Supplementary figure S3C). Notably, the clustering patterns 
seen for the CMV-specific CD8+ T cells of healthy donors versus allo-SCT patients were
relatively similar (Figure 5A). These data were confirmed by unsupervised cluster 
analysis, displayed in a heatmap, where MiHA-specific CD8+ from allo-SCT patients 
clustered together in a distinctive pattern compared to CMV-specific CD8+ T cells
(Figure 5B). These differences could be predominantly attributed to increased 
expression of co-stimulatory CD27 and CD28, collectively with elevated levels of 
co-inhibitory PD-1, TIGIT, TIM-3 and BTLA on the MiHA-specific CD8+ T cells.
To look at these co-expression profiles from a different angle we performed additional
SPICE analysis. This analysis demonstrated that the MiHA-specific CD8+ T cells almost
all expressed CD27 and CD28 (Figure 5C). Furthermore, this population contained a
higher proportion of cells triple-positive for CD27, CD28 and CD137 as compared to
CMV-specific CD8+ T cells, regardless of healthy donor or allo-SCT patient origin. 
The number in the plots indicates the percentage of MiHA-specific CD8+ T cells positive for both 
tetramers. (B) Combined data of the subset composition within the antigen-specific CD8+ T cell 
population are shown (HD: n=10, Allo-SCT pt CMV: n=10; Allo-SCT pt MiHA: n=20). Naïve-like T 
cells (Tn), CD45RA+CCR7+ (black); central memory T cells (Tcm), CD45RA- CCR7+ (grey); effector 
memory T cells (Tem), CCR7- (white). Data are expressed as mean + SEM for each subset as
proportion of the MiHA-specific CD8+ T cell populations. (C) Surface expression of the different
co-signaling molecules is shown for the MiHA-specific CD8+ T cell population (black) and CD8+
T cell subsets of 1 Allo-SCT pt (no. 7) (Tn: green; Tcm: orange; Tem: red), as compared to the
corresponding isotype control staining (grey). Dotted lines represent gates set at <1% positive
for the isotype control, and the numbers in the plots represent the percentage of cells positive
for the respective receptor. (D) Combined data showing the percentage of cells positive for each
co-signaling molecule within the total CD8+ Tem versus CMV- and MiHA-specific CD8+ T cell 
populations of Allo-SCT pt (Allo-SCT pt Tem: n=30; Allo-SCT pt CMV: n=10; Allo-SCT pt MiHA:
n=20). Statistical analysis was performed using one-way ANOVA followed by a bonferroni
post-hoc test.* P<0.05, **P<0.01, ***P<0.001.
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Figure 5. MiHA-speciﬁc CD8+ T cells have a distinct co-expression proﬁle with high
expression of inhibitory and stimulatory receptors. Antigen-specific CD8+ T cells of 
healthy donors (HD) and allo-SCT patients (allo-SCT pt) were examined for expression of 
co-inhibitory and co-stimulatory molecules by flow cytometry using three different panels. CMV- and
MiHA-specific CD8+ T cells were gated based on dual color tetramer staining. (A) bh-SNE 
clustering analysis was performed for each flow cytometry panel, containing 5 antibodies 
against different co-signaling molecules. Composite overlays (left) and individual maps (right)
visualize the clustering signatures of HD CMV (green), Allo-SCT pt CMV (yellow) and allo-SCT pt 
MiHA (red). (B) Unsupervised average linkage analysis was performed with the pearson 
coefficient for each antigen-specific CD8+ T cell population, and displayed in a heat-map. The
color scale indicates expression from 0% (blue) to 100% positivity (red) for the corresponding
marker. Each row represents a different co-signaling molecule, and each column represents a
different individual. Below the heat-map, the donor population and corresponding antigen 
specificities are indicated with a colored asterisk: HD CMV (green), allo-SCT Pt CMV (orange) 
and allo-SCT MiHA Pt (red). (C) Co-expression patterns were determined with the SPICE software.
The pies depict the average proportion of cells expressing 0 to 5 of the co-signaling molecules
and the arcs indicate which of the markers are expressed by the corresponding pies. Statistical
differences were analyzed using the build-in statistical tool. *P<0.05, **P<0.01, ***P<0.001.
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Furthermore, the MiHA-specific CD8+ T cell population had lower expression of the 
terminal differentiation marker CD57 and contained a higher frequency of TIGIT+CD57-
cells. Finally, MiHA-specific CD8+ T cells showed increased co-expression of PD-1, 
TIM-3 and BTLA, wereas lower KLRG-1 levels were observed compared with
CMV-specific CD8+ T cells. Notably, in all three panels, MiHA-specific CD8+ T cells 
co-expressed significantly more co-signaling molecules than CMV-specific CD8+ T
cells. This was especially striking in panel 3, where the average proportion of cells 
co-expressing ≥3 co-inhibitory molecules was 57,2 ± 5.6% (SEM) for the MiHA-specific 
CD8+ T cells, versus only 25.1 ± 5.7% and 30.0 ± 6.6%, respectively, in case of 
CMV-specific CD8+ T cells of healthy donors and allo-SCT patients. Together, these
findings indicate that MiHA-specific CD8+ T cells exhibit distinctive clustering profiles,
with an increased proportion of cells simultaneously expressing multiple co-inhibitory 
molecules, including PD-1, TIM-3 and TIGIT, as well as CD27 and CD28. 
High expression of OX-40, PD-1, TIGIT, and KLRG-1 on MiHA-specific CD8+
T cells is associated with relapse in allo-SCT patients
Finally, we evaluated whether distinct T cell expression signatures showed associations 
with clinical outcome. To do so, we compared the expression of co-signaling molecules
on MiHA-specific CD8+ T cells of patients staying in remission (n=12; Pt 1-12) with 
those of patients who suffered from persistent or relapsed disease after allo-SCT (n=8; 
Pt 13-20). The median age at transplant was 43 years (range 28-58) for the relapsed
patients versus 50 years (range 26-63) in the remission group. Analyzed samples were 
obtained at a median of 11 months (range 3-40) after allo-SCT for relapsed patients 
versus 7 months (range 1-14) for non-relapsed patients. At time of analysis, 8 of 
12 patients in remission were still treated with immunosuppressive drugs versus 2 of 
8 relapsed patients. This corresponds with higher graft-versus-host-disease (GVHD)
rates in the remission group (7 of 12) versus the relapse group (3 of 8). There were no 
differences in DLI administration for both patient groups. Notably, none of the patients 
with a MiHA-specific CD8+ T cell response had detectable CMV disease at sample date.
We found significantly higher expression of OX-40, KLRG-1, PD-1 and TIGIT on 
MiHA-specific CD8+ T cells of allo-SCT patients who relapsed (Figure 6A). The other 
co-signaling molecules were not differentially expressed and did not exhibit any 
differences in co-expression patterns (Figure 6A and Supplementary figure S4). 
Observations were similar for percentage positive cells and expression based on MFI 
(data not shown). To further demonstrate that co-expression of OX-40, KLRG-1, PD-1 
and TIGIT defined a distinct T cell signature in patients who relapsed after allo-SCT, we
established a new panel dedicated to these four receptors and re-measured
MiHA-specific CD8+ T cells of 9 patients with mostly myeloid malignancies (Remission
patients: no. 5, 8, 9, 11 and 12; Relapse patients: no. 15, 17, 19 and 20; Figure 6B). 
Interestingly, relapsed patients had a small subset of quadruple-positive MiHA-specific 
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Figure 6. High expression of PD-1, TIGIT, OX-40 and KLRG-1 on MiHA-speciﬁc CD8+
T cells is associated with relapse in allo-SCT patients. Expression levels of co-signaling 
molecules on MiHA-specific CD8+ T cells of allo-SCT patients (allo-SCT Pt) were evaluated using 
flow cytometry and analyzed in the context of relapse post-transplantation. (A) For each
receptor the percentage positive cells was determined within the MiHA-specific CD8+ T cell 
populations of non-relapsed (n=12, open circles) and relapsed patients (n=8, black solid
squares). Lines indicate the mean. Statistical analysis was performed using a two-tailed t-test. 
*P<0.05, ***P<0.001. (B) Co-expression profiles of a dedicated panel specific for the 4 receptors 
that were significantly differentially expressed in non-relapsed versus relapsed Allo-SCT Pt,
were examined with flow cytometry and analyzed using SPICE software. The pie charts depict 
the average proportion of cells expressing 0-4 of the co-signaling molecules, while the arcs 
indicate whether KLRG-1 (red), OX-40 (green), TIGIT (light blue) and/or PD-1 (dark blue) is 
expressed by the corresponding pies. Statistical differences were analyzed using the build-in
statistical tool.
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CD8+ T cells that was not found in the remission patient group. Furthermore, a larger 
proportion of MiHA-specific CD8+ T cells in relapsed patients was triple-positive. The 
expression of OX-40 and TIGIT seemed mutually exclusive. Importantly, this expression
signature was independent of treatment with immunosuppressive drugs and GVHD 
occurrence (data not shown). To conclude, our explorative studies show that 
MiHA-specific T cells of relapsed patients exhibit a distinct phenotype characterized
by enhanced co-expression of PD-1, TIGIT and KLRG-1. This expression signature may 
either be the result of T cell activation or reflect T cell dysfunction due to continuous 
antigen encounter. Treatment with novel combinations of antagonistic and agonistic 
antibodies would be an attractive strategy to boost the potency of these T cells to treat 
relapse after allo-SCT.
Discussion
The involvement of co-signaling molecules in tumor immune escape mechanisms has
become increasingly evident in the last years. The impressive results achieved in 
clinical trials blocking the PD-1/PD-L1 axis in solid and hematological malignancies15
illustrate the potency of releasing the co-inhibitory “breaks” on reinvigoration of 
anti-tumor immunity. Dysfunctional T cells can simultaneously express multiple
co-inhibitory receptors and subsequent signaling can contribute to their dysfunctional 
state. Interestingly, combined blockade of CTLA-4 and PD-1 resulted in additive or 
even synergistic clinical efficacy in cancer patients.24, 31 In addition to CTLA-4 and
PD-1, novel co-signaling molecules are now being investigated, including BTLA, LAG-3, 
TIM-3 and TIGIT.8-11, 32 We previously reported the involvement of PD-1 and BTLA 
signaling in suppressing MiHA-specific CD8+ T cell functionality, which could be
alleviated by antibody-mediated blockade in vitro.13 However, not all patients respond 
to single antibody therapy, which may reflect differences in dominance of immunosup-
pressive mechanisms utilized by the tumor.13, 15-17 This emphasizes the need for new
immunotherapeutic strategies targeting novel combinations of co-inhibitory
molecules, and potentially also co-stimulatory receptors, to boost tumor-reactive T 
cell responses. The aim of this study was to identify (co-)expression profiles of a
comprehensive set of co-signaling molecules on MiHA-specific CD8+ T cells in relation 
to clinical outcome after allo-SCT. Major challenges of multi-color flow cytometry 
include the complex data analyses and limitations of 2D data visualizations. Here, we
analyzed our data extensively through unsupervised clustering, bh-SNE and SPICE
analyses to elucidate potential expression signatures associated with clinical outcome.
We utilized a well-established T cell effector/memory subset definition based on
CD45RA and CCR7 expression33 to evaluate the expression patterns of 15 co-signaling
molecules during T cell differentiation using unsupervised clustering analysis.
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Interestingly, Tn, Tcm and Tem clustered perfectly together for the CD8+ T cells based 
on defined co-signaling molecule expression patterns. Partial clustering was observed 
for the CD4+ T cell subsets. These data illustrate the importance of evaluating 
co-signaling molecule expression profiles in the context of T cell differentiation. In 
accordance with this, others also have reported that changes in the expression of 
CD27, CD28, BTLA, KLRG-1 and CD57 correlates with T cell differentiation stages.29, 34
Here, we analyzed CD4+ and CD8+ T cell subsets of healthy donors versus allo-SCT 
patients. We observed that allo-SCT patients had significantly higher expression of 
PD-1 and CD57 on CD4+ and CD8+ Tcm and Tem populations and increased levels of 
OX-40 in Tcm and Tem CD4+ T cells. These data support that T cells of allo-SCT patients 
exhibit a highly activated/terminally differentiated phenotype.35 These observations
likely can be attributed to inflammation caused by the conditioning regimen,36 viral 
reactivation, development of anti-viral and allo-reactive immune responses and 
occurrence of GVHD.37, 38
We next studied the (co-)expression patterns of co-signaling molecules on MiHA-
specific CD8+ T cells, because these target highly immunogenic antigens expressed by 
hematologic tumor cells. CMV-reactive CD8+ T cells served as control for MiHA-specific 
CD8+ T cells. We identified increased expression levels of multiple co-inhibitory molecules, 
including PD-1, TIM-3 and TIGIT on MiHA-specific CD8+ T cells, wereas these T cells
retained an early differentiation phenotype with lower CD57, KLRG1 and high CD27, 
CD28 expression. The distinctive phenotype of the MiHA-specific CD8+ T cells, as
compared to CMV-specific CD8+ T cells, was also confirmed with bh-SNE analysis and 
unsupervised clustering analysis and could be attributed to increased expression
levels of PD-1, TIGIT, TIM-3, BTLA, CD27 and CD28. Notably, a larger proportion of 
MiHA-specific CD8+ T cells simultaneously expressed multiple co-signaling molecules
at their cell surface compared with CMV-specific CD8+ T cells. High expression of 
co-inhibitory molecules, such as PD-1, TIM-3 and TIGIT by tumor-reactive T cells can
either reflect T cell activation, but also be a hallmark of functional impairment.8, 9, 18-22
Although individual expression of co-inhibitory receptors is not selective nor indicative
of exhaustion, simultaneous expression of multiple co-inhibitory receptors is a key 
feature of T cell dysfunction in cancer and chronic viral infections.10, 11, 35 These
co-expression patterns are mechanistically relevant, because these receptors can act
together in impairing T cell function. Simultaneous blockade of multiple co-inhibitory 
molecules can result in synergistic reversal of T cell dysfunction, as has been 
demonstrated for PD-1 and TIM-3, and PD-1 and TIGIT.21, 32, 35
Most importantly, we analyzed the phenotype of MiHA-specific CD8+ T cells in relation
to clinical outcome. MiHA-specific CD8+ T cells of patients who relapsed showed 
increased expression of PD-1, TIGIT, OX-40 and KLRG-1. This is in accordance with the 
results published by Schnorfeil et al., who reported increased PD-1 expression on total 
CD8+ T cells to correlate with relapse.39 Similarly, Kong et al. reported the association 
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of high PD-1 and TIM-3 co-expression with leukemia relapse in acute myeloid leukemia 
patients post allo-SCT.40 In addition, TIGIT was found to be associated with CD8+ T cell
exhaustion and poor clinical outcome in acute myeloid leukemia.14 Furthermore, 
up-regulation of the co-stimulatory molecules OX-40 and 4-1BB was observed on 
dysfunctional CD8+ tumor infiltrating lymphocytes in human and murine melanoma.41,
42 Interestingly, in our analyses, approximately 10% of the T cells simultaneously 
expressed the 4 markers: PD-1, TIGIT, OX-40 and KLRG-1, although, TIGIT and OX-40
seemed mutually exclusive on the other MiHA-specific CD8+ T cells. On average, more 
than half of the cells were positive for ≥3 of these markers in the relapsed group 
compared with only ~25% of the MiHA-specific CD8+ T cells being triple-positive in
patients who stayed in remission. Notably, this expression signature was independent 
of the type of MiHA-specific CD8+ T cell response, CMV reactivation, treatment with 
immune suppressive drugs and GVHD occurrence. In the future this signature may
potentially be used for monitoring after allo-SCT.
This study has some limitations that should be addressed. Owing to limited availability 
of material, it was not possible to include more patients, select patients with a similar 
malignancy and/or MiHA-specific T cell response, use samples obtained at fixed
time-points after allo-SCT, or study kinetics of checkpoint profiles. Malignant cell 
intrinsic factors may have differentially altered co-expression profiles of checkpoint
molecules on MiHA-specific CD8+ T cells. In addition, the local tumor microenviron-
ment may play a significant role in modulating T cell phenotype and functionality. 
Therefore, in the analyses with the dedicated PD-1, TIGIT, OX-40 and KLRG-1 panel, 
mostly MiHA-specific CD8+ T cells of patients with myeloid malignancies were 
examined (7x AML, 1x myeloid dysplastic syndrome, 1x Non-Hodgkin lymphoma).
Future studies in larger, more homogenous, cohorts are warranted to validate our 
findings and further elucidate the functional consequences and clinical importance of 
the expression signatures described in this explorative study. 
Combined targeting of PD-1, TIGIT, OX-40 and KLRG-1 may allow tailored tuning of the 
type and magnitude of the tumor-reactive T cell responses. In previous ex vivo studies
we already demonstrated that PD-1 and BTLA expressing MiHA-reactive T cells respond 
to PD-1 and/or BTLA blockade, with most pronounced effects observed for patients 
who relapsed after allo-SCT.12 In addition to enhanced signaling via co-inhibitory
molecules, it has become clear that desensitization of co-stimulatory molecule
signaling through the loss of adaptor molecules is another mechanism that can contribute 
to T cell dysfunction.43 This indicates that both co-stimulatory and co-inhibitory 
receptors are appealing targets for parallel agonistic and antagonistic antibody treatment.
In solid cancer, mono-therapy with antagonistic or agonistic antibodies targeting PD-1, 
TIGIT, or OX-40 has showed promising results.20 Importantly, CTLA-4 and PD-1/PD-L1 
blockade are now established treatment options for multiple solid cancers and
combination therapy with anti-TIGIT and/or anti-OX-40 is emerging.20, 21, 35, 44
518627-L-bw-Hutten
Processed on: 11-4-2018 PDF page: 146
146
Chapter 5
Chauvin et al. demonstrated that dual blockade of TIGIT and PD-1 potently augmented 
anti-tumor CD8+ T-cell responses, as indicated by increased proliferation, cytokine 
production, and degranulation in vitro.35 Furthermore, OX-40 agonistic antibody
treatment has been reported to promote proliferation and survival of activated CD8+ T
cells.45, 46 The crux of allo-SCT is the separation of GVT and GVHD reactivity. Systemic 
release of the immune brakes (checkpoints) may lead to induction and/or aggravation 
of GVHD in these patients. Recent studies on CTLA-4 and PD-1 blockade in patients 
with relapsed acute myeloid leukemia (AML) and Hodgkin lymphoma (HL) after 
allo-SCT showed beneficial GVT responses, but also raised concerns about GVHD.47-56
There are few important caveats, however. Interestingly, in the study by Haverkos et al. 
none of the patients treated with a haploidentical HLA-mismatched transplant 
developed GVHD after anti-PD-1 treatment. All 4 patients received post-transplanta-
tion cyclophosphamide in addition to calcineurin inhibitor as GVHD prevention. Thus, 
it is possible that incidence of GVHD after checkpoint inhibitors administration may 
vary depending on the type of GVHD prophylaxis. Further clinical studies are warranted 
to establish guidelines for checkpoint interference after allo-SCT. Alternatively, novel
strategies for local interference with checkpoint signaling pathways in the tumor mi-
cro-environment, for instance using targeted siRNA-nanoparticles, might hold the key
to boost GVT immunity without inducing and/or aggravating GVHD after allo-SCT.
In conclusion, we have shown that MiHA-specific CD8+ T cells have a distinctive 
co-signaling molecule expression profile as compared to CMV-reactive CD8+ T cells. 
MiHA-specific CD8+ T cells highly express the inhibitory receptors PD-1, TIGIT and
TIM-3, as well as the stimulatory receptors CD27 and CD28, while having a recently 
activated early differentiation phenotype based on low KLRG-1 and CD57, accompanied
with CD137 positivity. Most importantly, high co-expression of PD-1, TIGIT and KLRG-1
on MiHA-reactive CD8+ T cells was associated with relapse after allo-SCT. Taken
together, these data suggest that multiple co-signaling molecules may act together in
regulating T cell-mediated tumor control. Treatment with antibodies targeting different 
co-signaling molecules would be an attractive adjuvant treatment strategy to boost 
the potency of these highly activated, potentially dysfunctional, tumor-reactive T cells
to treat relapse after allo-SCT.
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Supplementary Figure S1. Flow cytometry gating strategy for analysis of CD4+ and 
CD8+ T cell subsets and detection of antigen-speciﬁc CD8+ T cell populations. First,
single cells were gated using forward- and side-scatter characteristics. Then, life cells were
gated using a life/dead discriminator and auto-fluorescence negative cells were selected using a 
non-stained empty flow channel. Subsequently, lymphocytes were selected based on forward-
and sideward scatter. T cells were defined as CD3+CD56-, encompassing CD3+CD8+ cytotoxic
T cells and CD3+CD8- helper T cells (i.e. CD4+ T cells). Within the CD8+ T cell population CMV- or 
MiHA-specific T cells were gated as positive for both tetramer-BV605 and tetramer-BV711. 
Furthermore, memory cell subsets were gated and defined as follows: CCR7+CD45RA+ naïve(-like)
T cells (Tn); CCR7+CD45RA- central memory T cells (Tcm) were, and CCR7- effector/effector memory 
T cells (Tem). Flow cytometry plots of one representative allo-SCT patient (no. 14) are shown.
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Supplementary Figure S2. MiHA-speciﬁc CD8+ T cells exhibit an early differentia-
tion phenotype accompanied with high expression of co-inhibitory molecules
Antigen-specific CD8+ T cells of healthy donors (HD) and allo-SCT patients (allo-SCT pt) were 
examined for expression of co-inhibitory and co-stimulatory molecules using dual colour 
tetramer-based flow cytometry. Combined data showing the percentage of cells positive for 
each co-signaling molecule within the total CD8+ Tem versus CMV- and MiHA-specific CD8+ T
cell populations of HD (white) and allo-SCT pt (grey; HD Tem: n=10; HD CMV: n=10; allo-SCT pt 
Tem: n=30; allo-SCT pt CMV: n=10; allo-SCT pt MiHA: n=20). Statistical analysis was performed
using one-way ANOVA followed by a Bonferroni post-hoc test.* P<0.05, **P<0.01, ***P<0.001.
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Supplementary Figure S3. MiHA-speciﬁc CD8+ T cells have a distinctive co-expression 
proﬁle with high co-expression of co-inhibitory molecules. Antigen-specific CD8+ T 
cells of healthy donors (HD) and allo-SCT patients (allo-SCT pt) were examined for expression of 
co-inhibitory and co-stimulatory molecules by flow cytometry using three different panels. 
CMV- and MiHA-specific CD8+ T cells were gated based on dual color tetramer staining. bh-SNE 
clustering analysis was performed for each flow cytometry panel, containing 5 antibodies 
against different co-signaling molecules. (A-C) Composite overlays in the tSNE1/tSNE2 fields
(top) and individual maps (below composite overlay) visualize the clustering signatures of HD
CMV (green), allo-SCT pt CMV (yellow) and allo-SCT pt MiHA (red). In addition, per panel the
intensity for each individual co-signaling molecule is shown in density plots with a scale bar 
indicating low (dark blue) versus high (dark red) expression. HD CMV: n=10; allo-SCT pt CMV:
n=10; allo-SCT pt MiHA n=20.
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Supplementary Figure S3. Continued. 
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Supplementary Figure S4. Analysis of co-expression proﬁles with clinical outcome
using the initial panels containing ﬁve co-receptors. Expression levels of co-signaling
molecules on MiHA-specific CD8+ T cells of allo-SCT patients (allo-SCT Pt) were evaluated using 
flow cytometry and analyzed in the context of relapse post-transplantation using SPICE 
software. The pie charts depict the average proportion of cells expressing 0 to 5 of the
co-signaling molecules, while the colored arcs indicate which co-signaling molecule is 
expressed by the corresponding pies. Statistical differences were analyzed using the build-in
statistical tool. Non-relapsed pt: n=12; relapsed pt: n=8
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Supplementary Table S1. Patient characteristics.
Pt. no. Disease Sex Age
(years)
Cond. regimen Donor 
relation
CMV reactivation
(months after 
allo-SCT)
Antigen-speciﬁc 
CD8+ T cell 
response
(HLA restriction)
Sampling date 
(months after
allo-SCT)
1 MM F 49 Flu-Cyclo SIB No HA-1 (A2) 6
2 NHL M 28 Flu-Cyclo-ATG MUD No SP110 (A3) 3
3 CML M 47 Cyclo-ATG-TBI MUD No HA-1 (A2) 6
4 MDS M 60 Ida-Cyclo-TBI SIB No HY (B7) 8
5 MDS M 63 Dec-Flu-TBI MUD No HA-1 (A2) 5
6 MDS F 53 Ida-Cyclo-Bus SIB Yes, 8 HA-1 (A2) 11
7 AML M 56 Ida-Cyclo-Bus SIB No ARHGDIB (B7) 7
8 AML M 26 Ida-Cyclo-TBI SIB N.A. HY (A2) 12
9 AML M 58 Dec-Flu-TBI SIB No HA-1 (A2) 1
10 AML F 62 Flu-TBI MUD Yes, 4 ARHGDIB (B7) 6
11 AML M 50 Ida-Cyclo-TBI SIB N.A. HA-8 (A2) 6
12 AML F 52 Cyclo-TBI SIB N.A. ARHGDIB (B7) 14
13 MM M 58 TBI SIB No PANE (A3) 6
14 NHL M 28 Ida-Cyclo-TBI SIB No HY (A2) 4
15 NHL F 48 Ida-Cyclo-TBI SIB No ARHGDIB (B7) 11
16 CML F 35 Ida-Cyclo-TBI SIB No LRH-1 (B7) 14
17 AML F 34 Ida-Cyclo-TBI SIB No LRH-1 (B7) 40
18 AML M 50 Ida-Cyclo-TBI SIB No HY (A2) 3
19 AML M 57 Cyclo-ATG-Bus MUD No HY (A2) 5
20 AML F 33 Ida-Cyclo-TBI SIB No ARHGDIB (B7) 3
21 MM M 59 Flu-Cyclo SIB No CMV (B7) 2
22 MM F 56 Flu-Cyclo SIB No CMV (B7) 5
23 MM F 47 TBI SIB No CMV (B7) 7
24 MM M 66 Flu-Cyclo SIB Yes,1-6 CMV (B7) 4
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DLI prior to
sampling date
(months after
allo-SCT)
Disease status at
sampling date
GVHD at
sampling date
ISD at 
sampling date
Relapse
(months after
allo-SCT)
Alive (at last FU, 
months after
allo-SCT)
Yes, 6
(Prophylactic)
CR No No No Yes, 86
Yes, 2
(Boost)
CR Yes (aGvHD, Grade 3) MMF, prednison,
etanercept and 
inolimomab
No
Yes, 4
(Prophylactic)
CR Yes (aGvHD, Grade 3) No No No, 15 (NRM)
No CR Yes (cGvHD, extensive) No No Yes, 43
No CR No Tacrolimus No Yes, 24
Yes, 6
(Prophylactic)
CR Yes (cGvHD, extensive) CSA and prednison No No, 49 (NRM)
Yes,6
(Prophylactic)
CR Yes (aGvHD, Grade 1) CSA and
Prednisone
No Yes, 151
No CR No (resolved) CSA No Yes, 199
No CR No CSA No Yes, 39
No CR Yes (cGvHD, extensive) CSA and 
prednisone
No Yes, 39
No CR Yes (cGvHD, mild) CSA No Yes, 255
Yes, 8
(Prophylactic)
CR No No No Yes, 145
No CR Yes (cGvHD, mild) No Yes, 9 No,10 (RRM)
Yes, 4
(Therapeutic)
Relapse No CSA Yes, 3 No, 19 (RRM)
No CR No No Yes, 21 Yes, 250
Yes, 10 + 12
(Therapeutic)
Relapse No No Yes, 9 No, 75 (RRM)
Yes, 5
(Prophylactic)
Relapse No No Yes, 38 and 75 No, 94 (RRM)
No CR Yes (aGvHD, Grade 3) MMF Yes, 10 No, 10 (RRM)
No Relapse No No Yes, 4 No, 5 (RRM)
No MRD Yes (aGvHD, Grade 2) No No Yes, 32
No VGPR No CSA Yes, 40 No, 76 (RRM)
Yes, 4
(Prophylacic)
PR No CSA Yes, 11 No, 48 (RRM)
No PR Yes (cGvHD) No Yes, 63 Yes, 154
No PR Yes (aGvHD, Grade 1) No Yes, 45 Yes, 69
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Supplementary Table S1. Continued.
Pt. no. Disease Sex Age
(years)
Cond. regimen Donor 
relation
CMV reactivation
(months after 
allo-SCT)
Antigen-speciﬁc 
CD8+ T cell 
response
(HLA restriction)
Sampling date 
(months after
allo-SCT)
25 CML M 47 Cyclo-Bus SIB No CMV (B7) 6
26 AML M 50 Ida-Cyclo-TBI SIB Yes, 2 CMV (B7) 2
27 AML M 50 Ida-Cyclo-Bus SIB No CMV (B7) 6
28 AML F 48 Ida-Cyclo-TBI, 
Flu-TBI
MUD Yes, 1-2 CMV (B7) 12
29 AML M 55 Cyclo-ATG-Bus MUD Yes, 0-2 CMV (B7) 4
30 AML M 55 Ida-Cyclo-TBI SIB Yes, 1 CMV (B7) 1
Abbreviations: FU, follow-up time-point; NHL, non-Hodgkin lymphoma; CML, chronic myeloid leukemia;
AML, acute myeloid leukemia; MM, multiple myeloma; MDS, myelodysplastic syndrome; Age, age in years 
at time of allo-SCT; Cond Regimen, conditioning regimen; Cy, cyclophosphamide; Ida, idarubicin; TBI, total
body irradiation; Bus, busulphan; Dec, decitabine; SIB, sibling donor; MUD, matched unrelated donor; CMV, 
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DLI prior to
sampling date
(months after
allo-SCT)
Disease status at
sampling date
GVHD at
sampling date
ISD at 
sampling date
Relapse
(months after
allo-SCT)
Alive (at last FU, 
months after
allo-SCT)
No Chronic Phase No No Yes, 24 Yes, 218
No CR No CSA No Yes, 202
No CR No No No Yes, 131
No CR Yes (cGvHD, mouth) CSA Yes, 23 Yes, 34
No CR No No No Yes, 45
No CR Yes (aGvHD, Grade 1) No No No, 4 (NRM)
cytomegalovirus ; DLI, donor lymphocyte infusion; CR, complete remission; VGPR, very good partial 
response; PR, partial remission; MRD, minimal residual disease; N.A., not available; cGVHD, chronic graft-
versus-host-disease; aGVHD, acute graft-versus-host-disease; ISD, immune suppressive drugs; CSA, 
cyclosporin A; MMF, mycophenolic acid; RRM, relapse-related mortality; NRM, non-relapse mortality.
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Supplementary Table S2.  Patient T cell memory characteristics.
Pt. no. CD4+ T cells CD8+ T cells
Tn (%) Tcm (%) Tem (%) Tn (%) Tcm (%) Tem (%)
1 2.7 41.8 55.4 0.6 10.1 89.3
2 53.0 21.7 25.2 13.8 3.5 82.6
3 2.5 30.9 66.5 1.0 14.0 84.9
4 4.6 16.3 79.0 1.0 11.4 87.5
5 45.9 2.4 51.5 8.8 1.7 89.4
6 1.9 35.2 62.7 8.7 23.2 68.1
7 23.3 17.7 58.8 17.1 2.7 80.1
8 0.5 7.4 91.9 0.2 1.5 98.2
9 38.4 8.5 52.9 14.9 1.0 83.9
10 7.9 32.2 59.8 13.1 7.7 79.1
11 4.1 35.7 60.1 1.1 32.2 66.6
12 0.7 10.2 89.0 0.5 8.9 90.5
13 16.5 33.6 49.8 12.6 11.7 75.5
14 36.2 21.1 42.5 9.6 3.0 87.2
15 20.4 46.0 33.4 5.5 16.1 78.3
16 0.2 23.3 76.4 0.1 6.2 93.6
17 1.7 33.1 65.0 3.6 11.5 84.7
18 15.3 31.9 52.6 6.4 9.3 84.2
19 3.0 27.2 69.7 1.9 2.8 95.1
20 8.4 29.2 62.2 4.1 5.3 90.4
21 0.1 10.6 89.2 0.1 5.2 94.7
22 0.1 21.8 78.0 0.2 0.6 99.3
23 9.0 36.9 54.0 2.2 14.8 82.8
24 1.2 48.7 49.9 10.5 18.8 70.7
25 2.2 19.9 77.7 1.7 5.0 93.2
26 15.6 9.1 75.1 5.8 0.8 93.3
27 0.3 12.0 87.6 0.4 4.1 95.4
28 12.8 15.2 71.9 7.3 8.1 84.5
29 0.2 6.5 93.2 0.1 1.3 98.5
30 0.1 24.8 75.1 0.1 11.1 88.8
Abbreviations: Tn, naïve/naïve-like T cells; Tcm, central memory T cells; Tem, effector memory T cells; 
percentage of tetramer-specific T cells within CD8+ T cell population Percentage of T cell respectively CD4+
or CD8+ T cells; Frequency, percentage of tetramer-specific CD8+ T cells population; ND, non-detectable.
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Antigen speciﬁc CD8+ T cells response
Antigen Freq. (%) Tn (%) Tcm (%) Tem( %)
HY (A2) 0.2 0.1 14.4 85.6
HA-1 (A2) 0.1 0.3 5.5 94.2
ARHGDIB (B7) 0.1 0.2 20.7 79.0
HA-1 (A2) 0.6 0.1 11.3 88.6
ARHGDIB (B7) 1.1 0.3 0.3 99.4
HY (B7) 0.5 8.5 6.9 84.7
LRH-1 (B7) 0.1 0.1 0.5 99.5
LRH-1 (B7) 7.1 0.1 1.2 98.6
HY (A2) 0.1 0.2 1.0 98.8
HY (A2) 0.2 6.9 3.6 89.4
HY (A2) 0.3 0.8 13.9 85.2
ARHGDIB (B7) 0.1 ND 4.1 95.9
HA-1 (A2) 0.7 1.1 1.0 97.9
ARHGDIB (B7) 0.1 0.6 8.6 90.7
HA-1 (A2) 0.1 1.3 24.0 74.6
HA-8 (A2) 0.1 ND 5.9 94.1
HA-1 (A2) 0.1 0.8 6.4 92.8
ARHGDIB (B7) 0.1 2.1 ND 97.9
SP110 (A3) 0.1 1.9 2.9 95.2
PANE (A3) 0.3 1.2 2.8 96.0
CMV (B7) 26.8 0.1 11.3 88.6
CMV (B7) 12.6 ND 1.6 98.4
CMV (B7) 5.2 0.1 6.4 93.6
CMV (B7) 7.1 0.1 6.2 93.8
CMV (B7) 7.4 0.1 0.5 99.4
CMV (B7) 2.8 0.7 0.1 99.3
CMV (B7) 2.3 0.1 1.7 98.1
CMV (B7) 2.1 4.2 4.9 91.0
CMV (B7) 1.2 0.1 1.3 98.7
CMV (B7) 1.4 0.2 9.1 90.7
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Supplementary Table S3. Panel design.
Marker ﬂuorophore Clone Isotype Company Laser (nm)
Life/Dead UV - - Life Technologies 355
CD56 BUV737 NCAM16,2 mIgG2b BD Biosciences 355
Tetramer BV605 - - Custom 405
Tetramer BV711 - - Custom 405
CD3 BV510 UCHT1 mIgG1 BD Biosciences 405
CD8 PerCP SK1 mIgG1 BD Biosciences 488
CCR7 PECF594 150503 mIgG2a BD Biosciences 561
CD45RA AF700 HI100 mIgG2b BD Biosciences 638
PD-1 BV421 EH12.1 mIgG BD Biosciences 405
CD57 BV421 NK-1 mIgM BD Biosciences 405
CTLA-4 BV421 BNI3 mIgG2a BD Biosciences 405
KLRG1 FITC (human) mIgG1 Miltenyi Biotec 488
CD200R FITC 380525 mIgG2b R&D systems 488
CD27 FITC M-T271 mIgG1 BD Biosciences 488
BTLA PE J168-540 mIgG1 BD Biosciences 561
2B4 PE 2-69 mIgG2a BD Biosciences 561
ICOS PE DX29 mIgG1 BD Biosciences 561
TIM PE-Cy7 F38-2E2 mIgG Biolegend 561
OX-40 PE-Cy7 Ber-ACT35 mIgG1 Biolegend 561
CD28 PE-C7 CD28.2 mIgG1 BD Biosciences 561
LAG-3 APC - gIgG R&D systems 638
TIGIT APC 741182 mIgG2b R&D systems 638
CD137 APC 4B4-1 mIgG1 BD Biosciences 638
mIgG1 BV421 MOPC-21 - Biolegend 405
mIgG2a BV421 MOPC-173 - Biolegend 405
mIgG1 FITC MOPC-21 - Biolegend 488
mIgG2a FITC 7T4-1F5 - Beckman Coulter 488
mIgG2b FITC A-1 - Beckman Coulter 488
mIgG1 PE MOPC-21 - Biolegend 561
mIgG2 PE MOPC-173 - Biolegend 561
mIgG1 PE-Cy7 679.1Mc7 - Beckman Coulter 561
mIgG1 APC MOPC-21 - Biolegend 638
gIgG APC APC - - R&D systems 638
mIgG2b APC MPC-11 - Biolegend 638
Abbreviations: m, Mouse; g, goat 
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Abstract 
Immunotherapeutic strategies are highly interesting for the treatment of myeloid 
malignancies, as demonstrated with allogeneic stem cell transplantation (allo-SCT). 
However, by creating a suppressive micro-environment, leukemia cells can escape
attack by tumor-reactive T cells. Generally, tumor cells display low expression of 
co-stimulatory molecules and can up-regulate co-inhibitory molecules, which upon 
ligation with their counter receptors expressed on the tumor-reactive T cells results in
T cell inhibition. Systemic immune checkpoint blocking antibodies have demonstrated 
impressive clinical results, but can elicit severe toxicity, especially after allo-SCT.
Therefore, the aim of this study was to determine dominant co-inhibitory ligands 
expressed on AML cells for targeted siRNA interference in the tumor milieu to prevent
dampening of tumor-reactive T cell responses. We found that primary AML cells 
expressed multiple co-signaling ligands, amongst which the stimulatory molecules 
ICOS and CD70, but also the inhibitory PD-L1, Galectin-9 and B7-H3 ligands. Notably,
using siRNA/SAINT-RED transfection technology we demonstrated efficient silencing 
of PD-L1 in AML cell lines as well as in patient’ AML cells. Most importantly, we showed 
significantly enhanced recognition and activation of minor histocompatibility antigen
(MiHA)-specific T cells upon co-culture with PD-L1 silenced MiHA positive AML cells.
This was equally efficient as PD-1 antibody blockade. Together, these results
demonstrate that PD-L1 expressed by AML cells is in involved in dampening T cell
functionalities and that siRNA-mediated knockdown of PD-L1 is an effective strategy 
to improve leukemia-reactive T cell responses. This provides rationale for development
of targeted siRNA delivery technology to selectively interfere with immune escape
mechanisms in the local myeloid tumor micro-environment. 
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Introduction
Myeloid malignancies, including acute myeloid leukemia (AML), are characterized by 
clonal expansion and accumulation of immature myeloid progenitor cells in the bone
marrow. The incidence rates increase with age and outcome is dismal, especially in 
patients >60 years.1 Standard treatment includes intensive chemotherapy to reduce
tumor burden and to achieve clinical remission. Immunotherapy has proven to be 
highly powerful and has curative potential in these patients with hematological
malignancies, as demonstrated with allogeneic stem cell transplantation (allo-SCT). 
The therapeutic efficacy of allo-SCT, the so called graft-versus-tumor (GVT) effect, can 
be attributed amongst others to CD8+ T cells recognizing antigens expressed on the 
recipient tumor cells, including minor histocompatibility antigens (MiHA) and tumor-
associated antigens (TAA).2, 3 However, despite induction of tumor-reactive T cell 
responses, many patients eventually relapse.4, 5
Effective T cell activation depends on the T cell receptor-mediated recognition of 
antigenic peptides-loaded on HLA molecules and on signaling via co-stimulatory 
molecules including CD28 which interacts with CD80/86 on the antigen presenting
cells (APCs).6 Upon activation, T cells acquire effector functions, start to proliferate, 
migrate to the tumor site and attack tumor cells. However, tumor cells are capable of 
evading immune attack via different mechanisms, thereby creating a suppressive mi-
cro-environment through which they can ‘shield’ themselves from T cells.7, 8 Via 
secretion of suppressive factors, such as IL-10, TGF-у and IDO, tumor cells inhibit
tumor-reactive T cells, promote tolerance and recruit suppressive immune cells. 
Additionally, tumor cells and suppressive APCs impair T cell functionality by modulating 
expression levels of co-stimulatory and co-inhibitory molecules.9-11 The sum of these 
co-signals determines the T cell activation state. In hematologic and also in solid 
malignancies, low expression of co-stimulatory ligands and high expression of 
co-inhibitory ligands has been associated with poor prognosis.12, 13 Furthermore, we 
and others have shown that MiHA-specific CD8+ T cells exhibit high expression of 
co-inhibitory receptors, including PD-1, BTLA, TIGIT and TIM-3. Especially, patients 
with relapsed disease have increased expression of PD-1 and TIGIT compared to
non-relapsed patients.14-17 Together, these mechanisms enable tumor escape from 
immune control. Recently, impressive clinical responses have been reported with 
blocking antibodies targeting the co-inhibitory PD-1/PD-L1 signaling pathway in solid 
and hematologic malignancies.18-21 Yet, the negative consequence of systemically 
releasing the immune brake is induction of severe toxicity in healthy tissues. These
immune-related adverse events (irAEs) mainly involve the gut, skin, endocrine glands, 
liver, and lung but can potentially affect any tissue.22 irAEs occurred in up to 90% of 
patients treated with CTLA-4 antibody and in 70% of patients treated with PD-1/PD-L1
antibody.23 Notably, in patients treated with allo-SCT checkpoint blocking antibodies 
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have elicited severe GHVD.24, 25 To prevent such severe systemic toxicity, strategies
 for targeted interference with checkpoint signaling pathways in the tumor micro-
environment are required. In this regard, siRNA technology is highly interesting. 
The aim of this study was to silence dominant co-inhibitory molecules expressed in 
human AML. We found that AML cells express multiple co-stimulatory and co-inhibitory 
ligand, including ICOS and CD70 but also PD-L1, Galectin-9 and B7-H3. Importantly,
we demonstrated efficient silencing of PD-L1 in AML cell lines as well as in patient’ 
AML cells using siRNA technology. Furthermore, we showed enhanced recognition
and activation of MiHA-specific CD8+ T cells upon co-culture with PD-L1 silenced 
MiHA positive AML cells. Together, these results demonstrate that PD-L1 expression 
on AML is involved in dampening T cell functionality, and that provides rationale for 
development of targeted knockdown of PD-L1 results in a selective improvement of 
the GVT responses.
Material and Methods
Patient and donor material
Mononuclear cells were isolated from bone marrow using Ficoll-Hypaque (Healthcare, 
WI, USA) density centrifugation and subsequently cryopreserved. Bone marrow
samples of 21 AML patients were obtained at diagnosis, the characteristics of these
patients are included in Table 1. LRH-1 and HA-1 specific cytotoxic T cell (CTL) were
isolated from 2 different allo-SCT patients and cultured as described previously.5, 14
Patient material and data were obtained in accordance with the Declaration of Helsinki 
and institutional guidelines and regulations (CMO 2013/064). 
Expression profiles of co-signaling molecules
Expression profiles of co-inhibitory and co-stimulatory ligands on patient’ AML cells 
were analyzed by 13-color flow cytometry. Upon thawing of the cryopreserved cells 
half of the sample was cultured overnight in IMDM (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% human serum (HS; Sanquin, Nijmegen, the Netherlands), 15.9 
ng/ml GM-CSF, 12.5 ng/ml G-CSF, 6.25 ng/ml IL-3, 3 ng/ml SCF and 2.5 ng/ml FLT3L
(AML cytokine mix) and with 100 IU/ml IFN-ф and 1.25 ng/ml TNF-т (all from 
Immunotools, Friesoythe, Germany). The other half was directly incubated for 15
minutes at room temperature in PBS + 0.5% BSA supplemented with 1 mg/ml total 
hIgG (Sanquin). Thereafter, cells were labeled with the following antibodies: CD45 
(clone HI30), CD123 (clone 7G3), CD34 (clone 581), CD33 (clone WM53) CD38 (clone 
HB7), CD19 (clone SJ25C1; all BD Biosciences, Franklin Lakes, NJ, USA), CLEC12A (clone 
687317; R&D Systems, Minneapolis, MN, USA). For analysis of co-stimulatory and 
co-inhibitory molecules the following antibodies were used: PD-L1 (clone MIH1), CD48 
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(clone TÜ145), CD200 (clone MRC OX-104), CD80 (clone L307.4), CD70 (clone KI-24), 
CD137L (clone C65-485), CD86 (clone FUN-1, all from BD), Human leukocyte antigen 
(HLA)-DR (clone L243), CD270 (clone 122), Galectin-9 (clone 9M1-3, all from Biolegend), 
PD-L2 (clone PC7, Beckman Coulter, Fullerton, CA, USA), CD155 (clone 300907), CD258
(clone 115520), B7-H3 (clone 185504) and OX-40L (clone 159403, all from R&D systems).
IgG1-FITC, -PE, -PerCP, and -APC (clone MOPC-21), IgG2a-PerCP and -APC (clone
MOPC-173), IgG2b-PerCP (clone MPC-11), IgG3-FITC (clone MG3-35); IgM-PE (MM-30, all
from Biolegend), IgG1-PE-Cy7 (679.1Mc7, Beckman Coulter), IgG2b Alexa-Fluor 700 
(clone 133303, R&D Systems) were used as isotype controls. Cells were incubated for 
30 minutes at 4°C, and thereafter washed with PBS. Next, for live/dead discrimination,
cells were incubated for 30 minutes at 4°C with Fixable eFluor780 (Thermo Fisher 
Scientific, Waltham, MA, USA) 1:1000 diluted in PBS. Subsequently, cells were washed
with PBS + 0.5% BSA and analyzed on a 5-laser FACS ARIA II SORP (BD). 
siRNAs targeting PD-L1
The sequences of PD-L1 siRNA (Nitto-Denko Avecia, Milford, MA. USA) were as follows: 
5’AGAccuuGAuAcuuucAAAdTsdT-3’ (sense), 5’-UUUGAAAGuAUcAAGGUCUdTsdT-3’
(anti-sense).26, 27 As a negative control Luciferase (Luci) siRNA was used: 5’-cuuAcG-
cuGAGuAcuucGAdTsdT-3’ (sense) and 5’-UCGAAGuACUcAGCUcAGCGuAAGdTsdT-3’
(anti-sense). Small cases represent 2’-O-methyl modified residues. 
Silencing PD-L1 in AML cells
AML cell lines or primary AML cells were plated in 24-well plates (Corning Costar) with
0.25x106 cells per well. The cells were incubated with siRNA/SAINT-RED lipoplexes in 
a total volume of 0.5 mL serum-free phenol red-free X-VIVO-15. 1.3 or 4 μg Luci siRNA
(negative control) or PD-L1 siRNA was pre-complexed for 15 minutes with 0.75 mM 
SAINT-RED at a 1:10 w/v ratio (Synvolux Therapeutics, Groningen, The Netherlands) in
a total volume of 150 μL phenol red-free serum-free X-VIVO-15 (Lonza, Verviers,
Belgium). After 1-2 hours of siRNA transfection at 37˚C, 0.5 mL phenol red-free X-VIVO-15
medium supplemented with 20% FCS (Integro, Zaandam, the Netherlands), with or 
without 500 IU/ml IFN-ф for AML cell lines, 200 IU/ml IFN-ф for primary AML cells and 
2.5 ng/ml TNF-т and all cells were cultured for 24-48 h. In case of the 48 h culture, after 
24 h, half of the medium was refreshed with addition of 100 IU/ml IFN-ф and 1.25 ng/
ml TNF-т. Primary AML cultures were additionally supported with the AML cytokine 
mix during the culture, and analyzed only after 24 h. After culture, AML cells were 
harvested and PD-L1 knockdown efficiency was determined by flow cytometry. AML 
cells were harvested and incubated for 15 minutes at room temperature in PBS + 0.5% 
BSA supplemented with 1 mg/ml total hIgG (Sanquin). Thereafter, cells were labeled for 
30 minutes with PD-L1 (clone MIH1, BD), ICAM-1 (clone HCD54) or isotype controls IgG1
(clone MOPC-21, all Biolegend). To gate on CD45dimSSlow AML blasts CD45 (clone J.33, 
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Beckman Coulter) was additionally used. After washing, cells were resuspended in
1:5000 diluted Sytox blue (Thermo Fisher Scientific, Waltham, MA, USA) to enable live/
dead discrimination. All cells were analyzed using the Gallios flow cytometer (Beckman 
Coulter). The ΔMFI was calculated by subtraction of the mean fluorescence intensity 
(MFI) of the isotype control from the PD-L1 MFI. Subsequently, PD-L1 knockdown
efficiency was calculated as follows: 100%-((ΔMFI PD-L1 siRNA treated AML/ΔMFI 
control siRNA treated AML) x 100%). 
CTL stimulation assays
Primary AML cells were treated with/without 4 μg PD-L1 or Luci siRNA as described 
above. Thereafter, AML cells of all conditions were activated overnight in X-VIVO-15/10% 
HS with 100 IU/ml IFN-ф and 1.25 ng/ml TNF-т, and AML cytokine mix to support 
survival. Cells were cultured in 24-well plates (Corning Costar) with 0. 5x106 cells per 
well in a total volume of 1 ml. The following day, AML cells were harvested and PD-L1 
knockdown efficiency was determined via flow cytometry (Beckman Coulter). 
Thereafter, AML cells were loaded with 10μM LRH-1 peptide (TPNQRQNVC) or HA-1 
peptide (VLHDDLLEA) for 30 minutes at 37°C. Then, AML cells were washed,
resuspended at 2x104 cells/ml and seeded in 100 μl in a 96-well round bottom plates 
(Corning Costar). Subsequently, corresponding MiHA-specific CTL were added at a 1:1 
E:T ratio. Beforehand, LRH-1 and HA-1 specific CTL clones were analyzed using 
tetramers, that were kindly provided by prof. dr. F. Falkenburg (Department of 
Hematology, Leiden University Medical Center, Leiden, the Netherlands). CTL were 
incubated with 0.2 μg PE-labeled tetramers (LRH-1: TPNQRQNVC; HA-1: VLHDDLLEA)
for 15 minutes at room temperature. Subsequently, cells were labeled with CD8 (clone 
SK1), CD3 (clone UCHT1, both Biolegend) and PD-1 (EH12.1, BD) or isotype control IgG1 
(MOPC-21, Biolegend) for 30 minutes at 4°C. After washing the cells were analyzed via
flow cytometry. As control conditions, PD-1 antibody (BMS-936558; MDS-1106;
ONO-4538) or hIgG4 control (kindly provided by Dr. A. Korman (Bristol-Myers Squibb,
Biologics Discovery Milpitas, CA, USA) were taken along at final concentrations of 10
μg/ml. Co-cultures were performed in a total volume of 200 μl IMDM/10% HS in the 
presence of CD107a antibody (clone H4A4, Biolegend). After overnight culture,
supernatant was harvested for IFN-ф analysis. The CTLs were harvested and incubated
for 30 minutes at 4°C with CD69 (clone FN50), CD8 (clone RPA-T8; both Biolegend) and 
CD137 (clone 4B4-1, BD). After washing cells, were resuspended in 1:5000 diluted Sytox 
blue (Thermo Fisher Scientific) for live/dead discrimination. All cells were analyzed 
using the Gallios flow cytometer (Beckman Coulter).
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IFN-ʺ ELISA
Production of IFN-ф by MiHA-specific CTL was determined by enzyme-linked 
immunosorbent assay (ELISA; Pierce Endogen, Rockford, IL, USA;) according to
manufacturer’s protocol.
Data and statistical analysis
Flow cytometry data were analyzed using Kaluza (V1.5a, Beckman Coulter). The gating
strategy is depicted in detail in Supplementary figure S1. Isotype-matched controls 
were used to evaluate the positivity for the co-signaling molecules (i.e. each isotype 
gate was set at ≤1% positive). Data quantifications were made in Graphpad Prism
(V5.03, GraphPad Software, La Jolla, CA, USA). The p-values were obtained using a 
two-tailed t-test or One-way ANOVA followed by a Bonferroni post-hoc test, as 
indicated, with * p<0.05; ** p<0.01, *** p<0.001.
Results
Co-stimulatory and co-inhibitory ligand expression on primary AML cells
To identify dominant co-signaling ligands expressed by AML cells, we analyzed AML 
patient bone marrow using flow cytometry. AML cells were analyzed directly after 
thawing, as well as after overnight culture under inflammatory conditions with 
low-dose IFN-ф and TNF-т. AML cells were gated as indicated in Supplementary figure 
S1. Co-stimulatory ligand CD275 (ICOSL) showed variable expression on primary AML 
blasts, but was significantly expressed under inflammatory conditions (Figure 1). 
Furthermore, stimulatory ligand CD70 expression was significantly induced upon
exposure to inflammatory cytokines. In contrast, the other co-stimulatory ligands
were unresponsive to IFN-ф and TNF-т stimulation. Low to no expression of CD258 
(LIGHT), CD80, OX-40L and CD137L was observed by primary AML blasts, and low to 
variable surface expression was shown for CD86 and CD48. Furthermore, variable 
HLA-DR expression was observed. Interestingly, CD270 (HVEM) expression slightly
reduced upon stimulation. On the other hand, expression of inhibitory ligands PD-L1 
and B7-H3 was significantly induced by inflammatory conditions. Although,
unresponsive to IFN-ф and TNF-т exposure, Galectin-9 and CD200 expression was
observed on AML cells. No expression of PD-L2 and CD155 was seen on AML cells.
Similar expression profiles were obtained for MFI of each co-stimulatory and
co-inhibitory ligand (data not shown).
Collectively, these data demonstrate that primary AML blast in the bone marrow 
express both co-stimulatory and co-inhibitory ligands, and that profiles change under 
inflammatory conditions for both stimulatory and inhibitory ligands with PD-L1 but not 
CD80 and CD86 being up-regulated.
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PD-L1 can be efficiently silenced in AML cells
To investigate whether the involvement of PD-L1 in AML immune escape and to 
establish siRNA silencing technology, we studied siRNA-mediated silencing of PD-L1 in
AML cells. Here, we delivered 1.3 μg or 4 μg of PD-L1 or control siRNA into the AML cells 
using SAINT-RED transfection reagent. After 24 h and 48 h, PD-L1 and ICAM-1 surface 
expression was analyzed by flow cytometry. First, we investigated if PD-L1 could be 
Figure 1. Surface expression of different co-stimulatory and co-inhibitory ligands 
on primary AML tumor cells. Patient AML cells, gated on CD45dim, were analyzed using flow 
cytometry for the expression of multiple co-stimulatory and co-inhibitory ligands directly after 
thawing (open circles) and after overnight incubation with 100 U/ml IFN-ф and 1.25 μg/ml TNF-т
(filled black squares). For each ligand, the percentage of positive cells was determined compared 
to isotype control (<1%). Lines indicate the mean. Statistical analysis was performed using 
one-way ANOVA followed by a Bonferroni post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001.
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silenced in AML cell line HL60 that had been pre-activated with IFN-ф and TNF-т. The 
inflammatory milieu promoted efficient up-regulation of PD-L1 surface expression on 
HL60 cells (PD-L1 ΔMFI 4.5 ± 0.6; Figure 1A-B) as compared to unstimulated control 
cells (PD-L1 ΔMFI 0.3 ± 0.1). Treatment with 1.3 or 4 μg Luci siRNA/SAINT-RED lipoplexes 
did not affect PD-L1 expression levels on AML cells with respective ΔMFI of 4.9 ± 0.3 
and 5.8 ± 0.7. Most importantly, we observed a dose-dependent down-regulation of 
PD-L1 on HL-60 cells treated with PD-L1 siRNA/SAINT-RED lipoplexes (ΔMFI PD-L1 of 
3.4 ± 0.4 and 2.8 ± 0.3) after 24 h. This resulted in knockdown efficiencies of 22.9% ± 
0.7 using 1 μg PD-L1 siRNA and 51.1% ± 7.4 in case of 4 μg PD-L1 siRNA, as compared to 
PD-L1 expression following stimulation with IFN-ф and TNF-т by Luci treated AML cells 
(Figure 2C). PD-L1 expression by non siRNA treated AML cells remained stable for 48 h
(Figure 2D). However, after 48 h the 4 μg PD-L1 siRNA treated cells showed lower 
knockdown (34.1% ± 4.0), while the 1.3 μg PD-L1 siRNA treated cells had similar 
knockdown efficiency as compared to the 24 h condition (21.9% ± 4.0) (Figure 2E). 
Notably, similar results were obtained with other AML cell lines (Mono-MAC6 and
THP-1, data not shown).
Next, we investigated PD-L1 siRNA silencing efficacy in patient’ AML cells. We assessed 
PD-L1 surface expression of AML cells subjected to IFN-ф and TNF-т activation and 
treatment with Luci or PD-L1 siRNA/SAINT-RED lipoplexes. ICAM-1 expression was
used as a control for activation of the AML cells due to the inflammatory conditions, 
and at the same time served as a control to monitor potential off-target effects of the
siRNAs. Patient’ AML cells efficiently up-regulated PD-L1 as well as ICAM-1 expression 
upon treatment with IFN-ф and TNF-т compared to non-treated cells (Figure 3A-D). In 
none of the patients Luci siRNA/SAINT-RED lipoplex treatment affected PD-L1 or 
ICAM-1 surface expression. Notably, PD-L1 siRNA treatment resulted in efficient
reduction of PD-L1 expression (Figure 3A-D) and no effect was observed on ICAM-1
surface expression. Combining data of all patients, PD-L1 knockdown efficiency for the 
1.3 μg and 4 μg siRNA conditions was respectively 65.8% ± 6.4 and 68.3% ± 13.9 (Figure 3E) 
and minimal ICAM-1 knockdown of respectively 8.2% ± 2.7 and 9.3% ± 5.2 (Figure 3F). 
In conclusion, PD-L1 can be efficiently and specifically silenced in AML cell lines and 
patient AML cells. 
PD-L1 silencing in primary AML patient samples results in enhanced 
tumor-reactive T cell responses 
To determine the effect of siRNA-mediated PD-L1 knockdown on recognition and
activation of MiHA-specific CD8+ T cells by AML cells, we performed antigen recall
experiments using PD-L1 silenced AML cells expressing the hematopoietic-restricted
MiHA LRH-1 or HA-1.14 The MiHA-specific CTLs exhibited high PD-1 expression at start 
of the co-culture (Supplementary figure S2A). Patient AML cells were pre-activated
with IFN-ф and TNF-т, treated with/without 4 μg PD-L1 or control siRNA and loaded
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6Figure 2. Efﬁcient siRNA-mediated knockdown of PD-L1 on AML cell line. HL60 cells 
were treated with/without 1.3 μg or 4 μg Luci or PD-L1 siRNA/SAINT-RED lipoplexes at a 1:10 w/v
and subsequently cultured for 24 or 48 hours with/without 250 IU/ml IFN-ф and 1.25 ng/ml 
TNF-т. Samples were analyzed for PD-L1 surface expression using flow cytometry. (A) PD-L1 
surface expression by HL60 cells. Data of 1 representative experiment out of 5 are shown. The 
dashed line is set at the isotype control (≤1%); numbers in the plots represent the mean 
fluorescence intensity. (B and D) The Δ mean fluorescence intensity (MFI) of PD-L1 surface
expression by HL60 cells after 24 hours (B) and 48 hours (D) stimulation with/without 250 IU/ml 
IFN-ф and 1.25 ng/ml TNF-т. (C and E) The knockdown efficiency of HL60 cell treated with 1.3 μg 
or 4 μg Luci or PD-L1 siRNA/SAINT-RED lipoplexes. Knockdown efficiency is calculated as
follows: 100%-((ΔMFI PD-L1 siRNA treated AML/ΔMFI control siRNA treated AML) x 100%). The 
mean ± SEM is shown (n=5). Statistical analysis was performed using an one-way ANOVA 
followed by a Bonferroni post hoc test (B and D) or a two-sample two-tailed t test with repeated 
measures (C and E). *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 3. Efﬁcient and speciﬁc siRNA-mediated knockdown of PD-L1 on patient 
AML cells. Primary AML patient bone marrow samples were incubated with/without 1.3 μg or 
4 μg Luci or PD-L1 siRNA/SAINT-RED lipoplexes at a 1:10 w/v and subsequently cultured for 
24 hours with/without 100 IU/ml IFN-ф and 1.25 ng/ml TNF-т. samples were analyzed for PD-L1
and ICAM-1 surface expression using flow cytometry. (A and B) PD-L1 and ICAM-1 surface 
expression by patient AML cells, gated on CD45dim. Data is shown for two representative 
patients (pt 16 and pt 17) out of three. The dashed line is set on the isotype control and numbers 
in the plots represent the mean fluorescence intensity of PD-L1 and ICAM-1 expression. (C and 
D) The Δ mean fluorescence intensity (MFI) of PD-L1 surface expression by primary AML cells
after 24 hours stimulation. Data is shown for two representative patients (pt 16 and pt 17) out of 
three patients. Knockdown efficiency of primary AML cells treated with 1.3 μg or 4 μg Luci or 
PD-L1 siRNA/SAINT-RED lipoplexes for PD-L1 (E) and for ICAM-1 (F) was determined. Knockdown 
efficiency is calculated as follows: 100%-((ΔMFI PD-L1 siRNA treated AML/ΔMFI control siRNA
treated AML) x 100%). The mean ± SEM is shown (n=3). Statistical analysis was performed using 
a two-sample two-tailed t test with repeated measures.
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Figure 4. PD-L1 knockdown in primary AML patient samples results in improved 
CTL activation and tumor recognition. AML patient bone marrow samples were treated
with 4 μg Luci or PD-L1 siRNA/SAINT-RED lipoplexes at a 1:10 w/v or not transfected (medium,
isotype and тPD-1 conditions) and then cultured for 24 hours with 100 IU/ml IFN-ф and 1.25 ng/
ml TNF-т. Then, CTLs were co-cultured for 24 hours with MiHA peptide-loaded or not 
peptide-loaded (medium condition) primary AML cells in a 1:1 ratio and the CTLs. Thereafter 
CTLs were analyzed using flow cytometry for activation and degranulation using CD69 (B), 
CD107a (A and C), and CD137 (A and D). (A) Dot plots show CD107a and CD137 expression after 
co-culture of AML cells CTLs for one representative patient. Numbers in the plot indicate 
percentage positive CTLs for the indicated gate. (B-E) Data are depicted as the mean ± SD of a 
triplo measurements of one representative patient. (B-D) surface expression of activation and
degranulation markers were measured using flow cytometry and indicate percentage positive 
CTLs and (E) IFN-ф production was analyzed using ELISA. One representative experiment (pt 21) 
of 3 is shown and One-way ANOVA was performed. **, P < 0.01; ***, P < 0.001.
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with MiHA peptide. PD-L1 knockdown efficiency was above 50% for all cultures
(Supplementary figure S2B). As an additional control, PD-1 blocking antibody was
taken along. Both PD-L1 silencing and PD-1 blocking antibody treatment resulted in
significantly increased activation of MiHA-specific CTLs in the AML co-culture, as 
reflected by augmented expression of CD69, CD107a and CD137 (Figure 4A-D). 
Furthermore, the IFN-ф production by the CTLs upon recognition of the patient’ AML
cells was significantly improved in case of PD-L1 knockdown and PD-1 blockade as 
compared to the corresponding controls. Together, these data demonstrate that
siRNA-mediated silencing of PD-L1 on AML cells results in improved T cell recognition 
and activation, providing a rationale for the development for targeted siRNA-mediated 
interference of PD-L1 on AML cells.
Discussion
The past decade immunotherapy has made significant progress, causing major 
breakthroughs for effective cancer treatment. A potential curative immunotherapeutic 
strategy for hematological malignancies is allo-SCT, due to the induction of 
tumor-reactive CD8+ T cell responses. Nevertheless, despite the induction of these
tumor-reactive T cells many patients still suffer from refractory or reoccurring disease. 
It has become evident that tumor-reactive T cells can be inhibited in their function due
to distinct mechanisms employed by tumor cells,7 including signaling via co-inhibitory
receptors on these T cells.28 Previously, we and others have shown that the co-inhibitory 
receptors PD-1, TIM-3 and TIGIT contribute to the functional suppression of 
tumor-reactive T cells and that these T cells could be functionally reinvigorated ex vivo 
and in vivo by checkpoint blockade.14, 15, 29-32 The last years, impressive clinical
responses have been reported with blocking antibodies targeting these co-inhibitory 
molecules.18-21
However, systemic checkpoint blockade can cause toxicity in healthy tissues irAEs 
were reported in up to 90% of the patients treated with CTLA-4 antibody, and 70% in 
case of PD-1 and PD-L1 blockade.18, 19 In a phase III trial with ipilimumab, 25% of the
irAEs were grade 3–4 toxicities and 10–15% were severe or life-threatening.33, 34
Especially patients suffering from auto-immune disease and patients who received
allo-SCT are at risk of developing severe irAEs or GVHD, respectively.35-38 In the study 
of Haverkos et al. rapid onset (after 1 or 2 infusions of PD-1 blocking antibody) of severe
GVHD was reported in 55% of patients, of whom only 2 out of 17 patients responded to
GVHD therapy.24 Although, improvement of GVT immune responses is essential to 
enhance disease-free and overall survival after allo-SCT, the risk of inciting detrimental
GVHD with systemic checkpoint blockade is considerable. Therefore, development of 
strategies to locally interfere with checkpoint pathways is highly attractive to improve
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GVT immunity with minimal risk of toxicity in healthy tissues. That prompted us to 
determine which co-inhibitory ligands are dominantly expressed on AML cells for 
siRNA interference in the tumor milieu to prevent dampening of tumor-reactive T cell 
responses. First, we investigated the expression of a broad range of co-stimulatory
and co-inhibitory ligands to gain more insight in the immune stimulatory phenotype of 
AML cells directly ex vivo and following exposure to inflammatory factors, mimicking 
the tumor microenvironment. We found that AML blasts express the co-stimulatory 
ligands ICOS-L (binds ICOS) and CD70 (binds CD27), which are further induced during
inflammation.39 Furthermore, we could observe low levels of CD86 (binding CD28/
CTLA-4) and moderate expression levels of HVEM, which is in line with others reports.15, 
40, 41 HVEM is part of an intricate receptor/ligand network. On one hand it can bind to 
LIGHT on T cells, giving a stimulatory effect, while on the other hand it can bind BTLA 
and CD160 resulting in inhibitory signals.42, 43 In addition, other co-inhibitory ligands
were expressed on AML blasts: Galectin-9 (binding TIM-3), CD200 (binding CD200R) 
and B7-H3 (receptor unknown). Interestingly, the ligand of PD-1, PD-L1 was expressed 
and further up-regulated under inflammatory conditions.44-46 Altogether, this results 
in a framework of co-stimulatory and co-inhibitory ligands of which the sum of all 
signals determines the T cell activation state. As the total contribution of different 
co-stimulatory and co-inhibitory interactions is complex this needs to be further 
elucidated in future blocking experiments. Although, by silencing co-inhibitory
molecules on the tumor cells the balance can be turned towards a more stimulatory 
phenotype for improved AML recognition and T cell activation. 
To investigate whether tumor-reactive T cell immunity could be improved by targeted 
interference of co-inhibitory molecules, we explored siRNA-mediated silencing of 
PD-L1 in myeloid tumor cells. Therefore, PD-L1 siRNA was transfected into AML cells 
using SAINT-RED lipoplexes, which was previously demonstrated to be an effective 
and non-toxic approach in monocyte-derived dendritic cells (DC).47 Efficient PD-L1 
silencing was observed in activated AML cells treated with the highest dose of siRNA/
SAINT-RED lipoplexes. After 48 h, silencing efficacy had reduced, which could be 
related to mRNA/protein renewal in relation to siRNA expenditure. Another explanation 
for this observation is that the cell line is rapidly dividing and thereby diluting out the
cytosolic siRNA. This indicates that repeated siRNA/lipoplex treatment might be
required to efficiently silence PD-L1 expression in vivo. For both siRNA dosages we 
demonstrated significant PD-L1 knockdown in activated patient’ AML cells with 
minimal off-target effects. Importantly, PD-L1 silencing on AML cell resulted in better T 
cell recognition and activation. Notably, these results were confirmed by using the 
PD-1 blocking antibody Nivolumab, as was previously shown by Norde et al.48
Our data illustrate that targeted siRNA-mediated interference with the PD-1/PD-L1
pathway in the tumor micro-environment would be an attractive approach to 
strengthen anti-tumor T cell responses in AML patients with minimal risk of eliciting
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severe toxicity. Applying this strategy, patients treated with allo-SCT could also benefit 
from checkpoint interference as the siRNA-mediated approach is expected to be safer 
than systemic checkpoint blockade.49-51 In order to deliver the siRNAs into the myeloid 
blasts, a clinically applicable nanocarrier should be used to protect the siRNAs from
RNAses in the serum. Currently, different carriers, including lipid nanoparticles and 
poly-lactic-co-glycolic acid (PLGA) particles, are being developed and explored for in
vivo delivery of drugs, including siRNAs.52-54 Furthermore, a targeting moiety is 
required to facilitate specific targeting of AML cells. There are various targeting 
candidates, including CD33 and CD123, that are highly but not selectively expressed 
by AML cells, as they are also expressed by normal hematopoietic progenitors and on
other healthy (non-hematopoietic) cells.55, 56 CLEC12A, on the contrary, was found to
be more selectively expressed by AML stem cell and blasts, as expression on healthy
hematopoietic stem cells was lacking. Furthermore, CLEC12A is expressed on more 
mature myeloid cells including monocytes, DC subsets as well as macrophages, my-
eloid-derived suppressor cells (MDSCs) and granulocytes found in the tumor microen-
vironment and not on lymphoid cells or other healthy tissue cells.57 Importantly, we 
and others have demonstrated that CLEC12A is capable of internalizing and delivering
cargo, which is essential for the targeted delivery of siRNAs.58-63 When a siRNA-loaded
nanocarrier is than coated with CLEC12A antibodies it would be directed to AML blasts 
and also to immune suppressive myeloid cells, including MDSCs or type 2 macrophages.
Another advantage of using nanocarriers is that these can be easily loaded with 
multiple siRNAs targeting different immunosuppressive mechanisms, including
immune checkpoint molecules, suppressive cytokines, iNOS, arginase. As a result the 
immune suppressive “shield” created by the myeloid tumor cells and surrounding 
suppressive antigen-presenting cells can be dismantled from multiple angles allowing 
immune-mediated tumor control. 
Altogether, we have demonstrated that AML cells express different co-stimulatory 
ligands including ICOS-L, CD70, CD8 and HVEM, but also the co-inhibitory ligands 
PD-L1, Galectin-9 and B7-H3. Furthermore, we have shown that PD-L1 can be efficiently 
silenced in AML cell lines as well as in patient’ AML cells using siRNA technology. 
Importantly, T cell activation, degranulation and IFN-ф production was enhanced upon 
silencing of PD-L1 in patient’ AML cells. These data provide rationale for the
development of siRNA-nanocarriers for in vivo AML targeting to improve anti-tumor 
immunity, without evoking severe systemic toxicity in AML patients. 
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Supplementary Figure S1. Flow cytometry gating strategy of patient AML cells.
First, single cells were gated using forward- and sideward-scatter characteristics. Then, life cells
were gated using a life/dead discriminator and auto-fluorescence negative cells were selected 
using a non-stained empty flow channel. Subsequently, B cell progenitors were discarded. 
Then, the malignant population was gated on CD45dim expression. This population was used for 
analysis for co-stimulatory and co-inhibitory ligand expression patterns. Additionally, CD33, 
CD34, CD38, CD123 and CLEC12A expression by the CD45dim population was analyzed. Flow
cytometry plots of one representative AML patient (no. 15) are shown.
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Supplementary Figure S2. High PD-1 expression of CTLs and efﬁcient PD-L1 
knockdown in patient AML sample. (A) PD-1 expression of MiHA-specific CD8+ CTL was
determined prior to co-culture with patient AML cells. CTL was characterized as life, CD3+, CD8+
and HA-1 tetramer positive. The number in the plot indicates the percentage positive CD8+
T cells for HA-1 tetramer staining. Thereafter, PD-1 (black open histogram) expression by the CTL
was determined compared to the isotype control staining (filled gray histogram). The numbers 
in the plots represent the mean fluorescence intensity (MFI). (B) PD-L1 surface expression was 
determined for the AML patient samples pre-treated with/without 4 μg Luci or PD-L1 siRNA after 
overnight stimulation with 100 IU/ml IFN-ф and 1.25ng/ml TNF-т. One representative patient (pt 
21) out of 3 is shown. The dashed line is set at the isotype control and the numbers in the plot 
represent the mean fluorescence intensity of protein expression.
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Summary 
Hematological malignancies are a heterogeneous group of disorders originating from 
the hematopoietic system. In the last years, progress has been made in the treatment
of these malignancies and the introduction of new therapies has greatly improved
outcome. Allogeneic stem cell transplantation (allo-SCT) is one of the most effective 
and potential curative therapies for patients suffering from aggressive hematological 
malignancies.1 First, patients are conditioned with chemotherapy and/or radiotherapy 
followed by infusion of partially or completely human leukocyte antigen (HLA)-matched
donor stem cells. These donor stem cells replace the autologous hematopoietic 
system of the patient. However, the therapeutic efficacy of allo-SCT is mostly attributed
to the graft-versus-tumor (GVT) effect, mediated by long-lasting donor-derived T cell 
and natural killer (NK) cell responses against residual patient’ hematopoietic cells,
including the malignant tumor cells. During this response donor-derived T cells 
become activated by recipient minor histocompatibility antigens (MiHA), tumor-
associated antigens (TAA) and mutated neo-antigens that are presented by antigen 
presenting cells (APCs).2, 3 The activated T cells subsequently proliferate and 
differentiate into effector T cells and have the capability to target and lyse MiHA or TAA
expressing tumor cells. A proportion of these activated naïve T cells becomes memory 
T cells with the capacity to provide long term protection against recurring tumor cells.
Nevertheless, despite memory formation, many patients eventually relapse after 
allo-SCT. There are a various potential causes for tumor relapse in these patients, 
including inadequate tumor reduction prior to transplant, insufficient induction of 
tumor-reactive T cell and NK cell responses or dampening of anti-tumor immunity due
to immune evasion by the tumor cells.4, 5 This immune escape may result from immuno-
suppressive mechanisms exploited by the tumor cells, including disrupted antigen
presentation, secretion of immuno-suppressive cytokines, recruitment of regulatory 
T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), but also modulation of 
the expression levels (and subsequent signaling) of co-stimulatory and co-inhibitory 
molecules.6, 7 Although allo-SCT is potentially curative, it can be accompanied by the
life-threatening complication graft-versus-host-disease (GVHD).8 This is caused by 
donor T cells recognizing ubiquitously expressed MiHA in healthy tissues of the
patient. To improve disease-free survival in patients suffering from hematological 
malignancies it is important to selectively boost GVT responses, without inducing or 
aggravating GVHD. This thesis describes novel immunotherapeutic approaches to 
induce and reactivate tumor-specific T cells by use of dendritic cell (DC)-based
strategies and/or interference with negative regulating immune checkpoint molecules
involved in immune escape. 
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DC-based cancer vaccination has been widely investigated for the past two decades
due to the central role of DC in orchestrating adaptive and innate immunity. DC take up
antigens, subsequently mature and up-regulate co-stimulatory molecules for immune
activation as well as lymph node homing receptors. Upon arrival in the lymph nodes,
DC drive the activation and polarization of naïve T cells or memory T cells, and elicit
productive immune responses against the processed antigen. For this reason, they are 
considered excellent candidates for therapeutic anti-cancer vaccines to boost existing
anti-tumor immunity, tipping the balance from tumor tolerance towards tumor control. 
The DC in these vaccines, when they are of donor origin, need to be loaded with tumor 
antigens (i.e. tumor lysate, peptide, mRNA) to induce potent tumor-specific T cell 
responses, capable of killing antigen-expressing tumor cells. Multiple clinical trials
have been conducted using ex vivo-generated monocyte-derived dendritic cells 
(MoDCs) in various types of solid and hematological cancers. These trials have
demonstrated that DC vaccination is feasible, safe and capable of inducing
tumor-specific immune responses in vivo, although the clinical benefit should be
further maximized as few patients developed objective clinical response. This 
emphasizes that further improvement and optimization of DC vaccines are required. 
One option is to optimize the efficacy of the commonly used MoDC, for instance by 
silencing co-inhibitory molecules to improve T cell boosting9, 10 or by pulsing with 
IL-15Rт/IL-15 mRNA to facilitate IL-15 trans-presentation and secretion for enhanced T 
cell and NK cell activation and maintenance.11 Alternatively, the application of natural
occurring DC subsets found in skin and/or blood is gaining interest. It has been shown
that primary DC are stronger inducers of anti-tumor immune responses than MoDCs.12
Moreover, studies indicate that the different DC subsets can act synergistically via
cross-talk, thereby potentiating each other’s stimulatory capacity.13 We hypothesized
that simultaneous vaccination with different DC subsets result in broader and more 
potent immune responses, with superior therapeutic efficacy as compared to
conventional MoDC vaccines. In chapters 2 and 3 we explored the feasibility to
generate high numbers of different DC subsets ex vivo from hematopoietic stem and
progenitor cells (HSPC) of the corresponding transplant donor for multiple vaccination
rounds post allo-SCT. In chapter 2 we aimed to establish a culture protocol for the
generation of large numbers of highly functional skin DC subsets to boost anti-cancer 
immunity. CD34+ HSPC derived from umbilical cord blood (UCB) were used for DC 
generation, since these cells exhibit the best expansion and differentiation potential. 
In our culture protocol, we could generate clinically relevant numbers of mature CD1a+
myeloid DC (mDC), resembling interstitial/dermal DC, and CD207+ Langerhans cells 
(LC)-like DC from CD34+ HSPC with >95% purity. Both DC subsets exhibited a cytokine
profile that favored CD8+ T cell responses. Furthermore, these DC possessed superior 
capacity to induce proliferation of allogeneic as well as viral antigen-specific CD8+ T 
cells, both in vitro and in vivo, as compared to conventional MoDC. Additionally,
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UCB-DC and UCB-LC efficiently boosted the expansion of HA-1-specific CD8+ T cells of 
allo-SCT patients and primed MiHA-specific CD8+ T cells in vitro. In chapter 3 we
further improved the culture protocol to generate naturally occurring blood DC subsets,
including BDCA1+ and BDCA3+ mDC and plasmacytoid DC (pDC), from CD34+ HSPCs. 
Here, we showed that inhibition of the aryl hydrocarbon receptor, using antagonist 
StemRegenin 1 (SR1), improved the expansion and differentiation of BDCA2+BDCA4+
pDCs, BDCA1+ mDC, and BDCA3+CLEC9A+ mDC from HSPCs. This resulted in 
clinical-scale numbers of highly functional DC. These DC were phenotypically and 
functionally comparable to their peripheral blood DC counterparts and secreted high
levels of pro-inflammatory cytokines, including interferon (IFN)-т, interleukin (IL)-12, 
and tumor necrosis factor (TNF)-т. Furthermore, they upregulated co-stimulatory 
molecules and maturation markers following stimulation with Toll-like receptor (TLR) 
ligands. Most importantly, they efficiently boosted allogeneic CD4+ and CD8+ T cell
responses and activated MiHA-specific CD8+ T cells. 
Since production of ex vivo-generated DC products is time consuming and costly, we
also pursued an alternative DC-based strategy. In chapter 4, we aimed to directly
target natural DC subsets with tumor antigens to promote tumor-reactive T cell 
responses in vivo. Here, we investigated the applicability of the endocytic C-type lectin 
receptor (CLR) CLEC12A as targeting receptor for functional delivery of antigens into 
natural occurring DC subsets to boost CD4+ and CD8+ T cell responses. We confirmed
that CLEC12A is selectively expressed by hematopoietic cells of myeloid origin,
including the BDCA1+ and BDCA3+ mDC subsets and pDCs. Moreover, we demonstrated 
that these DC subsets efficiently internalized CLEC12A upon antibody binding,
whereupon CLEC12A quickly translocated to the early endosomes and subsequently 
routed to the lysosomes. Notably, as CLEC12A contains an immunoreceptor 
tyrosine-based inhibitory motif (ITIM) in its cytoplasmic tail, it might function as an 
inhibitory receptor upon triggering. However, upon antibody targeting of the CLEC12A 
receptor we did not observe any negative effects on MoDC maturation nor function. 
More importantly, CLEC12A-mediated delivery of keyhole limpet hemocyanin (KLH) 
resulted in enhanced proliferation and cytokine secretion by KLH-experienced CD4+ T 
cells. Furthermore, CLEC12A-targeted delivery of a long peptide MiHA (HA-1) resulted 
in efficient antigen cross-presentation by mDCs and pDCs, leading to productive ex 
vivo activation of MiHA-specific CD8+ T cells from allo-SCT patients. In conclusion, 
both the generation of different DC subset and the direct in vivo targeting of DC showed 
promising preclinical results for the induction and boosting of anti-tumor immunity. 
Therefore, these strategies should be further brought to allo-SCT patients in order to
test their in vivo potential to selectively boost anti-tumor immunity.
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Despite the formation of MiHA or TAA specific T cell responses, tumor cells can evade
immune recognition and destruction using various mechanisms. One of these
mechanisms is the dis-balance in co-stimulatory and co-inhibitory signals that 
tumor-reactive T cells receive in the tumor micro-environment, which contributes to 
their dysfunctionality. Therefore, we evaluated in chapter 5 immune checkpoint
expression profiles of MiHA-reactive CD8+ T cells of allo-SCT patients using a 13-color 
flow cytometry panel. We correlated these expression patterns to clinical outcome,
and compared the MiHA-specific CD8+ T cells with cytomegalovirus (CMV)-reactive 
CD8+ T cells of healthy donors and allo-SCT patients. We found that MiHA-reactive
CD8+ T cells exhibited an early differentiated CD27++/CD28++ phenotype with low 
KLRG-1 and CD57 expression. These T cells also displayed increased expression of 
co-inhibitory molecules PD-1, TIM-3 and TIGIT compared to total effector-memory 
T cells and CMV-specific CD8+ T cells in healthy donors and allo-SCT patients.
Interestingly, high co-expression of PD-1, TIGIT and KLRG-1 on MiHA-reactive CD8+
T cells was associated with relapse after allo-SCT. Together, these findings indicate
that MiHA-specific CD8+ T cells of relapsed patients have a distinctive co-inhibitory 
expression signature compared to patients who remain in remission. This phenotype 
may serve as a potential monitoring tool in patients. Moreover, these findings suggest 
that PD-1 and TIGIT play an important role in regulating T cell-mediated tumor control,
providing rationale for interference with these immune suppressive checkpoint
molecules by using blocking antibodies. Although, systemic immune checkpoint 
blocking antibodies have demonstrated impressive clinical efficacy, they can elicit 
severe toxicity, especially after allo-SCT in the form of detrimental GVHD. Therefore, in
chapter 6, we investigated an alternative strategy to locally interfere with those 
inhibitory signaling pathways. The aim of this study was to determine dominant 
co-inhibitory ligands expressed on acute myeloid leukemia (AML) cells for targeted 
siRNA interference in the tumor milieu to prevent dampening of tumor-reactive T cell 
responses. We found that primary AML cells express multiple co-signaling ligands,
amongst which are not only the co-stimulatory molecules ICOS and CD70, but also the 
co-inhibitory PD-L1, Galectin-9 and B7-H3 ligands. The sum of these co-signals
eventually determines the activation state, magnitude and duration of the T cell 
responses, thereby tightly balancing tumor tolerance and elimination. Notably, by 
silencing co-inhibitory molecules on AML cells the tip of this balance can be moved 
towards a more stimulatory environment for superior AML recognition and immune 
control. To achieve this we used siRNA/SAINT-RED transfection technology, that was 
previously developed by our group to silence PD-L1 and PD-L2 surface expression on 
MoDC.9 We demonstrated efficient silencing of PD-L1 in AML cell lines as well as in 
patient’ AML cells. Most importantly, we showed significantly enhanced recognition 
and activation of MiHA-specific CD8+ T cells upon co-culture with PD-L1 silenced 
MiHA-positive AML cells. Notably, this was equally efficient as PD-1 antibody blockade. 
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These results demonstrate that PD-L1 expressed by AML cells is involved in dampening 
tumor-reactive T cell functionalities. Hence, siRNA-mediated knockdown of PD-L1 is an 
attractive strategy to improve leukemia-reactive T cell responses in the local tumor 
micro-environment.
General discussion and future perspective 
The immune system is a very powerful and effective defense mechanism against not
only infections but also cancer. The adaptive immune system can form immune memory, 
thereby providing long-term surveillance and protection against recurring disease. 
Recently, harnessing the immune system to battle cancer was marked as a great break-
through in cancer treatment with the clinical successes of chimeric antigen receptor 
(CAR)-T cell therapy and immune checkpoint blockade. Previously, allo-SCT was the first
immunotherapeutic strategy that demonstrated clinical efficacy and improved survival 
of patients with aggressive hematological malignancies like AML, lymphoma and 
multiple myeloma. However, a considerable number of patients still develop recurrent
disease. This can arise amongst others because there are too few tumor-reactive 
T cells or NK cells induced or because tumor cells escape the immune system. Tumor 
cells can exploit a plethora of escape mechanisms to avoid recognition and attack by 
the immune system. Therefore, it is important to implement novel immunotherapeutic 
strategies to enhance T and NK cell numbers by vaccination strategies and to improve 
effector cell functionality by interference with immunosuppressive pathways. 
As DC are the most potent professional APC and orchestrators of innate and adaptive 
immune responses, they are considered to be the ideal means to enhance anti-tumor 
immunity. Although, DC vaccination trials demonstrated to be feasible and safe, only 
few patients achieved objective clinical responses. Therefore, we investigated 
alternative possibilities to harness DC vaccination for cancer therapy. It has been 
postulated that natural DC subsets, such as pDCs and mDCs, are more effective for use 
in DC vaccinations than conventional MoDC.14 Recently, vaccination with naturally 
occurring blood DC subsets, using pDC15, or BDCA1+ mDCs, has been investigated in
cancer patients.16, 17 These studies demonstrated the safety and efficacy of primary 
blood DCs as cancer immunotherapy. Interestingly, two out the three studies showed 
promising immunological and clinical results. So far, these studies only used separate
DC subsets, while pDC and mDC combined are postulated to induce a broader immune
response because of their specialized functionalities. Currently, a phase III clinical trial 
by de Vries et al. is recruiting melanoma patients for combined pDC and mDC 
vaccination (NCT02993315). However, the low frequencies of these natural occuring
DC in the circulation, as well as the costs for isolation and difficulties to transfect them, 
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might limit their applicability for clinical exploration. Furthermore, in case of myeloid 
malignancies, DC numbers and functionalities are likely negatively affected thereby 
rendering them less suitable for vaccination purposes.18 Alternatively, DC subsets can
be generated ex vivo from CD34+ HSPCs. Notably, the culture protocol described in 
chapter 3 of blood DC subsets was later further improved for clinical applicability by
us. Here, we showed that BDCA1+ mDC were superior in priming naïve T cells and 
expanding patient-derived MiHA-specific CD8+ T cells.19 Interestingly, HSPC-derived 
pDCs were superior in inducing IFN-ф secretion by antigen-experienced tumor-reactive
T cells and enhancing the cytolytic activity of NK cells. Murine models have also shown 
that combined administration of both pDCs and mDCs results in enhanced T cells
priming as well as improved anti-tumor T cell immune responses.20 These data support
that vaccines based on combinations of natural occurring DC subsets possess great
promise for future immunotherapy. Hence, we will further develop and evaluate our 
HSPC-pDC and -mDC vaccines in pre-clinical studies, with the aim to eventually
translate this into clinical trials in allo-SCT patients. 
Although, vaccination with ex vivo generated DC is promising, the production is time 
consuming and costly. Good Manufacturing Practice-licensed (GMP) clean room 
facilities are required, the reproducibility is depending on donor variation, and in most
cases DC cannot be generated as an off-the-shelf product. Therefore, we and others
pursued the idea to empower the DC subsets in vivo using targeted off-the-shelf 
products. Vital for this approach is to choose the most suitable targeting receptor for 
antigen delivery into the DC. Multiple endocytic receptors have been studied for this
purpose, including CLEC9A, DC-SIGN or DEC205.21 Key characteristics for an effective
DC targeting candidate are its expression profile, internalization capacity, intracellular 
routing and capability of delivering antigens in the cytoplasm. For selective delivery, 
the target molecule should, if possible, be only expressed by the different DC subsets 
to harness their synergistic effects. Furthermore, antigens that are targeted should be
internalized in the DC and be loaded onto HLA molecules to facilitate T cell activation.
In addition, it is essential, that the internalized antigen can also be cross-presented to
not only induce CD4+ T cell, but also CD8+ T cell responses. Furthermore, some of the 
most studied targeted receptors possess an inhibitory intracellular signaling domain,
that can potentially trigger negative signaling upon antibody binding. So the choice 
of the targeting receptor determines the efficacy of antigen delivery and thereby 
its potency to promote productive immune response.22 In humans, there are few
candidate receptors that are universally expressed by all primary DC subsets, including 
DEC205, CLEC9A, DC-SIGN, CD40, CD32 and CLEC12A.21, 23 Importantly, it has been 
demonstrated in vitro for all these receptors that they can facilitate targeted delivery 
of antigens to the different blood DC subsets, enabling antigen uptake, processing and 
(cross)-presentation to both CD4+ and CD8+ T cells.23-27 Recently, in vivo targeting 
of DC was accomplished in patients using CDX1401 (Celldex Therapeutics, USA),
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a DC-based vaccine consisting of a fully human DEC205 monoclonal antibody fused 
to the human tumor associated antigens (TAA) cancer/testis antigen 1B (NY-ESO-1).28
In this phase I clinical trial, cancer patients receiving CDX1401 in combination with 
TLR3 and TLR7/8 agonists developed NY-ESO-1-directed T cell and humoral responses. 
No dose-limiting nor grade 3 toxicities were reported, and 13 out of 45 patients 
experienced stabilization of disease, with a median duration of 6.7 months. Two 
patients even showed tumor regression. Interestingly, 6/8 patients who received
additional immune checkpoint inhibitors within 3 months after CDX-1401 administration 
developed objective tumor regression. These are promising results for in vivo DC
targeting and need further investigation. Besides DEC205 we believe CLEC12A is also 
an interesting candidate for in vivo targeting, because CLEC12A is not only expressed
on DC it is also expressed on AML cells, thereby allowing combined targeting of DC, 
with antigens, as well as AML cells, with immune modulating agents such as siRNA as 
discussed in next paragraphs.
Even though tumor-reactive T cells are administered via adoptive transfer (for instance
by donor lymphocyte infusion) or boosted in vivo by DC, these T cells may still become 
functionally impaired in the tumor micro-environment due to immune escape 
mechanisms. For instance, co-inhibitory signaling pathways have been shown to play 
an important role in damping anti-tumor immunity, as described in chapter 1. The new
kids on the block in cancer immunotherapy are checkpoint inhibitors. Anti-CTLA-4 and 
anti-PD-1/PD-L1 blockers have been shown to successfully boost tumor-reactive
immune responses, resulting in tumor regression and improved survival in solid and 
hematological malignancies. These imposing findings paved the way for further 
exploration of these checkpoint inhibitors as monotherapy or combination therapy in 
other malignancies, including AML. Furthermore, it initiated the identification of novel 
checkpoint players as targets for cancer immunotherapy.
Immunologically responsive tumors are considered to respond best to checkpoint
inhibitors.29 However, in daily practice, blockade of one checkpoint molecule, such as 
PD-1, is not effective in all patients with immunologically responsive tumors.
Furthermore, other patients only show delayed or mixed tumor regression.30 These 
observations may reflect differential dominance of immune editing mechanisms 
utilized by the tumor. For instance, lack or aberrant expression of TAA and MiHA, loss
of HLA molecules or low expression of co-stimulatory molecules limits tumor 
recognition and subsequent activation of the T cells.31 Although, AML holds strong 
immunogenic potential in the context of allo-SCT, in the autologous setting combination
therapy with chemotherapy, radiotherapy and/or immunomodulatory agents might be 
required to enhance expression and release of TAA, thereby allowing effective T cell 
priming and activation. The concept of combining idarubicin/cytarabine induction
therapy with nivolumab treatment is currently studied in a phase II trial in patients 
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aged <60 years with newly diagnosed AML (NCT02464657). Furthermore, a phase II
study combines fludarabine/melphalan and auto-SCT with anti-PD-1 therapy in poor-
risk AML patients in remission (NCT02771197). The combination of high-dose cytarabine 
with pembrolizumab is investigated in relapse/refractory AML (NCT02768792).
Furthermore, tumor responsiveness to checkpoint blockers is dependent on the 
different parameters, including immune cell infiltration, mutational load of the tumor 
and PD-L1 (over-)expression by the tumor.32 Immunogenic tumors tend to have 
numerous T cells within the tumor microenvironment. Furthermore, tumors with high 
mutational load express (high levels of) neo-antigens, towards which potent immune 
responses can be formed. Although the mutational load in AML is low, AML shows
good response to allo-SCT and donor lymphocyte infusions, demonstrating its
immunogenic potential.33, 34 Additionally, recruitment of immune suppressive cells, 
including Tregs or MDSCs, may serverly hamper productive anti-tumor immunity.
Biomarkers to predict whether a patient will respond to and benefit from checkpoint
interference are warranted. An interesting approach in this regard is PD-1/PD-L1
imaging, as shown by Heskamp et al.35 In this study they showed the feasibility of 
noninvasive in vivo imaging of PD-L1 expression in tumors. (111)In-PD-L1.3.1 showed
efficient and specific uptake in PD-L1 expressing xenografts in mice. This technique
may enable patient selection for PD-1 and PD-L1-targeted therapy. However, also
genetic profiling of the tumor could be an interesting option before starting checkpoint 
therapy.36 Notably, as described above, severe immune related adverse events (irAEs)
are frequently observed, with profiles varying per type of inhibitor and underlying 
malignancy. Early detection of irAEs, followed by dose modification and/or immuno-
suppressive treatment depending on the type and severity of the irAE, according to 
published guidelines, is critical to master the double-edged sword of checkpoint 
inhibition, as reviewed by Davies and Duffield.37
The key to success of increasing the response rate in the total patient population may 
lie in combination treatment with multiple antibodies targeting different checkpoint
pathways. Recently, a double-blind, phase III randomized study investigated the 
combination of nivolumab and ipilimumab against the single treatment arms in 945 
patients with treatment-naïve advanced melanoma.38 Remarkably, the overall 
response rate for the combination therapy was 57.6%, compared to 43.7% in the 
nivolumab monotherapy and 19% in the ipilimumab monotherapy arm. Furthermore, 
this combined  checkpoint therapy also improved progression-free survival. These 
data support the strength and potential synergy of interferencing with multiple immu-
nosuppressive mechanisms. Currently, anti-TIM-3/anti-PD-1 is being evaluated for 
clinical efficacy. Similarly, combinations of co-inhibitory antagonists and/or agonists 
of co-stimulatory pathways are being explored. For instance, in a mouse ovarian 
cancer model, combined OX40 agonism and PD-1 blockade resulted in significant
inhibition of tumor growth, while monotherapy was ineffective.39
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Alternatively, other combination strategies for checkpoint interference are being 
investigated, these include co-administration of drugs with direct anti-tumor and/or 
immunomodulatory efficacy. For instance, hypomethylating agents (HMA) in AML. In 
addition to direct anti-proliferative and pro-apoptotic effects on leukemia cells, 
through reactivation of epigenetically silenced tumor suppressor genes, HMA possess
immune promoting properties.40 Importantly, HMA have been shown to up-regulate
expression levels of TAA and MiHA, including PRAME, MAGE-A, NY-ESO-1 and HA-1.
Thereby, they can improve AML recognition and promote priming of tumor-reactive T 
cells.41-44 Recently, we also observed that HMA, specifically decitabine, potentiate
AML-reactive NK cell responses.45 HMA may further modulate tumor immunogenicity 
by up-regulation of immune stimulatory molecules, including CD80 and CD8646, 47
However, azacitidine was also reported to up-regulate PD-1, PD-L1, and PD-L2 in >50% 
of 61 evaluable patients with MDS/AML during their first course of therapy.46 As the
sum of stimulatory and inhibitory signals eventually determines the magnitude and
functionality of tumor-reactive T and NK cell responses, it is highly attractive to
favorably modulate this balance by combining HMA and checkpoint interference. The 
interest in this combination therapy is reflected by the numerous trials in AML and 
MDS that are currently ondoing. These studies mainly focus on elderly patients and 
patients with higher-risk or relapse/refractory disease. Recently, the interim results of 
a phase II trial with azacitidine and nivolumab in relapse/refractory AML patients were
presented (NCT02397720). These first results showed comparable toxicity with other 
trials investigating checkpoint blockade, and improved outcome with a median 
survival of 9.3 months for poor-risk patients.48, 49
We and others have demonstrated the role of co-inhibitory signaling pathways in
hampering GVL immunity after allo-SCT, providing rationale for checkpoint interference. 
Furthermore, patients showed differential responses to different ex vivo checkpoint 
blockades, which may reflect differences in dominance of immunosuppressive 
mechanisms utilized by the tumor.50-53 Therefore, we further investigated in chapter 5
(co-)expression profiles of checkpoint molecules on MiHA-specific CD8+ T cells in
relation to clinical outcome after allo-SCT. Here, we identified increased expression
levels of multiple co-inhibitory molecules, including PD-1, TIM-3 and TIGIT on 
MiHA-specific CD8+ T cells, while these T cells retained an early differentiation 
phenotype with lower CD57, KLRG1 and high CD27, CD28 expression. Importantly, we
also observed significantly higher expression of PD-1, TIGIT, OX-40 and KLRG-1 on
MiHA-specific CD8+ T cells of relapsed patients. In the subsequent study we want to 
increase the number of patients and to have a more homogenous cohort in order to 
validate these findings. Furthermore, it would be interesting to follow co-signaling 
expression profiles at multiple time points after allo-SCT in the same patient to observe 
possible changes in regard to relapse. In addition, analyzing the co-signaling profile in 
bone marrow samples would be very interesting and since the tumor is mostly located 
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here we could also analyze the co-signaling ligands on the tumor cells in this sample.
In the analyses with the dedicated PD-1, TIGIT, OX-40 and KLRG-1 panel we selected 
mostly patients with myeloid malignancies (7x AML, 1x MDS, 1x NHL) and this 
expression signature was independent of CMV reactivation, treatment with immune 
suppressive drugs and GVHD occurrence. Future studies at multiple time-points 
investigating peripheral blood and bone marrow in larger, more homogenous, cohorts
of patients are warranted to further elucidate the functional consequences and clinical 
importance of the expression signatures described in this study. In the future this 
signature may potentially be used for monitoring after allo-SCT and used as targets for 
post allo-SCT checkpoint interference. In previous ex vivo studies we already 
demonstrated that PD-1 and BTLA expressing MiHA-reactive T cells respond to PD-1 
and/or BTLA blockade, with most pronounced effects observed for patients who 
relapsed after allo-SCT.50, 54 Recently, the first studies on ipilimumab or nivolumab 
treatment in patients with relapsed AML and Hodgkin lymphoma post allo-SCT showed
clinical benefit.55 Nevertheless, these beneficial graft-versus-tumor responses were 
accompanied by severe treatment-refractory GVHD, especially in case of nivolumab. 
This might be related to the intensive prior treatments of these patients. This is the
downside of “releasing the immune break ,´ severe toxicity in healthy tissues. The 
occurrence of irAEs in cancer immunotherapy is very common: in solid tumors this can
be up to 60% of the patients treated with CTLA-4 blocking antibody suffered from 
irAEs.56 In a phase III trial with ipilimumab, 25% of the irAEs were grade 3–4 toxicities
and 10–15% were severe or life-threatening.57, 58 Treatment with PD-1 or PD-L1 blocking
antibodies resulted in irAEs in 70% of the patients.30, 59 Most at risk are patients who
already have auto-immune disease, and those who have been treated with allo-SCT as
they are vulnerable for induction of (severe) GVHD.55, 60-62 Haverkos et al. reported the
rapid onset of severe GVHD in 55% of patients after 1 or 2 dosages of PD-1 blocking
antibody, with only 2 of these 17 patients having a complete response to GVHD
therapy.63 Notably, no induction or exacerbation of GVHD was observed in the 
ipilimumab trial where patients were treated at late time-points after allo-SCT.64 These 
findings emphasize the importance of defining the optimal treatment window for 
checkpoint inhibitors post allo-SCT. However, still these side effects of checkpoint
inhibition are worrisome and underline the medical need for development of alternative 
‘safer’ therapies to reinvigorate GVT immunity in post allo-SCT, without risk of 
promoting induction of severe GVHD.
An interesting approach to interfere with immune checkpoint molecules without 
risking GVHD post allo-SCT is a targeted approach using silencing RNA (siRNA).65-67
When these siRNAs selectively silence co-inhibitory molecules in malignant cells, the
tumor cells acquire a more stimulatory phenotype making them more vulnerable for 
anti-tumor immunity. In this regard, we demonstrated in chapter 6 of this thesis that 
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PD-L1 siRNA could be efficiently transfected into AML cells using SAINT-RED lipoplexes, 
which resulted in effective PD-L1 silencing and thereby improved recognition by 
tumor-reactive T cells. Hence, siRNA-mediated interference with the PD-1/PD-L1 
pathway in the tumor micro-environment is an attractive approach to strengthen 
anti-tumor T cell responses in AML patients with minimal risk of eliciting severe toxicity. 
In order to deliver the siRNAs into the myeloid blasts in vivo, a clinically applicable
nanocarrier should be used to shield the siRNAs from RNAases in the serum. Currently, 
different carriers, including liposomes and poly-lactic-co-glycolic acid (PLGA) particles, 
are being developed and explored for in vivo delivery of drugs, including siRNAs.68-70
Recently, Alnylam Pharmaceuticals is the first to complete a large phase III clinical trial 
with siRNA loaded lipid nanoparticles. Here, familial amyloid polyneuropathy was 
treated very successfully.71 An additional advantage of using nanocarriers is that these 
can be easily loaded with multiple siRNAs targeting different immunosuppressive
mechanisms, including combinations of immune checkpoint molecules, suppressive 
cytokines, iNOS, arginase (Figure 1). As a result the immune suppressive “shield” 
created by the myeloid tumor cells and surrounding suppressive antigen-presenting 
cells can be dismantled from multiple angles allowing the tumor to be more 
immunogenic and thereby better susceptible for anti-tumor immunity. Interestingly,
delivery of TLR ligands in leukemia cells does not have any negative effects.72, 73
However, additional antigen can be directed towards the leukemia cells making them 
more immunogenic. 
Next to a nanocarrier, a targeting moiety is required to facilitate specific targeting of 
AML cells in vivo. There are various targeting candidates like CD33 and CD123, that are 
highly but not selectively expressed by AML cells, as they are also expressed by
normal hematopoietic progenitors and non-hematopoietic cells.74-76 By targeting 
these stem cells there is a major risk of losing the continuous production and
replenishment of normal hematopoietic cells necessary for the patients. Therefore, the
preservation of healthy hematopoietic stem cells is essential. In this regard, CLEC12A 
is an interesting targeting candidate for myeloid malignancies. We and other showed 
that this receptor is expressed by AML stem cell and blasts, as well as mature myeloid 
cells, while expression on healthy hematopoietic stem cells is lacking (Figure 2A-B).77-81
Furthermore, to allow effective delivery of the proposed nanoparticle vaccines into the
AML cells, CLEC12A should internalize. In Figure 2C-F we demonstrate that CLEC12A is 
efficiently internalized in AML cell lines as well as patient’ AML cells upon antibody 
binding. These data provide rationale to coat siRNA-loaded nanocarriers with CLEC12A 
antibodies to direct them to AML blasts for specific silencing of co-inhibitory molecules.
Furthermore, an additional advantage for using CLEC12A is that also immune
suppressive myeloid cells like myeloid derived suppressor cells or type 2 macrophages
express (data not shown). So immune suppressive mechanism exploited by these cells
could also be disrupted by siRNA-mediated CLEC12A targeting. Another benefit of 
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CLEC12A is that it is also expressed by natural occurring blood DC subsets, i.e. the
BDCA1+ mDC and pDC, as described in chapter 4. Delivery of siRNA targeting
co-inhibitory molecules would also make these DC more immune stimulatory.9-11
Besides the delivery of siRNA to DC it is pivotal to co-deliver antigens, like MiHA or 
TAA, and maturation stimuli, like TLR agonists, in order to properly activate 
tumor-reactive T cells. Altogether, we believe that this strategy (Figure 3) can on one
hand boost and reinvigorate tumor-reactive T cells, and on the other hand dismantle 
the immune suppressive tumor micro-environment to improve T cell recognition and
lysis of malignant cells. By selective targeting of the tumor micro-environment, 
systemic toxicity may also be prevented.
Figure 1. siRNA nanoparticle vaccine to target CLEC12A-positive dendritic cells and
leukemia cells. To boost anti-tumor immunity it is essential to activate and expand tumor- 
reactive T cells in vivo. Dendritic cells are the most powerful candidates to achieve this. For this
reason, it is highly interesting to specifically deliver antigens (purple) into DC via targeted 
nanoparticles. In this regard, CLEC12A antibody (blue) coating is attractive, as CLEC12A is
selectively expressed by cells of myeloid origin, including DC and myeloid leukemia stem cells.
In addition, to make the dendritic cells more immune stimulatory, maturation stimuli (green)
and siRNA (red) targeting co-inhibitory molecules are incorporated. To shield the particles for 
non-specific uptake by scavenger cells like macrophages, they can be coated with poly ethylene
glycol (black). Next to improving anti-tumor immunity by modulating DC immunogenicity, the 
nanoparticle can also target the co-inhibitory signaling pathways in the leukemic microenviron-
ment. By loading the nanoparticles with multiple siRNAs (red, orange and yellow) simultaneous 
silencing of different immunosuppressive mechanisms, including combinations of immune
checkpoint molecules, suppressive cytokines, iNOS, arginase can be achieved.
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Figure 2. CLEC12A is highly expressed and efﬁciently internalized by myeloid leukemia 
cell lines and primary blasts of AML patients. (A) CLEC12A expression was analyzed on 
two different acute myeloid leukemia cell lines (HL60 and U937) by flow cytometry. Open black 
histograms correspond CLEC12A staining, whereas filled gray histograms represent the isotype 
control. Numbers in the plots represent the mean fluorescence intensity (MFI). Data of one 
representative experiment out of three are shown. (B) MFI of CLEC12A expression on CD34+ cells
of healthy donors (white) or AML patients (black). Data are shown as mean ± SEM; n=6 for 
healthy donors and n=17 for AML patients. Leukemia cell lines (C) and primary blasts of leukemia
patients (D and E) were labeled with CLEC12A antibody, followed by 0 to 180 min incubation at
37°C to allow receptor internalization. Surface expression of bound anti-CLEC12A was analyzed
by flow cytometry following labeling with goat anti-mouse IgG. CLEC12A internalization is
calculated relative to the surface expression at the start based on the mean fluorescence 
intensity. (C) CLEC12A internalization in time is shown for two leukemia cell lines. (D)
Representative histograms of CLEC12A internalization by CD34+ cells in time are shown for one
AML patient. Numbers in the plots represent the MFI of CLEC12A or the isotype control. (E)
Relative CLEC12A internalization is shown as mean ± SEM of 11 AML patients.
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Concluding remarks
In conclusion, allo-SCT is a potent and curative treatment option for patients suffering
from high-risk hematological malignancies. However, relapse remains the major cause
of treatment failure due to amongst others insufficient numbers of tumor-reactive 
T cells and NK cells and/or their inadequate functionality due to cancer immune escape 
mechanisms. This underlines the medical need for development of novel immuno-
therapeutic options to selectively boost GVT immunity, without eliciting detrimental
GVHD. This thesis describes the investigation of various immunotherapeutic strategies 
that could be safely applied post allo-SCT. We established culture protocols to generate
different natural DC subset vaccines from HSPC. These are highly attractive for 
induction and boosting of powerful GVT responses in allo-SCT patients. Furthermore, 
we showed that CLEC12A is an interesting new targeting receptor for in vivo antigen 
delivery into myeloid cells, including DC and AML cells, to boost tumor-reactive T cell
immunity in cancer patients. In addition, we identified multiple co-signaling molecules 
expressed by AML that are likely involved in hampering T cell-mediated tumor control.
Moreover, we demonstrated that siRNA-mediated knockdown of co-inhibitory 
molecules in AML cells is an effective strategy to improve leukemia-reactive immunity.
These data provide a rationale for the development of siRNA-nanocarriers for in vivo
targeting of DC and the immune suppressive tumor micro-environment to improve
anti-tumor immunity, without eliciting severe systemic toxicity in patients suffering 
from hematological malignancies. Altogether, we believe that the conducted research 
in this thesis contributes to the development of novel and powerful therapies to 
improve survival of patients suffering from hematological or solid cancers. 
Figure 2. Continued. (F) Image stream analysis of CLEC12A internalization in two representative 
CD34+ cells of one AML patient. Patient’ cells were stained with mouse anti-CLEC12A, followed
by labeling with Alexa-Fluor 647-conjugated goat anti-mouse IgG (red). Then, internalization was
allowed for 1 to 2 h at 37°C, with subsequent staining for extracellular CD34 using anti-CD34-FITC 
(green).
F
518627-L-bw-Hutten
Processed on: 11-4-2018 PDF page: 201
201
Summary, general discussion and future perspective
7
Figure 3. Targeting dendritic cells and leukemia cells to improve anti-tumor immunity. 
(A) In the pre-treatment phase, dendritic cells and tumor cells present tumor associated 
antigens (purple) in human leukocyte antigen molecules (yellow) to the T cell receptor (dark 
blue) on tumor-reactive CD8+ T cells. To adequately activate T cells, co-stimulation via 
co-stimulatory ligand/receptor (green) interactions are required. However, the immune
response can be dampened by co-inhibitory ligand/receptor (red) signaling. Leukemia cells can 
form an immune suppressive “shield” to escape immune attack by upregulating expression 
levels of co-inhibitory ligands and by secreting immune suppressive factors (red, orange and
yellow dots). (B) By treatment with the siRNA-nanoparticle vaccine (described in Figure 1) CLE-
C12A-positive (light blue) dendritic cells and tumor cells can targeted. Hereby, dendritic cell 
immunogenicity can be enhanced due to co-delivery of tumor associated antigens, maturation 
stimuli and siRNAs targeting co-inhibitory ligands. This allows superior activation and boosting
of tumor-reactive CD8+ T cells. Furthermore, the vaccine can favorably modulate the inhibitory
tumor micro-environment by delivery of siRNAs, that interfere with different immunosuppres-
sive mechanism, into CLEC12A+  AML cells. Thereby, AML immunogenicity can be improved,
enabling effective recognition and attack by tumor-reactive CD8+ T cells.
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Hematologische maligniteiten omvatten een heterogene groep van verschillende 
bloed- en beenmergkanker soorten die ontstaan uit het hematopoïetische systeem.
In de laatste jaren is er, mede dankzij de invoering van nieuwe behandelingen, veel
vooruitgang geboekt in de behandeling van deze ziekten. Allogene stam cel 
transplantatie (allo-SCT) wordt gezien als één van de meest effectieve behandel 
opties. Daarnaast kan het potentieel ook genezend werken voor patiënten die lijden 
aan een hematologische kanker.1 Voor deze behandeling worden patiënten eerst
behandeld met chemotherapie en/of bestraling. Vervolgens vindt een partieel of 
compleet humaan leukocytenantigeen (HLA)-gematchte donor stamceltransplantatie 
plaats. Deze donor stamcellen vervangen het hematopoïetische systeem van de
patiënt, dat door de hoge dosis chemotherapie uitgeschakeld is. Het therapeutisch
effect van deze behandeling wordt voornamelijk toegeschreven aan de reacties van 
het nieuwe donor immuunsysteem tegen eventueel achtergebleven tumorcellen van 
de patiënt. Deze reactie wordt graft-versus-tumor (GVT)-respons genoemd en wordt 
gemedieerd door donor T cellen en natural killer (NK) cellen die tumor cellen kunnen
opsporen, herkennen en vernietigen. Tijdens deze reactie worden de donor T cellen
geactiveerd doordat minor histocompatibiliteit antigenen (MiHAs), tumor-geasso-
cieerde antigenen (TAA) en gemuteerde neo-antigenen worden gepresenteerd door 
antigeen presenterende cellen (APCs).2, 3 Vervolgens vermeerderen en differentiëren
de geactiveerde T cellen zich in effector T cellen. Deze T cellen hebben de kracht om 
tumorcellen die MiHA, TAA of neo-antigenen tot expressie brengen aan te vallen. Een 
deel van de geactiveerde naïeve T cellen differentieert tot geheugen (memory) T cellen 
met de capaciteit om langdurige bescherming te geven tegen terugkerende
tumorcellen. Ondanks de vorming van dit geheugen, komt uiteindelijk in veel patiënten
de ziekte terug na allo-SCT plaats. Er zijn een aantal mogelijke oorzaken aan te wijzen
voor de terugkeer van de ziekte in deze patiënten, zoals onvoldoende vernietiging van
de tumorcellen voor de transplantatie, onvoldoende activatie van tumor-reactieve T en 
NK cellen of remming van de anti-tumor afweerreacties als gevolg van ontsnappings-
mechanismen van de tumorcellen.4, 5 Tumorcellen kennen verschillende afweer 
remmende mechanismen. Ze kunnen bijvoorbeeld een verstoorde of verminderde 
antigen presentatie hebben, verschillende afweer onderdrukkende cytokines 
produceren, T suppressor cellen (Tregs) en myeloid-derived suppressor cellen (MDSCs) 
aantrekken, maar ook het expressieniveau (en daarbij ook de signalering) van
co-stimulerende moleculen en co-remmende moleculen veranderen.6, 7 Hoewel de
behandeling met allo-SCT potentieel genezend is, kan er ook een levensbedreigende 
bijwerking optreden, omgekeerde-afstotingsziekte, ook wel graft-versus-host disease 
(GVHD) genoemd.8 Deze bijwerking wordt veroorzaakt door donor T cellen die MiHA 
herkennen die voorkomen op gezonde patiënt’ weefsels. Om de ziekte-vrije overleving 
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van patiënten die aan een hematologische kanker lijden te verbeteren is het belangrijk
om de GVT reactie selectief te versterken zonder GVHD te induceren of te verergeren. 
Deze thesis beschrijft nieuwe immuun-therapeutische strategieën om tumor-speci-
fieke reacties te stimuleren en te versterken. We beogen dit te bereiken door gebruik te 
maken van dendritische cel (DCs) gebaseerde strategieën en/of aan te grijpen op
negatief regulerende immuun checkpoint moleculen die betrokken zijn bij ontsnapping 
van tumorcellen aan het afweersysteem.
De afgelopen decennia is er uitvoerig onderzoek gedaan naar DC vaccinatiethera-
pieën. Deze cellen hebben een centrale rol in het aansturen van zowel het aangeboren
als het verworven afweersysteem. In het lichaam nemen DC antigenen op, waarna ze
verder uitrijpen. Vervolgens brengen DC meer activerende moleculen tot expressie om 
het immuunsysteem te activeren en verkrijgen ze receptoren voor migratie naar de 
lymfeklieren. Wanneer de DC de lymfeknoop bereiken, activeren en polariseren ze 
naïeve T cellen en/of geheugen cellen en stimuleren ze dus een afweerreactie tegen 
het opgenomen antigen. Om deze reden worden DC beschouwd als een uitstekend 
middel om een therapeutisch anti-kanker vaccin te ontwikkelen om de bestaande 
anti-tumor immuunreactie te versterken en de balans van tumor-tolerantie te verschuiven 
naar tumorcontrole. Als de DC in deze vaccins van een donor komen moeten ze worden 
beladen met tumor antigenen (bijvoorbeeld gelyseerde tumorcellen, peptiden of 
mRNA) om een adequate afweerrespons op te wekken gericht tegen de tumorcellen
die het betreffende antigen tot expressie brengen. Er zijn meerdere klinische studies
uitgevoerd met ex vivo ontwikkelde monocyte-derived DC (MoDC, uit monocyten
gekweekte DC) in verschillende typen solide en hematologische tumoren. Deze studies
hebben aangetoond dat DC vaccinaties haalbaar en veilig zijn, en dat DC in staat zijn 
om een anti-tumor reactie in vivo te genereren. Echter gezien het feit dat weinig 
patiënten een (langdurige) klinische respons hebben op behandeling, moeten de
vaccins nog geoptimaliseerd worden. Eén optie is om de werkzaamheid van deze veel 
gebruikte MoDC te verhogen door bijvoorbeeld de expressie van co-remmende
moleculen op het cel oppervlak van de DC te verminderen om zodoende betere T cel 
activatie te verkrijgen.9, 10 Verder zou er IL-15Rт/IL-15 mRNA aan de MoDC kunnen
worden toegevoegd om IL-15 uitscheiding en transexpressie te generen, waardoor 
betere T en NK cel activatie bewerkstelligd wordt.11 Een interessant alternatief voor het 
verbeteren van DC vaccinatie is het inzetten van natuurlijke DC subsets die voorkomen 
in de huid en/of het bloed. Het is al eerder aangetoond dat deze primaire DC betere 
anti-tumor reacties kunnen induceren dan MoDC.12 Verder laten studies zien dat
verschillende primaire DC subsets synergistisch kunnen samenwerken en daarbij 
elkaars stimulerende eigenschappen versterken.13 Onze hypothese is daarom ook dat, 
wanneer deze verschillende DC subsets tegelijk worden gebruikt in een vaccin, ze een 
bredere en krachtigere afweerreactie genereren met superieure effecten ten opzichte 
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van de conventionele MoDC vaccins. In hoofdstuk 2 en 3 hebben wij de mogelijkheid 
onderzocht om ex vivo een groot aantal verschillende DC subsets te maken vanuit he-
matopoïetische stam- en voorlopercellen (HSPCs). Dit mede om voldoende DC te 
generen voor meerdere vaccinatierondes in patiënten na allo-SCT. In hoofdstuk 2 was
het doel een kweekprotocol op te zetten voor het genereren van “huid” DC subsets om 
anti-tumor reacties in vivo te versterken. Hierbij zijn CD34+ HSPC afkomstig uit
navelstreng bloed (UCB) gebruikt, omdat deze cellen het beste kunnen expanderen en 
differentiëren. Met ons kweekprotocol konden we klinisch relevante aantallen mature 
CD1a+ myeloïde DC (mDC), vergelijkbaar met de interstitiële/dermale DC subset in vivo,
en CD207+ Langerhans-like DC (LC) subsets maken uit CD34+ HSPC met een zuiverheid 
van >95%. Beide DC subsets lieten een cytokine profiel zien dat CD8+ T cel activatie
bevorderd. Daarnaast waren deze DC subsets veel beter in het activeren van allogene
en viraal antigeen-specifieke CD8+ T cellen in vitro en in vivo, in vergelijking met 
conventionele MoDC. Tot slot hebben we laten zien dat UCB-DC en UCB-LC efficiënt
HA-1 specifieke CD8+ T cellen van allo-SCT patiënten in vitro laten expanderen. In 
hoofdstuk 3 zijn we verder gegaan om het kweekprotocol te optimaliseren om 
natuurlijk voorkomende bloed DC subsets te genereren vanuit CD34+ HPSC. Het betreft 
hier de BDCA1+ en BDCA3+ mDC subsets en plasmacytoïde DC (pDC). In dit hoofdstuk 
laten we zien dat remming van de aryl hydrocarbon receptor met behulp van 
StemRegenin 1 (aryl hydrocarbon antagonist) de expansie en differentiatie van 
BDCA2+BDCA4+ pDC, BDCA1+ mDC en BDCA3+CLEC9+ mDC vanuit HSPC verbetert.
Dit resulteerde in een klinisch relevant aantal functionele DC. Deze gegenereerde
DC subsets waren fenotypisch en functioneel vergelijkbaar met hun tegenhangers 
in het perifere bloed. Verder konden zij hoge niveaus pro-inflammatoire cytokines
produceren, waaronder inteferon (IFN)-т, interleukine (IL)-12 en tumor necrose factor 
(TFN)-т. Na activatie van de DC subsets met Toll-like receptor (TLR) liganden brachten 
zij co-stimulatoire moleculen en maturatie markers verhoogd tot expressie. Wij hebben
verder aangetoond dat de m DC en pDC subsets uitstekend in staat waren allogene
CD4+ en CD8+ T cel reacties te versterken en MiHA specifieke CD8+ T cellen te activeren.
Aangezien de productie van ex vivo genereerde DC vaccins een erg tijdrovend en duur 
proces is hebben we ook een alternatieve strategie onderzocht. In hoofdstuk 4
hebben we in vitro getest of we natuurlijk voorkomende DC subsets mogelijk direct 
in vivo kunnen beladen met antigenen om op deze manier tumor-reactieve T cellen te 
activeren. In dit hoofdstuk hebben we gekeken naar de mogelijkheid om de endocytic
C-type lectin receptor (CLR) CLEC12A te gebruiken als doelreceptor voor het afleveren
van antigenen in natuurlijk voorkomende DC subsets, om zodoende CD4+ en CD8+
T cel reacties te induceren. Hier hebben we aangetoond dat de CLEC12A receptor 
alleen op hematopoïetische cellen van myeloïde oorsprong voorkomt, waaronder de 
BDCA1+, BDCA3+ mDC subsets en de pDCs. Verder hebben we laten zien dat de 
CLEC12A receptor efficiënt internaliseert na binding met een antilichaam. Dit is
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belangrijk om de DC dus in vivo te kunnen beladen met antigen dat moet worden 
opgenomen. Na internalisatie wordt CLEC12A snel naar de vroege endosomen ge-
transporteerd en vervolgens eindigt CLEC12A in de lysosomen. Aangezien deze 
receptor een immunoreceptor tyrosine-based inhibitoir motief (ITIM) in zijn cytoplas-
matische staart heeft, zouden remmende signalen op kunnen treden na binding met 
een antilichaam dat wordt gebruikt om het antigen af te geven aan de DC. We hebben 
geen negatieve effecten of effecten op maturatie in MoDC kunnen waarnemen na
CLEC12A antilichaambinding. Wel zagen we dat als keyhole limpet hymocyanin via 
CLEC12A aan verschillende DC subsets werd afgegeven, een verbeterde proliferatie en 
cytokine uitscheiding van KLH getrainde CD4+ T cellen kon worden gerealiseerd. 
Daarnaast hebben we in dit hoofdstuk laten zien dat we het MiHA HA-1 lang peptide
via CLEC12A in mDC of pDC subsets konden afgeven. Dit resulteerde in efficiënte
antigeen presentatie en daaropvolgende effectieve activatie van HA-1-specifieke 
CD8+ T cellen van allo-SCT patiënten. Concluderend kunnen we stellen dat zowel de 
productie van verschillende DC subsets als wel het direct in vivo afgeven van antigenen,
veelbelovende preklinische resultaten laten zien voor het activeren en versterken van
anti-tumor immuun reacties. Om specifieke anti-tumor immuniteit te kunnen verbeteren
bij patiënten na allo-SCT is het belangrijk dat de bovengenoemde strategieën verder 
worden ontwikkeld en uiteindelijk in vivo worden getest.
Ondanks de vorming van MiHA- en TAA-specifieke T cel reacties kunnen tumor cellen 
via verschillende mechanismen ontsnappen aan herkenning en vernietiging door het
afweersysteem. Eén van deze mechanismen is gebaseerd op een onevenwichtige 
balans in co-stimulerende en co-remmende signalen in het tumor, wat kan leiden tot 
disfunctionaliteit van de tumor-reactieve T cellen. Daarom hebben we in hoofdstuk 5 
met behulp van een 13 kleuren flowcytometrie panel, het immuun checkpoint molecuul 
expressie profiel van MiHA-reactieve CD8+ T cellen van allo-SCT patiënten bestudeerd.
Wij hebben de expressie patronen gekoppeld aan klinische uitkomstmaten van de
patiënten. Verder zijn de expressiepatronen van MiHA-specifieke CD8+ T cellen
vergeleken met die van cytomegalovirus (CMV)-reactieve CD8+ T cellen van zowel
gezonde donoren als allo-SCT patiënten. We zagen hier dat MiHA-reactieve CD8+
T cellen een vroeg differentiatie patroon vertoonden met hoge CD27, CD28 en lage 
KLRG-1, CD57 expressie. Verder brachten deze T cellen verhoogd PD-1, TIM-3 en TIGIT 
tot expressie in vergelijking met de gehele effector geheugen T cel populatie en 
CMV-specifieke CD8+ T cellen van gezonde donoren en allo-SCT patiënten. Opmerkelijk
is dat hoge co-expressie van PD-1, TIGIT en KLRG-1 op MiHA reactieve CD8+ T cellen 
geassocieerd was met recidief van de ziekte na allo-SCT. Deze resultaten impliceren
dat MiHA-specifieke CD8+ T cellen van patiënten met terugkeer van ziekte een
onderscheidend co-remmende expressie patroon hebben in vergelijking met patiënten
die in remissie blijven. Dit gevonden fenotype zou mogelijk gebruikt kunnen worden
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terugkeer van de ziekte in patiënten te voorspellen. Daarnaast suggereren deze 
bevindingen dat PD-1 en TIGIT een belangrijke rol spelen in het reguleren van T cel 
activatie in het tumor milieu. Dit geeft aan dat het onderdrukken van de signalering via 
deze remmende moleculen, met behulp van bijvoorbeeld blokkerende antilichamen, 
een interessante strategie is om verder te onderzoeken. Echter, ondanks indruk-
wekkende resultaten van dergelijke checkpoint blokkers in kankerpatiënten, kan deze 
therapie gepaard gaan met ernstige bijwerkingen. Vooral in patiënten na allo-SCT 
wordt ernstige toxiciteit, in de vorm van schadelijke GVHD, gezien. Om deze reden 
hebben we in hoofdstuk 6 een alternatieve strategie onderzocht om lokaal te
interfereren met deze remmende signalering. Het doel van dit onderzoek was om te
bepalen welke co-remmende liganden dominant voorkomen op acute myeloïde
leukemiecellen (AML). Dit met als reden om de expressie van deze afweerremmende
moleculen te verlagen door middel van siRNA technologie, zodat remming van tumor-
reactieve afweerresponsen voorkomen kan worden. In deze studie hebben we gevonden 
dat patiënt’ AML cellen verschillende co-signalerende moleculen tot expressie brengen, 
waaronder de co-stimulerende moleculen ICOS en CD70, alsook de remmende PD-L1, 
Galectin-9 en B7-H3 liganden. De optelsom van deze co-signalen bepaalt uiteindelijk
de activatiestatus, omvang en duur van T cel reacties. Daarnaast beïnvloedt dit het
evenwicht tussen tumor tolerantie en eliminatie. Door het verlagen van de expressie 
niveaus van co-remmende moleculen op de AML cellen, waardoor een afweer 
stimulerend milieu gecreëerd wordt, kan de balans van tumor tolerantie omslaan naar 
tumor eliminatie. Om dit te bereiken hebben we siRNA/SAINT-RED transfectie 
technologie gebruikt. Deze technologie is onderzocht in onze groep om PD-L1 en 
PD-L2 expressie op MoDC te verlagen.9 In de huidige studie konden we efficiënte 
remming van PD-L1 expressie op het cel oppervlak van zowel AML cellijnen alsook
AML cellen van patiënten bereiken. Bovendien konden we aantonen dat wanneer de
AML cellen minder PD-L1 tot expressie brengen er betere herkenning en activatie van 
MiHA-specieke CD8+ cellen plaatsvindt. Opvallend is dat dit even effectief was als 
behandeling met een PD-1 blokkerend antilichaam. Deze resultaten tonen aan dat 
PD-L1 expressie op AML cellen betrokken is bij het remmen van anti-tumor T cel
reacties. Daarom is het remmen van de PD-L1 expressie met behulp van siRNA een
interessante strategie om de anti-tumor T cel reacties in het lokale tumor milieu te 
verbeteren. 
Samenvattend, geloven wij dat het in deze thesis beschreven onderzoek heeft 
bijgedragen aan de ontwikkeling van nieuwere en sterkere behandel therapieën om de
overleving van patiënten die lijden aan hematologische of solide kankers te verbeteren. 
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Dankwoord
Dit proefschrift was nooit gelukt zonder een belangrijke bijdrage van een groot aantal 
mensen. De laatste woorden van dit proefschrift wil ik graag aan jullie wijden. Zonder 
iemand tekort te doen wil ik graag een aantal mensen persoonlijk bedanken.
Allereerst wil ik graag mijn begeleidingsteam bedanken. Willemijn, toen jij je Bas 
Mulder project had binnen gehaald en een PhD student zocht tipte je mij om ook op die 
plek te solliciteren. Zelf had ik er nog geen moment aan gedacht omdat ik toen nog 
midden in mijn stage zat. Ik wil je bedanken voor die tip en voor het vertrouwen in mij 
om samen met jou aan dit project te mogen werken. Ik kon altijd alles met je overleggen,
iets wat ik erg waardeer. Je gaf goede aanvullingen, kon goed meedenken met het 
opzetten van experimenten en ik heb veel van je kunnen leren. Daarnaast was je ook
een hele fijne en gezellige collega.
Harry, ik wil jou ook graag bedanken voor jouw bijdrage aan dit project. Ik heb veel 
van jou kunnen leren en je deur stond altijd open om te overleggen. Ik heb jouw input
tijdens het schrijven van de papers altijd erg gewaardeerd. Daarnaast wil ik je ook 
graag bedanken voor de goede en open sfeer in de groep die jij erg belangrijk vond.
Verder vond ik het erg leuk en leerzaam om met jou en de anderen naar het EBMT 
congres in Marseille te gaan; ik vond het gezellig om een kamer te delen en heb geleerd
van jouw skills om ’s avonds laat een taxi te regelen. 
Ook wil ik mijn promotor Joop bedanken. Joop, bedankt voor je wetenschappelijke 
bijdrage, kritische houding, belangstelling voor mijn onderzoek en je optimisme. 
Verder wil ik je ook bedanken voor de jaarlijks terugkerende vraag wat ik na mijn 
promotie onderzoek wilde doen, dit heeft mij in een vroeg stadium gedwongen een
keuze te maken. 
Nu wil ik graag het woord aan jou richten Hanny. Ik ben je erg veel dank verschuldigd. 
Tijdens mijn sollicitatie gesprek heb je mij een paar goede tips gegeven en die ben
nooit vergeten, al was het in praktijk toch lastig uit te voeren. Jij was mijn steun en 
toeverlaat op het lab. Wist ik iets niet te vinden, dan wist jij het wel; had ik  een vraag
over een experimentele uitvoering jij kon daar wel een ingenieuze werkwijze voor 
bedenken; werkte een experiment niet, dan had jij wel weer een trucje of dacht je slim 
na hoe het anders gedaan kon worden om wel tot het antwoord te komen. Gelukkig 
konden we ook wel eens samen mopperen over van alles met als meest recente
voorbeeld iets met een vaatwasser of zo. Je was bereid om de hele dag “Hanny, 
vraagje” aan te willen horen zonder dat jouw glimlach van je gezicht verdween. 
Daarnaast ben ik erg blij dat jij mij als paranimf wil ondersteunen op deze dag.
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Beste collega’s van de GVL/CTI groep, allereerst wil ik jullie allemaal bedanken voor de
geweldige sfeer die wij in onze groep hadden. Ik heb erg genoten van de gewone
werkdagen maar ook van alle leuke feestjes en activiteiten. Soley en Lotte, mijn vaste
“roomies”. Wat ben ik blij dat we lange tijd de kamer hebben kunnen delen. We konden
heerlijk stil zijn en werken, ongelooflijk kletsen en lol hebben, maar ook veel steun aan
elkaar hebben. Ik ben blij dat ik jullie veel over carnaval heb kunnen leren, vooral de 
muziek. Soley, we hadden niet dezelfde muziek smaak maar het neuriën van jou op je
eigen muziek vond ik altijd ontspannend. Jammer dat de Nederlandse dinsdag nooit 
echt van de grond is gekomen, ik kan je nog zoveel onzinnige woorden in het 
Nederlands leren. Lotte, wat hebben wij heerlijk kunnen discussiëren over van alles en 
nog wat, we waren het gelukkig altijd wel met elkaar eens dat we het oneens waren.
Heel veel succes met het afronden van je promotie en de rest van je carrière, ik weet 
dat je het ver gaat schoppen in het onderzoek. 
Rob, de flow goeroe van het lab, ik heb enorm veel van je geleerd over flowcytometrie 
en de daarbij behorende data analyse. We hebben ook goed kunnen praten over welke 
nieuwe speeltjes we al dan niet zouden moeten aanschaffen, over de politiek binnen 
het ziekenhuis en vooral wie waar met wat bezig was. Ook al zat je niet meer in het 
midden van het lab, toch was je altijd goed op de hoogte en qua nieuwsgierigheid 
zaten we ook wel redelijk op één lijn. Marij, knap dat je het nog steeds volhoudt bij Rob 
op de kamer, wat een drukte daar soms. Ik heb altijd met veel interesse naar je 
geluisterd over je IFT tijd en de patiënt diagnostiek. Je was er altijd zo enthousiast over 
dat ik nu zelf ook een carrière in de diagnostiek achterna ga. Verder was je een top
collega, altijd in voor gezelligheid en een drankje. Ik wil jou en Hans ook graag 
bedanken voor de gastvrijheid bij jullie thuis voor alle super leuke, gezellige
teambuildings avonden. Frans, ik wil jou ook graag bedanken, voor de leuke tijd op het 
lab en je praktische tips en tricks, vooral rond het PD-L1 gebeuren. Mieke en Janneke, 
bedankt voor alle input op mijn project vanuit het perspectief van de kliniek, daar heb
ik veel van geleerd. Mieke, ik heb ook altijd graag al “mijn” spullen met je gedeeld ook
al liet ik je dat niet altijd merken. I could write this in French, Jeannette, however I 
finally will admit that I’m not that good in French as I made you think. Although after a
few beers my French improved significantly (I always thought) and then I enjoyed our 
conservations in French. Thanks for everything and good luck in France with Fred and 
the kids. Anniek, wat kun jij bezielend met studenten, stagiaires e.d. omgaan en
daarnaast ook nog tijd maken voor je onderzoek en alle randzaken die erbij komen
kijken, knap hoor. Ik heb veel van je geleerd over de systematische manier van werken
die jij hebt en dan bedoel ik vooral de lijstjes, aan het eind van de rit moet ik zeggen 
dat het wel werkt. Wieger, soms heb ik je slordig bijgehouden  labjournaal en data
vervloekt maar uiteindelijk hebben we van de CIM flow data nog aardige stukken
kunnen maken, dank hiervoor. Verder wil ik nog graag mijn bewondering uitspreken
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dat jij vanuit Vorden/Nijmegen de stap naar Amerika hebt durven te maken en je daar 
niet meer weg wilt! Beste Menno, we hebben niet heel lang samen gewerkt maar laat
ik het zo omschrijven het was kort maar krachtig vol gezelligheid. Trouwens zie je dat 
ik jou wel in mijn dankwoord noem ook al ben jij mij “vergeten” in je stageverslag. Ik 
wil je graag heel veel succes wensen met je carrière, ik weet zeker dat jij er komt en dat
onze paden elkaar in de toekomst vast nog zullen kruisen. John, I really enjoyed 
working with you. You always had a different look at things. I also enjoyed talking 
about all the quirks we Dutch have. And although I never have been to New Zealand, I 
feel I know and saw a lot about it, thank you for that. Basav, ik wil je graag bedanken 
voor alle dingen die je mij geleerd hebt in de immunologie tijdens mijn stage bij jou. Ik 
vond het een super leuk project. Robert, we hebben niet lang samen gewerkt maar ik 
had grote bewondering voor je nauwkeurigheid om alles tot op de bodem uit te zoeken,
dit probeer ik nog dagelijks toe te passen in mijn werk. Ralph en Jolien, bedankt voor 
de leuke tijd samen en heel veel succes met jullie promotie onderzoek. Verder wil ik
Marleen, Jan en Fenna bedanken voor de leuke tijd op het lab. 
Ik ben ook veel dank aan mijn beide studenten verschuldigd. Lisanne, jij was mijn 
eerste student die ik mocht begeleiden. Het was voor jou en mij een uitdaging maar 
gelukkig is het ons gelukt. We hebben samen een mooi artikel kunnen publiceren over 
CLEC12A en jij bent afgestudeerd met een verslag in het Engels én een baan bij Harry
in de groep. Loreto, I would like to thank you for all the effort you put into your 
internship, thereby helping the research and also learning me new things. Good luck 
with your own PhD project.
Verder kan ik natuurlijk de directe buren van onze unit niet vergeten, de moleculaire
research. Ik wil jullie graag bedanken voor de leuke en gezellige tijd op het lab en voor 
alle adviezen. Saskia, Ruth, Tessa, Leonie, Maaike, Rinske, Anne, Florentien, 
Niccolo, Jolanda, Davide, Pedro, Gorica en Bert.
De afdeling Laboratorium Hematologie is een lab waarbij er naast research ook patiënt
diagnostiek wordt gedaan. Dit maakt dat er veel kruisbestuiving is tussen onderzoek 
en diagnostiek. Daarom wil ik ook mijn dank en waardering uitspreken aan de collega’s 
van deze units. Iedereen van de BMT inclusief Hanna, bedankt voor alle informatie
over de stamcel transplantaties, voor de beschikbaarheid van materiaal en dat jullie
bij mijn laatste teambuilding er een leuke dag van hebben gemaakt. Ook wil ik graag
de collega’s van de IFT bedanken voor hun flow kennis en voor het lenen van soms
ontbrekende antilichamen. Erik, ik heb onze discussies over de afdeling en de flow 
analyses altijd erg leerzaam en plezierig gevonden. Frank, ik wil ook jou graag 
bedanken voor de kennis over de flow diagnostiek die je met mij hebt gedeeld in mijn
laatste maanden op het lab. Verder wil ik ook iedereen van de morfologie, moleculaire
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diagnostiek en trombose & hemostase. Daarnaast wil ik graag Paul en Nelleke
bedanken voor al hun ondersteuning.
Ik wil verder ook graag mijn vroegere stage begeleiders bedanken voor de leuke stages 
en de introductie in de wetenschap, Ingrid, Esmeralda en daar hoort natuurlijk ook
Arjan bij.
De totstandkoming van dit proefschrift is ook mede te danken aan een intensive 
samenwerking met de afdeling Hematologie. Ik wil hiervoor voornamelijk Michel
bedanken voor zijn al adviezen en gegeven informatie en Jesse voor het aanleveren 
van alle patiënten data. Daarnaast wil ik ook alle verdere samenwerkingen binnen en
buiten het Radboudumc bedanken. Ben en Alessandra, voor jullie hulp bij de routing
microscopie experimenten. Gerben en Otto, voor jullie chemische inbreng bij de 
koppeling van de antilichamen. Ik wil ook de mensen van het Tumor Immunologie Lab 
(TIL) bedanken voor het beschikbaar stellen van hun kennis en reagentia die het 
project hebben geholpen. Verder wil ik ook Michel, Mirjam en prof. dr. Fred Falkenburg 
bedanken voor onze samenwerking. Soﬁa and Leo, thank you for your input, advice 
and help with the analysis and statistics of the CIM MiHA specific T cell paper.
Daarnaast wil ik nog Johan en Iris bedanken voor de gezelligheid op het lab en op de
AIO kamer voor de tijd dat jullie er waren. 
Loek en Ralph, we  kennen elkaar al van de studie en later zaten we in hetzelfde 
schuitje als PhD studenten. Bedankt voor de leuke tijd samen en de steun die we aan
elkaar hebben gehad. Ralph, nog extra bedankt voor het toch elke keer willen delen 
van de kamer tijdens de PhD retraite. Succes met het laatste stukje van jullie promotie
onderzoek!
Graag wil ik ook mijn nieuwe collega’s van het Laboratorium Klinische Chemie en
Haematologie van het UMC Utrecht bedanken, voor de kans die ze mij bieden om mij 
te ontwikkelen tot Klinisch Chemicus. Daarnaast wil ik Lourens nog specifiek bedanken 
voor de steun tijdens de laatste lootjes van het schrijven van dit proefschrift en de 
goede sfeer die wij op ons hok hebben. 
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Naast de mensen van mijn werk wil ik ook een aantal mensen buiten de research
bedanken, zij hebben namelijk veel support geleverd tijdens mijn onderzoek. Maar zij 
hebben ook voor veel lol en ontspanning naast het werk gezorgd.
Ten eerste wil ik graag mijn vrienden uit het “verre oosten” bedanken: Koen, Jelle, 
Joost, Floris en Maarten. Al zijn we allemaal uitgevlogen en woont er bijna niemand 
meer in Oldenzaal. Elke keer als we samen wat afspreken is het weer als vanouds
reuze gezellig, onwijs ouwehoeren met natuurlijk een pilsje erbij. We kunnen ook altijd 
over van alles praten en discussiëren en hoe later op de avond hoe serieuzer de 
gesprekken worden. Koen RA (ik neem vast een voorsprongetje) jou wil ik graag nog 
even apart bedanken, de verbinder van de groep. Jij onderhoudt het contact met 
iedereen en zorgt dat we tijd voor elkaar vrij maken in onze drukke agenda’s. Het
spontaan langskomen als je in de buurt van Nijmegen bent kan ik erg waarderen. 
Daarnaast ook jouw tomeloze interesse in het onderzoek en nuttige tips hoe iets aan 
te pakken hebben mij erg geholpen.
Oud collega’s van de Albert Heijn, Marc Groothuismink, Joris en Merijn, ik denk nog 
vaak met veel plezier terug aan de periode dat we met z’n allen nog bij de AH werkten.
Wat een leuke, gezellige en leerzame tijd was dat. Wat ik nog het allerleukst vind is dat
we nog regelmatig met elkaar afspreken of elkaar spontaan treffen in de stad. Marc
Haafkes, ik reken jou ook wel een beetje tot de oud Albert Heijn medewerkers ook al 
werkte je bij de C1000. Het is altijd gezellig als je erbij bent! 
Paul, Marga, Pim, Soﬁe en Timo, heel erg bedankt voor de gezelligheid en dat jullie 
mij hebben opgenomen in jullie gezin. Ik vind het altijd gezellig om langs te komen.  
Opa en Oma Hutten, ooms en tantes: Marja, Jan, José, Jan, Harry, Marjan, Dory, 
René en mijn neven en nichten: Anne, Marleen, Michiel, Steven, Tom, Niek en Aileen, 
heel erg bedankt voor de getoonde interesse in het onderzoek en ook voor alle fijne 
herinneringen die wij samen hebben. 
Beste Bobje, of moet ik toch Bob zeggen? Ik weet dat ik soms het bloed onder jouw 
nagels kan halen, maar je bent en zult altijd mijn kleine broertje blijven en ik zal altijd 
het beste met je voor hebben. Je moet weten dat ik mij geen beter broertje zou kunnen 
wensen dan jou. Wat hebben wij vroeger een geweldige tijd gehad samen. Uren samen 
spelen en toen we wat ouder waren samen op stap gaan. Wij hebben alle twee een 
heel ander carrière pad gekozen en ik vind het dan ook heerlijk om jouw mening over 
allerlei zaken te horen ook al zijn we het niet altijd met elkaar eens. Bob, ik vind het 
geweldig dat jij mijn broer bent en  vind het een eer en  ben heel blij dat jij vandaag 
naast mij wil staan als mijn paranimf.
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Lieve Papa en Mama, waar moet ik beginnen. Ik kan jullie nooit genoeg bedanken voor 
alles wat jullie voor mij hebben gedaan. Jullie staan altijd voor mij klaar, voorzien mij
van gevraagd en soms ongevraagd advies en jullie hebben altijd het beste met me 
voor. Bedankt voor jullie luisterend oor en ik kan met alles maar dan ook alles bij jullie 
terecht en beuren mij op als het tegen zit. Bedankt voor dit alles en nog veel meer!
En pap jij hield me altijd voor dat ik gemaakt was om iets anders te bereiken dan dat 
ik wilde toen ik 7 jaar oud was en kijk waar ik nu sta.
Lieve Lieke, wat zou ik toch zonder jou moeten beginnen, jij bent al jaren mijn steun 
en toeverlaat. Bedankt voor al je steun, begrip en onvoorwaardelijke liefde ook als 
het even tegen zat en ik weer mopperend thuis kwam, zonder jou was het niet gelukt.
Dit gedeelte van ons leven is nu klaar en ik kijk uit naar alle avonturen en uitdagingen 
die ons in het verschiet liggen! Ik hou van jou!
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ACT adoptive cell transfer
AhR aryl hydrocarbon receptor
ALL acute lymphoblastic leukemia
Allo-MLR allogenic mixed leukocyte reaction
Allo-SCT allogeneic stem cell transplantation
AML acute myeloid leukemia
APC antigen-presenting cell
Auto-SCT autologous stem cell transplantation
BM bone marrow
BTLA B- and T-lymphocyte attenuator
BUS busulphan
CAR chimeric antigen receptor
Ceacam-1 carcinoembryonic antigen cell 
adhesion molecule 1
CFSE  carboxyfluorescein-diacetate-
succimidyl-ester
CLL C-type lectin-like molecule-1
CLR C-type lectin receptor
CML chronic myeloid leukemia
CMML chronic myelomonocytic leukemia
CMV cytomegalovirus
CR complete response
CRi complete response with incomplete 
blood count recovery
CSA cyclosporin A
CTL cytotoxic T cell
CTLA-4 Cytotoxic T lymphocyte antigen 4
Cy cyclophosphamide
DAMP damage associated molecular pattern
DC dendritic cell
DCAL dendritic cell–associated C-type lectin 2
DEC decitabine
DLI donor lymphocyte infusion
DNAM-1 DNAX accessory molecule-1
ECD Electron coupled dye
ELISA enzyme-linked immunosorbent assay
EMA European Medicines Agency
FCS fetal calf serum
FDA US food and Drug Administration
FITC Fluorescein isothiocyanate
FU follow-up time-point
GBGM Glycostem basal growth medium 
G-CSF granulocyte colony-stimulating factor
GM-CSF granulocyte-macrophage colony-
stimulating factor
GMP good manufacturing practice-licensed
GVHD graft-versus-host-disease
GVT graft-versus-tumor
HD healthy donor
HL hodgkin lymphoma
HLA human leukocyte antigen
HMA hypo-methylating agent
HMBG1 high mobility group protein B1
HPSC hematopoietic stem and progenitor cell
HS human serum
HVEM herpesvirus entry mediator
ICOS inducible T cell co-stimulator
Ida idarubicin
iDC interstitial dendritic cell
IFN interferon
Ig immunoglobulin
IL interleukin
i.p. intraperitoneal injection
irAE immune-related adverse event
ISD immune suppressive drugs
ITIM immunoreceptor tyrosine-based 
inhibition motif
ITSM immunoreceptor tyrosine-based switch
motif
ITT Ig tail-tyrosine
KIR killer cell immunoglobulin-like receptor
KLH keyhole limpet hemocyanin
LAG-3 lymphocyte activation gene 3
LC Langerhans cell
LIGHT lymphotoxin-like, exhibits inducible
expression, and competes with HSV 
glyocoprotein D or HVEM, a receptor 
expressed by T cells
LPS Lipopolysaccharides
MAPK mitogen-activated protein kinase
MCL mantle cell lymphoma
mDC myeloid dendritic cell
MDS myelodysplastic syndrome
MDSC myeloid-derived suppressor cell
MFI mean fluorescent intensity
MIC-L myeloid inhibitory C-type lectin-like
receptor
MiHA minor histocompatibility antigen
MM multiple myeloma
MMF mycophenolic acid
MoDC monocyte-derived dendritic cell
MRD minimal residual disease
MSU monosodium urate crystals
MUD matched unrelated donor
N number
N.A. not available
NA numerical aperture
ND non-detectable
ND not determined
NHL non-hodgkin lymphoma
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NK natural killer cell
No number
NRM non-relapse mortality
n.s. not significant
OS overall survival
OVA ovalbumin
PAMP pathogen associated molecular 
pattern
PB peripheral blood
PBL peripheral blood lymphocytes
PBMC peripheral blood mononuclear cell
PCR polymerase chain reaction
PD-1 Programmed death-1
pDC plasmacytoid dendritic cell
PDGB phorphobilinogen deaminase
PD-L1/2 programmed death-ligand 1/2
PE Phycoerythrin
PE-Cy5 PE-Cyanine-5
PE-Cy7 PE-Cyanine-7
PEG polyethylene glycol-lipid
PGE2 prostaglandin-2
PI3K phosphoinositide 3-kinase
PLGA poly-lactic-co-glycolic acid
PP2A serine/threonine phosphatise 2A
PR partial response
Pt patient
RNA ribonucleic acid
RRM relapse-related mortality
RT room temperature
SCF stem cell factor
SD stable disease
SD standard deviation
SEM standard error of the mean
SHP tyrosine phosphatase
SIB sibling donor
siRNA small interfering RNA
SNP single nucleotide polymorphism
SR1 StemRegenin 1
TAA tumor associated antigen
TBI total body irradiation
Tcm central memory T cell
TCR T cell receptor
Tem effector memory T cell
Th T helper cell
TIGIT T cell immunoglobulin and ITIM domain
TIL tumor-infiltrating lymphocyte
TIM-3 T cell immunoglobulin and mucin 
domain-containing protein 3
TLR toll like receptor
Tn naïve T cell
TNF tumor necrosis factor
TOF time of flight
TPO thrombopoietin
Treg regulatory T cell
UCB umbilical cord blood
VGPR very good partial response
VISTA V-domain Ig suppressor of T cell
activation
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Name PhD student:  T.J.A. Hutten
Department:   Department of Laboratory 
Medicine, Laboratory of 
Hematology
Graduate school:   Radboud Institute for  
Molecular Life Sciences
PhD period:  01-07-2013 – 01-07-2017 
Promotor(s):  Prof. Dr. J. Jansen
Co-promotor(s):  Dr. W.A. Hobo 
Dr. H. Dolstra
TRAINING ACTIVITIES Year(s) ECTS
a) Courses & Workshops
- RIMLS + Radboud specific introductory course
- Technical fora
- CDL workshops
- Course microscopy data analysis
- Academic writing
- Presentation skills
- Scientific integrity
- European network of immunology institutes summer school#
- BD HORIZON™ TOUR BENELUX
2013
2013-2017
2013-2014
2014
2016
2016
2016
2016
2017
2.6
0.4
0.3
1.75
3.0
1.5
0.5
2.25
0.25
b) Seminars & Lectures
- MACHT meetings***
- Radboud Research rounds
- RIMLS lecture series + seminars
- Laboratory of hematology research retreat***
- Hematology / strategy meetings
2013-2016
2013-2017
2013-2017
2013-2017
2015-2017
0.3
0.6
1.6
1.0
1.2
c) (Inter)national Symposia & Congresses
- Radboud New Frontiers symposia (2016#) 
- Radboud Science Days (RIO) (2013#, 2014#)
- RIMLS PhD retreat (2014#, 2015#, 2016#, 2017*)
- Dutch Hematology congress (2014*, 2016#)
- Dutch Tumor Immunology Meeting (2014*, 2015*, 2016*)
- NVVI meeting (2014#, 2016#)
- Tumor immunology symposium (RIMLS)*#
- European blood and marrow transplant conference#
2013-2016
2013,2014
2014-2017
2014-2016
2013-2016
2014,2016
2017
2017
2.25
1.0
3.5
1.5
2.25
2.5
0.5
1.5
d) Other
- Journal clubs***
- Organization of an RIML Technical forum “human challenge models”
2014-2017
2016
2.5
0.5
TEACHING ACTIVITIES Year(s) ECTS
e) Lecturing
- Teaching 5 VWO students
- Family day in the lab
- Teaching 2nd year honours students
2013-2015
2014, 2017
2016, 2017
0.2
0.1
0.4
f) Supervision of internships
- HLO student project (6 months)
- Master student literature thesis (2 months)
- Master student project (6 months)
2014-2015
2014
2015-2016
2.0
0.2
2.0
TOTAL 40.15
Oral and poster presentations are indicated with a * and # after the name of the activity, respectively.
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Paranimfen
Bob J. Hutten
bob-hutten@hotmail.com
Hanny Fredrix
hanny.fredrix@radboudumc.nl
Uitnodiging 
voor het bijwonen van 
de openbare verdediging
van mijn proefschrift
Harnessing 
dendritic cells 
and immune checkpoints 
to boost  
graft-versus-tumor 
immunity
op vrijdag 18 mei 2018
om 10.30 uur precies
in de aula van de
Radboud Universiteit Nijmegen,
Comeniuslaan 2 te Nijmegen.
U bent van harte welkom
bij deze plechtigheid
en de aansluitende receptie.
Tim J.A. Hutten
timhutten@gmail.com
Harnessing dendritic cells and im
m
une checkpoints to boost graft-versus-tum
or im
m
unity    Tim
 J.A. Hutten
Tim J.A. Hutten
Harnessing dendritic cells 
and immune checkpoints to boost  
graft-versus-tumor immunity
